<?xml version="1.0" encoding="UTF-8"?>
<data xmlns="http://www.aopkb.org/aop-xml">
  <chemical id="7a4588c2-c96d-4be1-ad01-a95763a68f41">
    <casrn>5746-04-3</casrn>
    <jchem-inchi-key/>
    <indigo-inchi-key/>
    <preferred-name>N(6)-Carboxymethyllysine</preferred-name>
    <dsstox-id>DTXSID80904133</dsstox-id>
  </chemical>
  <chemical id="578a9f44-fc12-4d28-a645-dd99b7010bcd">
    <casrn>92-87-5</casrn>
    <jchem-inchi-key>HFACYLZERDEVSX-UHFFFAOYSA-N</jchem-inchi-key>
    <indigo-inchi-key>HFACYLZERDEVSX-UHFFFAOYSA-N</indigo-inchi-key>
    <preferred-name>C.I. Azoic Diazo Component 112</preferred-name>
    <synonyms>
      <synonym>4-(4-Aminophenyl)aniline</synonym>
      <synonym>[1,1'-Biphenyl]-4,4'-diamine</synonym>
      <synonym>(1,1'-Biphenyl)-4,4'-diamine</synonym>
      <synonym>4,4'-Bianiline</synonym>
      <synonym>4,4'-Biphenyldiamine</synonym>
      <synonym>4,4'-Diamino-1,1'-biphenyl</synonym>
      <synonym>4,4'-Diaminobiphenyl</synonym>
      <synonym>4,4'-Diaminodiphenyl</synonym>
      <synonym>4,4'-Diphenylenediamine</synonym>
      <synonym>4'-Amino-[1,1'-biphenyl]-4-ylamine</synonym>
      <synonym>bencidina</synonym>
      <synonym>Benzidin</synonym>
      <synonym>C.I. Azoic Diazo Component 112</synonym>
      <synonym>Fast Corinth Base B</synonym>
      <synonym>NSC 146476</synonym>
      <synonym>p,p'-Bianiline</synonym>
      <synonym>p,p'-Diaminobiphenyl</synonym>
      <synonym>p-Diaminodiphenyl</synonym>
      <synonym>UN 1885</synonym>
    </synonyms>
    <dsstox-id>DTXSID2020137</dsstox-id>
  </chemical>
  <chemical id="dddd3726-e7c5-4ada-8181-497246c8e98f">
    <casrn>262-12-4</casrn>
    <jchem-inchi-key>NFBOHOGPQUYFRF-UHFFFAOYSA-N</jchem-inchi-key>
    <indigo-inchi-key>NFBOHOGPQUYFRF-UHFFFAOYSA-N</indigo-inchi-key>
    <preferred-name>Dibenzo-p-dioxin</preferred-name>
    <synonyms>
      <synonym>Dibenzo[b,e][1,4]dioxin</synonym>
      <synonym>Dibenzo[1,4]dioxin</synonym>
      <synonym>dibenzo-p-dioxina</synonym>
      <synonym>dibenzo-p-dioxinne</synonym>
      <synonym>Diphenylene dioxide</synonym>
      <synonym>Oxanthrene</synonym>
      <synonym>Phenodioxin</synonym>
    </synonyms>
    <dsstox-id>DTXSID8020410</dsstox-id>
  </chemical>
  <chemical id="c13b1899-9f0f-416c-88d3-a8f956877cc6">
    <casrn>118-74-1</casrn>
    <jchem-inchi-key>CKAPSXZOOQJIBF-UHFFFAOYSA-N</jchem-inchi-key>
    <indigo-inchi-key>CKAPSXZOOQJIBF-UHFFFAOYSA-N</indigo-inchi-key>
    <preferred-name>Hexachlorobenzene</preferred-name>
    <synonyms>
      <synonym>(HCB</synonym>
      <synonym>Benzene, hexachloro-</synonym>
      <synonym>Anticarie</synonym>
      <synonym>Benzene, 1,2,3,4,5,6-hexachloro-</synonym>
      <synonym>Benzenehexachloride</synonym>
      <synonym>Bunt-cure</synonym>
      <synonym>Bunt-no-more</synonym>
      <synonym>Co-op Hexa</synonym>
      <synonym>Hexachlorbenzol</synonym>
      <synonym>hexaclorobenceno</synonym>
      <synonym>Julin's carbon chloride</synonym>
      <synonym>No Bunt</synonym>
      <synonym>No Bunt Liquid</synonym>
      <synonym>NSC 9243</synonym>
      <synonym>Pentachlorophenyl chloride</synonym>
      <synonym>Perchlorobenzene</synonym>
      <synonym>Sanocide</synonym>
      <synonym>Snieciotox</synonym>
      <synonym>UN 2729</synonym>
      <synonym>Zaprawa nasienna sneciotox</synonym>
      <synonym>1,2,3,4,5,6-Hexachloro-benzene</synonym>
    </synonyms>
    <dsstox-id>DTXSID2020682</dsstox-id>
  </chemical>
  <chemical id="bdc281b8-2e13-4291-841a-f14405aeba1e">
    <casrn>313-67-7</casrn>
    <jchem-inchi-key>BBFQZRXNYIEMAW-UHFFFAOYSA-N</jchem-inchi-key>
    <indigo-inchi-key>BBFQZRXNYIEMAW-UHFFFAOYSA-N</indigo-inchi-key>
    <preferred-name>Aristolochic acid</preferred-name>
    <synonyms>
      <synonym>Aristolochic acid I</synonym>
      <synonym>Aristolochic acid A</synonym>
      <synonym>Tardolyt</synonym>
      <synonym>8-Methoxy-3,4-methylenedioxy-10-nitrophenanthrene-1-carboxylic acid</synonym>
      <synonym>Phenanthro[3,4-d]-1,3-dioxole-5-carboxylic acid, 8-methoxy-6-nitro-</synonym>
    </synonyms>
    <dsstox-id>DTXSID0040969</dsstox-id>
  </chemical>
  <chemical id="587a0fb8-5bff-401d-bcb1-af262d3fb787">
    <casrn>23214-92-8</casrn>
    <jchem-inchi-key>AOJJSUZBOXZQNB-TZSSRYMLSA-N</jchem-inchi-key>
    <indigo-inchi-key>AOJJSUZBOXZQNB-TZSSRYMLSA-N</indigo-inchi-key>
    <preferred-name>Doxorubicin</preferred-name>
    <synonyms>
      <synonym>DOX</synonym>
      <synonym>5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-</synonym>
      <synonym>14-Hydroxydaunomycin</synonym>
      <synonym>5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-</synonym>
      <synonym>5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-</synonym>
      <synonym>Biotransdox</synonym>
      <synonym>doxorrubicina</synonym>
      <synonym>Doxorubicine</synonym>
      <synonym>Hydroxydaunomycin</synonym>
      <synonym>NSC 123127</synonym>
      <synonym>Adriamycin</synonym>
    </synonyms>
    <dsstox-id>DTXSID8021480</dsstox-id>
  </chemical>
  <biological-object id="a695a3c6-32e7-48ff-aa26-69581260df08">
    <source-id>PR:000003858</source-id>
    <source>PR</source>
    <name>aryl hydrocarbon receptor</name>
  </biological-object>
  <biological-object id="ba198f4b-e042-407e-855c-f8842dbe1afd">
    <source-id>PR:000013428</source-id>
    <source>PR</source>
    <name>prostaglandin G/H synthase 2</name>
  </biological-object>
  <biological-object id="ad466b20-827e-4c6c-9492-c1178dd8756f">
    <source-id>PR:000017284</source-id>
    <source>PR</source>
    <name>vascular endothelial growth factor A</name>
  </biological-object>
  <biological-object id="c3dab278-d35a-43a5-a603-8db06423794a">
    <source-id>UBERON:0004535</source-id>
    <source>UBERON</source>
    <name>cardiovascular system</name>
  </biological-object>
  <biological-object id="5711cde6-e0e9-46b5-9762-6eec54ba7b96">
    <source-id>PR:000013058</source-id>
    <source>PR</source>
    <name>peroxisome proliferator-activated receptor gamma</name>
  </biological-object>
  <biological-process id="027addf6-122e-4553-8231-87946ff1d38b">
    <source-id>GO:0004874</source-id>
    <source>GO</source>
    <name>aryl hydrocarbon receptor activity</name>
  </biological-process>
  <biological-process id="ef32cf4d-166e-4cb1-aeb1-2568a0c476f7">
    <source-id>GO:0017162</source-id>
    <source>GO</source>
    <name>aryl hydrocarbon receptor binding</name>
  </biological-process>
  <biological-process id="2a9e9810-90f5-4a87-beee-31a21d9535dc">
    <source-id>GO:0010467</source-id>
    <source>GO</source>
    <name>gene expression</name>
  </biological-process>
  <biological-process id="5a290a1e-c8f5-4939-9c70-924dda1ea517">
    <source-id>MP:0008469</source-id>
    <source>MP</source>
    <name>abnormal protein level</name>
  </biological-process>
  <biological-process id="0ca3ec48-d6fb-4d7e-8ef9-8ac3bb71af6e">
    <source-id>MP:0001544</source-id>
    <source>MP</source>
    <name>abnormal cardiovascular system physiology</name>
  </biological-process>
  <biological-process id="f391422c-9e8d-417e-ae6e-348871e9938c">
    <source-id>GO:0072358</source-id>
    <source>GO</source>
    <name>cardiovascular system development</name>
  </biological-process>
  <biological-process id="2dd85acd-9c86-4210-b0f9-7659276b58b9">
    <source-id>GO:0035357</source-id>
    <source>GO</source>
    <name>peroxisome proliferator activated receptor signaling pathway</name>
  </biological-process>
  <biological-action id="858bfb7f-1f52-4390-9d28-4ea657198347">
    <source-id>1</source-id>
    <source>WIKI</source>
    <name>increased</name>
  </biological-action>
  <biological-action id="daf07ded-b29b-4e00-9e44-8a8de58b3293">
    <source-id>2</source-id>
    <source>WIKI</source>
    <name>decreased</name>
  </biological-action>
  <biological-action id="40170979-dec4-42d2-93fa-9785e9edd1e8">
    <source-id>8</source-id>
    <source>WIKI</source>
    <name>morphological change</name>
  </biological-action>
  <biological-action id="d174c842-9881-4c5e-a044-9c0b40492c6f">
    <source-id>4</source-id>
    <source>WIKI</source>
    <name>abnormal</name>
  </biological-action>
  <stressor id="3567f20c-d7cb-4772-8e3c-2b5cbd64d2ae">
    <name>N(6)-Carboxymethyllysine</name>
    <description></description>
    <chemicals>
      <chemical-initiator chemical-id="7a4588c2-c96d-4be1-ad01-a95763a68f41" user-term="123800"/>
    </chemicals>
    <exposure-characterization></exposure-characterization>
    <creation-timestamp>2026-11-16T21:51:05</creation-timestamp>
    <last-modification-timestamp>2026-11-16T21:51:05</last-modification-timestamp>
  </stressor>
  <stressor id="2b6845ea-b09b-4518-91d9-343753c6dc50">
    <name>Selected AHR Ligands</name>
    <description>Chemical properties for a selection of representative AHR ligands are provided in Table 3 in lieu of listing them separately. &lt;div class="thumb tright"&gt;&lt;div class="thumbinner" style="width:182px;"&gt;&lt;a href="/wiki/index.php/File:Table2.jpg" class="image"&gt;&lt;img alt="Table 2 alt text" src="/wiki/images/thumb/f/fb/Table2.jpg/180px-Table2.jpg" width="180" height="119" class="thumbimage" srcset="/wiki/images/thumb/f/fb/Table2.jpg/270px-Table2.jpg 1.5x, /wiki/images/thumb/f/fb/Table2.jpg/360px-Table2.jpg 2x" /&gt;&lt;/a&gt;  &lt;div class="thumbcaption"&gt;&lt;div class="magnify"&gt;&lt;a href="/wiki/index.php/File:Table2.jpg" class="internal" title="Enlarge"&gt;&lt;img src="/wiki/skins/common/images/magnify-clip.png" width="15" height="11" alt="" /&gt;&lt;/a&gt;&lt;/div&gt;Table 3: Chemical and AHR binding properties of selected AHR ligands&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;
&lt;p&gt;This table also provides the EC50, which itself is a measure of potency and one of the determinants of sustained AHR activation. These representative ligands demonstrate the diversity in chemical properties modelling pharmacokinetics and bioavailability as well as sources, including anthropogenic chemicals, dietary constituents, and endogenous substances formed in vivo.
&lt;/p&gt;</description>
    <exposure-characterization></exposure-characterization>
    <creation-timestamp>2016-11-29T18:42:23</creation-timestamp>
    <last-modification-timestamp>2016-11-29T21:20:17</last-modification-timestamp>
  </stressor>
  <stressor id="0ca7fc0b-e48d-4025-be17-47dbff123078">
    <name>Benzidine</name>
    <description></description>
    <chemicals>
      <chemical-initiator chemical-id="578a9f44-fc12-4d28-a645-dd99b7010bcd" user-term="Benzidine"/>
    </chemicals>
    <exposure-characterization></exposure-characterization>
    <creation-timestamp>2016-11-29T18:42:26</creation-timestamp>
    <last-modification-timestamp>2016-11-29T18:42:26</last-modification-timestamp>
  </stressor>
  <stressor id="c82a22dc-b1a0-40f1-871c-97e7c82aed60">
    <name>Dibenzo-p-dioxin</name>
    <description></description>
    <chemicals>
      <chemical-initiator chemical-id="dddd3726-e7c5-4ada-8181-497246c8e98f" user-term="Dibenzo-p-dioxin"/>
    </chemicals>
    <exposure-characterization></exposure-characterization>
    <creation-timestamp>2016-11-29T18:42:27</creation-timestamp>
    <last-modification-timestamp>2016-11-29T18:42:27</last-modification-timestamp>
  </stressor>
  <stressor id="fc8d1576-cdc5-44ac-8549-ba626ca01ec8">
    <name>Polychlorinated biphenyl</name>
    <description></description>
    <exposure-characterization></exposure-characterization>
    <creation-timestamp>2016-11-29T18:42:27</creation-timestamp>
    <last-modification-timestamp>2016-11-29T18:42:27</last-modification-timestamp>
  </stressor>
  <stressor id="1f9d4df7-b11c-4106-af4e-ed65dd875310">
    <name>Polychlorinated dibenzofurans</name>
    <description></description>
    <exposure-characterization></exposure-characterization>
    <creation-timestamp>2016-11-29T18:42:27</creation-timestamp>
    <last-modification-timestamp>2016-11-29T18:42:27</last-modification-timestamp>
  </stressor>
  <stressor id="06016acb-bf64-4755-ae45-0952f3499a41">
    <name>Hexachlorobenzene</name>
    <description></description>
    <chemicals>
      <chemical-initiator chemical-id="c13b1899-9f0f-416c-88d3-a8f956877cc6" user-term="Hexachlorobenzene"/>
    </chemicals>
    <exposure-characterization></exposure-characterization>
    <creation-timestamp>2016-11-29T18:42:27</creation-timestamp>
    <last-modification-timestamp>2016-11-29T18:42:27</last-modification-timestamp>
  </stressor>
  <stressor id="0e1bc0e6-64ee-419e-8c36-061ceabc5ba0">
    <name>Polycyclic aromatic hydrocarbons (PAHs)</name>
    <description></description>
    <exposure-characterization></exposure-characterization>
    <creation-timestamp>2017-02-09T15:43:00</creation-timestamp>
    <last-modification-timestamp>2017-02-09T15:43:00</last-modification-timestamp>
  </stressor>
  <stressor id="99526a5f-9ee3-4f6c-8be2-bb2c9442440b">
    <name>2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)</name>
    <description></description>
    <exposure-characterization></exposure-characterization>
    <creation-timestamp>2017-02-09T14:32:32</creation-timestamp>
    <last-modification-timestamp>2017-02-09T14:32:32</last-modification-timestamp>
  </stressor>
  <stressor id="ff730375-7759-42a3-b14e-80f5c4250211">
    <name>Aristolochic acid</name>
    <description></description>
    <chemicals>
      <chemical-initiator chemical-id="bdc281b8-2e13-4291-841a-f14405aeba1e" user-term="Aristolochic acid"/>
    </chemicals>
    <exposure-characterization></exposure-characterization>
    <creation-timestamp>2017-05-09T15:56:55</creation-timestamp>
    <last-modification-timestamp>2017-05-09T15:56:55</last-modification-timestamp>
  </stressor>
  <stressor id="4079ce24-b951-4dae-8050-fef47d1f718a">
    <name>Doxorubicin</name>
    <description></description>
    <chemicals>
      <chemical-initiator chemical-id="587a0fb8-5bff-401d-bcb1-af262d3fb787" user-term="Doxorubicin"/>
    </chemicals>
    <exposure-characterization></exposure-characterization>
    <creation-timestamp>2017-05-09T15:57:14</creation-timestamp>
    <last-modification-timestamp>2017-05-09T15:57:14</last-modification-timestamp>
  </stressor>
  <taxonomy id="ab767424-1286-466f-a43f-6630467eccc5">
    <source-id>7955</source-id>
    <source>NCBI</source>
    <name>zebra danio</name>
  </taxonomy>
  <taxonomy id="109ce903-310c-4030-80f5-fc444247f435">
    <source-id>WCS_9031</source-id>
    <source>common ecological species</source>
    <name>Gallus gallus</name>
  </taxonomy>
  <taxonomy id="e3cbe271-c1f7-4f0b-acb4-bb8ff3c737de">
    <source-id>143350</source-id>
    <source>NCBI</source>
    <name>Pagrus major</name>
  </taxonomy>
  <taxonomy id="d460d086-b9b4-4c4c-8dbc-e3ffe6c8d44e">
    <source-id>7904</source-id>
    <source>NCBI</source>
    <name>Acipenser transmontanus</name>
  </taxonomy>
  <taxonomy id="f8570d25-a83d-45ec-9a91-ddc74459a135">
    <source-id>41871</source-id>
    <source>NCBI</source>
    <name>Acipenser fulvescens</name>
  </taxonomy>
  <taxonomy id="905fad6d-2c9c-42a0-b683-1537a9dd6fb7">
    <source-id>WCS_8022</source-id>
    <source>common ecological species</source>
    <name>rainbow trout</name>
  </taxonomy>
  <taxonomy id="5ca49bb1-3efc-4115-b334-82e2761a586f">
    <source-id>8030</source-id>
    <source>NCBI</source>
    <name>Salmo salar</name>
  </taxonomy>
  <taxonomy id="7f4f5ccb-4d94-4574-87e9-0dcfcfe92608">
    <source-id>WCS_8355</source-id>
    <source>common ecological species</source>
    <name>Xenopus laevis</name>
  </taxonomy>
  <taxonomy id="9df39eac-d707-4c00-b1ea-9a1505f20c77">
    <source-id>8296</source-id>
    <source>NCBI</source>
    <name>Ambystoma mexicanum</name>
  </taxonomy>
  <taxonomy id="325e3fb3-0e5a-42ce-b834-ffaa584f3490">
    <source-id>WCS_9054</source-id>
    <source>common ecological species</source>
    <name>Phasianus colchicus</name>
  </taxonomy>
  <taxonomy id="a2e1100f-2c73-42ee-9356-2381f3f9de0d">
    <source-id>WCS_93934</source-id>
    <source>common ecological species</source>
    <name>Coturnix japonica</name>
  </taxonomy>
  <taxonomy id="ba982cc1-0376-4470-bed3-29bba8aceec4">
    <source-id>10090</source-id>
    <source>NCBI</source>
    <name>mouse</name>
  </taxonomy>
  <taxonomy id="b667fbe7-4be4-45d5-a707-316c7aaea8bc">
    <source-id>10116</source-id>
    <source>NCBI</source>
    <name>rat</name>
  </taxonomy>
  <taxonomy id="b8753f15-9ab7-4425-9f65-b67236d6993f">
    <source-id>WCS_9606</source-id>
    <source>common toxicological species</source>
    <name>human</name>
  </taxonomy>
  <taxonomy id="ca1e44ab-6ba7-4ca2-9dab-f769adf983d9">
    <source-id>34823</source-id>
    <source>NCBI</source>
    <name>Microgadus tomcod</name>
  </taxonomy>
  <taxonomy id="44a12808-8bd9-48d3-9450-2b9e10e95068">
    <source-id>9606</source-id>
    <source>NCBI</source>
    <name>Homo sapiens</name>
  </taxonomy>
  <taxonomy id="cfd455a8-25ff-4287-9ff1-c9f6c99224c5">
    <source-id>WCS_7955</source-id>
    <source>common ecological species</source>
    <name>Danio rerio</name>
  </taxonomy>
  <taxonomy id="40a96606-3ba7-4743-a401-22460d1b3c4b">
    <source-id>8090</source-id>
    <source>NCBI</source>
    <name>Oryzias latipes</name>
  </taxonomy>
  <taxonomy id="0924b029-7b44-4e61-92f9-cdaba5fd44d5">
    <source-id>WCS_9031</source-id>
    <source>common ecological species</source>
    <name>chicken</name>
  </taxonomy>
  <taxonomy id="42a83725-7234-4b5b-b126-4651c3467c4c">
    <source-id>WikiUser_17</source-id>
    <source/>
    <name>mammals</name>
  </taxonomy>
  <taxonomy id="f5c6c9e8-9327-462a-9035-4c7eb6f1eb01">
    <source-id>WCS_93934</source-id>
    <source>common ecological species</source>
    <name>Japanese quail</name>
  </taxonomy>
  <taxonomy id="6a5b376b-edcc-4703-a928-322458d212ae">
    <source-id>WCS_7955</source-id>
    <source>common ecological species</source>
    <name>zebrafish</name>
  </taxonomy>
  <taxonomy id="3677faa1-063d-42d3-8e25-00291c6359cf">
    <source-id>WikiUser_28</source-id>
    <source/>
    <name>Vertebrates</name>
  </taxonomy>
  <taxonomy id="3787a1aa-da69-47ff-926a-93ba5ba9626e">
    <source-id>WikiUser_29</source-id>
    <source/>
    <name>Invertebrates</name>
  </taxonomy>
  <key-event id="19a51ece-bc2e-4475-9636-2797e76dd4c4">
    <title>Activation, AhR</title>
    <short-name>Activation, AhR</short-name>
    <biological-organization-level>Molecular</biological-organization-level>
    <description>&lt;h3&gt;The AHR Receptor&lt;/h3&gt;

&lt;p&gt;The aryl hydrocarbon receptor (AHR) is a ligand-activated transcription factor that belongs to the basic helix-loop-helix Per-ARNT-Sim (bHLH-PAS) superfamily and consists of three domains: the DNA-binding domain (DBD), ligand binding domain (LBD) and transactivation domain (TAD)&lt;sup&gt;&lt;a href="#cite_note-Okey2007-1"&gt;[1]&lt;/a&gt;&lt;/sup&gt;. Other members of this superfamily include the AHR nuclear translocator (ARNT), which acts as a dimerization partner of the AHR &lt;sup&gt;&lt;a href="#cite_note-Hoffman1991-2"&gt;[2]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Poland1976-3"&gt;[3]&lt;/a&gt;&lt;/sup&gt;; Per, a circadian transcription factor; and Sim, the &amp;ldquo;single-minded&amp;rdquo; protein involved in neuronal development &lt;sup&gt;&lt;a href="#cite_note-Gu2000-4"&gt;[4]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Kewley2004-5"&gt;[5]&lt;/a&gt;&lt;/sup&gt;. This group of proteins shares a highly conserved PAS domain and is involved in the detection of and adaptation to environmental change&lt;sup&gt;&lt;a href="#cite_note-Gu2000-4"&gt;[4]&lt;/a&gt;&lt;/sup&gt;.&lt;/p&gt;

&lt;p&gt;Investigations of invertebrates possessing early homologs of the AhR suggest that the AhR evolutionarily functioned in regulation of the cell cycle, cellular proliferation and differentiation, and cell-to-cell communications (Hahn et al 2002). However, critical functions in angiogenesis, regulation of the immune system, neuronal processes, metabolism, development of the heart and other organ systems, and detoxification have emerged sometime in early vertebrate evolution (Duncan et al., 1998; Emmons et al., 1999; Lahvis and Bradfield, 1998).&lt;/p&gt;

&lt;h3&gt;The molecular Initiating Event&lt;/h3&gt;

&lt;div&gt;
&lt;div&gt;&lt;a class="image" href="/wiki/index.php/File:AHR_mechanism.jpeg"&gt;&lt;img alt="" class="thumbimage" src="/wiki/images/thumb/6/6e/AHR_mechanism.jpeg/450px-AHR_mechanism.jpeg" style="height:331px; width:450px" /&gt;&lt;/a&gt;

&lt;div&gt;Figure 1: The molecular mechanism of activation of gene expression by AHR.&lt;/div&gt;

&lt;div&gt;&amp;nbsp;&lt;/div&gt;
&lt;/div&gt;
&lt;/div&gt;

&lt;p&gt;The molecular mechanism for AHR-mediated activation of gene expression is presented in Figure 1. In its unliganded form, the AHR is part of a cytosolic complex containing heat shock protein 90 (HSP90), the HSP90 co-chaperone p23 and AHR-interacting protein (AIP)&lt;sup&gt;&lt;a href="#cite_note-Fujii2010-6"&gt;[6]&lt;/a&gt;&lt;/sup&gt;. Upon ligand binding, the AHR migrates to the nucleus where it dissociates from the cytosolic complex and forms a heterodimer with ARNT&lt;sup&gt;&lt;a href="#cite_note-Mimura2003-7"&gt;[7]&lt;/a&gt;&lt;/sup&gt;. The AHR-ARNT complex then binds to a xenobiotic response element (XRE) found in the promoter of an AHR-regulated gene and recruits co-regulators such as CREB binding protein/p300, steroid receptor co-activator (SRC) 1, SRC-2, SRC-3 and nuclear receptor interacting protein 1, leading to induction or repression of gene expression&lt;sup&gt;&lt;a href="#cite_note-Fujii2010-6"&gt;[6]&lt;/a&gt;&lt;/sup&gt;. Expression levels of several genes, including phase I (e.g. cytochrome P450 (CYP) 1A, CYP1B, CYP2A) and phase II enzymes (e.g. uridine diphosphate glucuronosyl transferase (UDP-GT), glutathione S-transferases (GSTs)), as well as genes involved in cell proliferation (transforming growth factor-beta, interleukin-1 beta), cell cycle regulation (p27, jun-B) and apoptosis (Bax), are regulated through this mechanism &lt;sup&gt;&lt;a href="#cite_note-Fujii2010-6"&gt;[6]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Giesy2006-8"&gt;[8]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Mimura2003-7"&gt;[7]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Safe1994-9"&gt;[9]&lt;/a&gt;&lt;/sup&gt;.&lt;/p&gt;

&lt;h3&gt;AHR Isoforms&lt;/h3&gt;

&lt;ul&gt;
	&lt;li&gt;Over time the AhR has undergone gene duplication and diversification in vertebrates, which has resulted in multiple clades of AhR, namely AhR1, AhR2, and AhR3 (Hahn 2002).&lt;/li&gt;
	&lt;li&gt;Fishes and birds express AhR1s and AhR2s, while mammals express a single AhR that is homologous to the AhR1 (Hahn 2002; Hahn et al 2006).&lt;/li&gt;
	&lt;li&gt;The AhR3 is poorly understood and known only from some cartilaginous fishes (Hahn 2002).&lt;/li&gt;
	&lt;li&gt;Little is known about diversity of AhRs in reptiles and amphibians (Hahn et al 2002).&lt;/li&gt;
	&lt;li&gt;In some taxa, subsequent genome duplication events have further led to multiple isoforms of AhRs in some species, with up to four isoforms of the AhR (&amp;alpha;, &amp;beta;, &amp;delta;, &amp;gamma;) having been identified in Atlantic salmon (&lt;em&gt;Salmo salar&lt;/em&gt;) (Hansson et al 2004).&lt;/li&gt;
	&lt;li&gt;Although homologs of the AhR have been identified in some invertebrates, compared to vertebrates these AhRs have differences in binding of ligands in the species investigated to date (Hahn 2002; Hahn et al 1994).&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Roles of isoforms in birds:&lt;/p&gt;

&lt;p&gt;Two AHR isoforms (AHR1 and AHR2) have been identified in the black-footed albatross (&lt;em&gt;Phoebastria nigripes&lt;/em&gt;), great cormorant (&lt;em&gt;Phalacrocorax carbo&lt;/em&gt;) and domestic chicken (&lt;em&gt;Gallus gallus domesticus&lt;/em&gt;)&lt;sup&gt;&lt;a href="#cite_note-Yasui2007-10"&gt;[10]&lt;/a&gt;&lt;/sup&gt;. AHR1 mRNA levels were similar in the kidney, heart, lung, spleen, brain, gonad and intestine from the great cormorant but were lower in muscle and pancreas. AHR2 expression was mainly observed in the liver, but was also detected in gonad, brain and intestine. AHR1 levels represented a greater proportion (80%) of total AHR levels than AHR2 in the cormorant liver&lt;sup&gt;&lt;a href="#cite_note-Yasui2007-10"&gt;[10]&lt;/a&gt;&lt;/sup&gt;, and while both AHR isoforms bound to TCDD, AHR2 was less effective at inducing TCDD-dependent transactivation compared to AHR1 in black-footed albatross, great cormorant and domestic chicken&lt;sup&gt;&lt;a href="#cite_note-Lee2009-11"&gt;[11]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Yasui2007-10"&gt;[10]&lt;/a&gt;&lt;/sup&gt;.&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;AhR1 and AhR2 both bind and are activated by TCDD &lt;em&gt;in vitro&lt;/em&gt; (Yasui et al 2007).&lt;/li&gt;
	&lt;li&gt;AhR1 has greater binding affinity and sensitivity to activation by TCDD relative to AhR2 (Yasui et al 2007).&lt;/li&gt;
	&lt;li&gt;AhR1 is believed to mediate toxicities of DLCs, while AhR2 has no known role in toxicities (Farmahin et al 2012; Farmahin et al 2013; Manning et al 2012).&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Roles of isoforms in fishes:&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;AhR1 and AhR2 both bind and are activated by TCDD &lt;em&gt;in vitro&lt;/em&gt; (Bak et al 2013; Doering et al 2014; 2015; Karchner et al 1999; 2005).&lt;/li&gt;
	&lt;li&gt;AhR1 has greater sensitivity to activation by TCDD than AhR2 in red seabream (&lt;em&gt;Pagrus major&lt;/em&gt;), white sturgeon (&lt;em&gt;Acipenser transmontanus&lt;/em&gt;), and lake sturgeon (&lt;em&gt;Acipenser fulvescens&lt;/em&gt;) (Bak et al 2013; Doering et al 2014; 2015)&lt;/li&gt;
	&lt;li&gt;AhR2 has greater binding affinity or activation by TCDD than AhR1 in zebrafish (&lt;em&gt;Danio rerio&lt;/em&gt;) and mummichog (&lt;em&gt;Fundulus heteroclitus&lt;/em&gt;) (Karchner et al 1999; 2005).&lt;/li&gt;
	&lt;li&gt;AhR2 is believed to mediate toxicities in fishes, while AhR1 has no known role in toxicities. Specifically, knockdown of AhR2 protects against toxicities of dioxin-like compounds (DLCs) and polycyclic aromatic hydrocarbons (PAHs) in zebrafish (&lt;em&gt;Danio rerio&lt;/em&gt;) and mummichog (&lt;em&gt;Fundulus heteroclitus&lt;/em&gt;), while knockdown of AhR1 offers no protection (Clark et al 2010; Prasch et al 2003; Van Tiem &amp;amp; Di Giulio 2011).&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;Roles of isoforms in amphibians and reptiles:&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Less is known about AhRs of amphibians or reptiles.&lt;/li&gt;
	&lt;li&gt;AhR1 is believed to mediate toxicities in amphibians (Hahn 2002; Lavine et al 2005; Oka et al 2016; Shoots et al 2015). However, all AhRs of amphibians that have been investigated have very low affinity for TCDD (Hahn 2002; Lavine et al 2005; Oka et al 2016; Shoots et al 2015).&lt;/li&gt;
	&lt;li&gt;Both AhR1s and AhR2 of American alligator (&lt;em&gt;Alligator mississippiensis&lt;/em&gt;) are activated by agonists with comparable sensitivities (Oka et al 2016). AhRs of no other reptiles have been investigated.&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;em&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;&lt;span style="font-size:14px"&gt;Role in mammals&lt;/span&gt;&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;&lt;span style="font-size:14px"&gt;AhR expression is essentially ubiquitous in mammals consistent with a broad-spectrum homeostatic role, however expression levels varying widely across tissues with the liver, thymus, lung, kidney, spleen, and placenta exhibiting greatest expression (Harper PA).&amp;nbsp;Additionally, AhR expression is developmentally regulated, and more recent evidence indicates a role for the AhR in developmental process affecting hematopoiesis, immune system biology, neural differentiation, and liver architecture (Wright E J)&amp;nbsp;.&amp;nbsp;AHR is involved in regulating the rate of apoptosis of oocytes in germ cell nests during embryonic life and in regulating survival of oocytes in the fetal and neonatal ovary. Specifically, studies have shown that ovaries obtained from AHRKO mice on ED13.5 and cultured for 72 h in the absence of hormonal support with the aim of inducing apoptosis, contained higher numbers of non-apoptotic germ cells compared to wild-type (WT) ovaries cultured in the same conditions (Hern&amp;aacute;ndez-Ochoa)&lt;/span&gt;&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;
</description>
    <measurement-methodology>&lt;p&gt;&lt;em&gt;Methods that have been previously reviewed and approved by a recognized authority should be included in the Overview section above. All other methods, including those well established in the published literature, should be described here. Consider the following criteria when describing each method: 1. Is the assay fit for purpose? 2. Is the assay directly or indirectly (i.e. a surrogate) related to a key event relevant to the final adverse effect in question? 3. Is the assay repeatable? 4. Is the assay reproducible? &lt;/em&gt;&lt;/p&gt;

&lt;h3&gt;Transactivation Reporter Gene Assays (recommended approach)&lt;/h3&gt;

&lt;h4&gt;Transient transfection transactivation&lt;/h4&gt;

&lt;p&gt;Transient transfection transactivation is the most common method for evaluating nuclear receptor activation&lt;sup&gt;&lt;a href="#cite_note-Raucy2010-12"&gt;[12]&lt;/a&gt;&lt;/sup&gt;. Full-length AHR cDNAs are cloned into an expression vector along with a reporter gene construct (chimeric luciferase, P-lactamase or CAT reporter vectors containing the appropriate response elements for the gene of interest). There are a number of commercially available cell lines that can serve as recipients for these vectors (CV-1, HuH7, FLC-7, LS174T, LS180 MCF-7, HEC1, LLC-PK1, HEK293, HepG2, and Caco-2 cells)&lt;sup&gt;&lt;a href="#cite_note-Raucy2010-12"&gt;[12]&lt;/a&gt;&lt;/sup&gt;. The greatest advantage of using transfected cells, rather than primary cell cultures, is the assurance that the nuclear receptor of interest is responsible for the observed induction. This would not be possible in a primary cell culture due to the co-regulation of different receptors for the same target genes. This model makes it easy to compare the responsiveness of the AHR across multiple species under the same conditions simply by switching out the AHR clone. One disadvantage to the transient transfection assay is the inherent variability associated with transfection efficiency, leading to a movement towards the use of stable cell lines containing the nuclear receptor and reporter gene linked to the appropriate response elements&lt;sup&gt;&lt;a href="#cite_note-Raucy2010-12"&gt;[12]&lt;/a&gt;&lt;/sup&gt;.&lt;/p&gt;

&lt;h5&gt;Luciferase reporter gene (LRG) assay&lt;/h5&gt;

&lt;p&gt;The described luciferase reporter gene (LRG) assays have been used to investigate activation of AhRs of:&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Humans&amp;nbsp;(&lt;em&gt;Homo sapiens&lt;/em&gt;)&amp;nbsp;(Abnet et al 1999)&amp;nbsp;&lt;/li&gt;
	&lt;li&gt;Species of birds, namely chicken (&lt;em&gt;Gallus gallus&lt;/em&gt;), ring-necked pheasant (&lt;em&gt;Phasianus colchicus&lt;/em&gt;), Japanese quail (&lt;em&gt;Coturnix japonica&lt;/em&gt;), and common tern (&lt;em&gt;Sterna hirundo&lt;/em&gt;)&amp;nbsp;(Farmahin et al 2012; Manning et al 2013), Mutant AhR1s with ligand binding domains resembling those of at least 86 avian species have also been investigated (Farmahin et al 2013). AhR2s of birds have only been investigated in black-footed albatross (&lt;em&gt;Phoebastria nigripes&lt;/em&gt;) and common cormorant (&lt;em&gt;Phalacrocorax carbo&lt;/em&gt;) (Yasio et al 2007).&lt;/li&gt;
	&lt;li&gt;American alligator (&lt;em&gt;Alligator mississippiensis&lt;/em&gt;) is the only reptile for which&amp;nbsp;AhR activation&amp;nbsp;has been investigated&amp;nbsp;(Oka et al 2016), AhR1A, AhR1B, and AhR2 of American alligator were assayed (Oka et al 2016).&lt;/li&gt;
	&lt;li&gt;AhR1 of two amphibians have been investigated, namely African clawed frog (&lt;em&gt;Xenopus laevis&lt;/em&gt;) and salamander (&lt;em&gt;Ambystoma mexicanum&lt;/em&gt;) (Lavine et al 2005; Shoots et al 2015; Ohi et al 2003),&lt;/li&gt;
	&lt;li&gt;AhR1s and AhR2s of several species of fish have been investigated, namely Atlantic salmon (&lt;em&gt;Salmo salar&lt;/em&gt;), Atlantic tomcod (&lt;em&gt;Microgadus tomcod&lt;/em&gt;), white sturgeon (&lt;em&gt;Acipenser transmontanus&lt;/em&gt;), rainbow trout (&lt;em&gt;Onchorhynchys mykiss&lt;/em&gt;), red seabream (&lt;em&gt;Pagrus major&lt;/em&gt;), lake sturgeon (&lt;em&gt;Acipenser fulvescens&lt;/em&gt;), and zebrafish (&lt;em&gt;Danio rerio&lt;/em&gt;) (Andreasen et al 2002; Abnet et al 1999; Bak et al 2013; Doering et al 2014; 2015; Evans et al 2005; Hansson &amp;amp; Hahn 2008; Karchner et al 1999; Tanguay et al 1999; Wirgin et al 2011).&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;For demonstrative purposes, a luciferase reporter gene assay used to measure AHR1-mediated transactivation for avian species is described here. However, comparable assays are utilized for investigating AHR1s and AHR2s of all taxa. A monkey kidney cell line (Cos-7) that has low endogenous AHR1 expression was transfected with the appropriate avian AHR1 clone, cormorant ARNT1, a CYP1A5 firefly luciferase reporter construct and a &lt;em&gt;Renilla&lt;/em&gt; luciferase vector to control for transfection efficiency. After seeding, the cells were exposed to DLC and luciferase activity was measured using a luminometer. Luminescence, which is proportional to the extent of AHR activation, is expressed as the ratio of firefly luciferase units to &lt;em&gt;Renilla&lt;/em&gt; luciferase units &lt;sup&gt;&lt;a href="#cite_note-Farmahin2012-13"&gt;[13]&lt;/a&gt;&lt;/sup&gt;. This particular assay was modified from its original version to increase throughput efficiency; (a) cells were seeded in 96-well plates rather than Petri dishes or 48- well plates, (b) DLCs were added directly to the wells without changing the cell culture medium, and (c) the same 96-well plates were used to measure luminescence without lysing the cells and transferring to another plate. Similar reporter gene assays have been used to measure AHR1 activation in domestic and wild species of birds, including the chicken, ring-necked pheasant (Phasianus colchicus), Japanese quail (Coturnix japonica), great cormorant, black-footed albatross and peregrine falcon (Falco peregrinus).&lt;sup&gt;&lt;a href="#cite_note-Farmahin2013b-14"&gt;[14]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Farmahin2012-13"&gt;[13]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Fujisawa2012-15"&gt;[15]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Lee2009-11"&gt;[11]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Manning2012-16"&gt;[16]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Mol2012-17"&gt;[17]&lt;/a&gt;&lt;/sup&gt;&lt;/p&gt;

&lt;h4&gt;Transactivation in stable cell lines&lt;/h4&gt;

&lt;p&gt;Stable cell lines have been developed and purified to the extent that each cell contains both the nuclear receptor and appropriate reporter vector, eliminating the variability associated with transfection &lt;sup&gt;&lt;a href="#cite_note-Raucy2010-12"&gt;[12]&lt;/a&gt;&lt;/sup&gt;. A stable human cell line containing a luciferase reporter driven by multiple dioxin response elements has been developed that is useful in identifying AhR agonists and antagonists&lt;sup&gt;&lt;a href="#cite_note-Yueh2005-18"&gt;[18]&lt;/a&gt;&lt;/sup&gt;. An added benefit of this model is the potential to multiplex 3 assays in a single well: receptor activation, cell viability and enzyme activity&lt;sup&gt;&lt;a href="#cite_note-Raucy2010-12"&gt;[12]&lt;/a&gt;&lt;/sup&gt;. Such assays are used extensively in drug discovery due to their high throughput efficiency, and may serve just as useful for risk assessment purposes.&lt;/p&gt;

&lt;h3&gt;Ligand-Binding Assays&lt;/h3&gt;

&lt;p&gt;Ligand binding assays measure the ability of a test compound to compete with a labeled, high-affinity reference ligand for the LBD of a nuclear receptor. It is important to note that ligand binding does not necessitate receptor activation and therefore cannot distinguish between agonists and antagonists; however, binding affinities of AHR ligands are highly correlated with chemical potencies&lt;sup&gt;&lt;a href="#cite_note-Poland1982-19"&gt;[19]&lt;/a&gt;&lt;/sup&gt; and can explain differences in species sensitivities to DLCs&lt;sup&gt;&lt;a href="#cite_note-Hesterman2000-20"&gt;[20]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Farmahin2014-21"&gt;[21]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Karchner2006-22"&gt;[22]&lt;/a&gt;&lt;/sup&gt;; they are therefore worth mentioning. Binding affinity and efficacy have been used to develop structure-activity relationships for AHR disruption&lt;sup&gt;&lt;a href="#cite_note-Hesterman2000-20"&gt;[20]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Lee2015-23"&gt;[23]&lt;/a&gt;&lt;/sup&gt; that are potentially useful in risk-assessment. There has been tremendous progress in the development of ligand-binding assays for nuclear receptors that use homogenous assay formats (no wash steps) allowing for the detection of low-affinity ligands, many of which do not require a radiolabel and are amenable to high throughput screening&lt;sup&gt;&lt;a href="#cite_note-Jones2003-24"&gt;[24]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Raucy2010-12"&gt;[12]&lt;/a&gt;&lt;/sup&gt;. This author however was unable to find specific examples of such assays in the context of AHR binding and therefore some classic radioligand assays are described instead.&lt;/p&gt;

&lt;h4&gt;Hydroxyapatite (HAP) binding assay&lt;/h4&gt;

&lt;p&gt;The HAP binding assay makes use of an &lt;em&gt;in vitro&lt;/em&gt; transcription/translation method to synthesize the AHR protein, which is then incubated with radiolabeled TDCPP and a HAP pellet. The occupied protein adsorbs to the HAP and the radioactivity is measured to determine saturation binding. An additional ligand can also be included in the mixture in order to determine its binding affinity relative to TCDD (competitive binding)&lt;sup&gt;&lt;a href="#cite_note-Gasiewicz1982-25"&gt;[25]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Karchner2006-22"&gt;[22]&lt;/a&gt;&lt;/sup&gt;. This assay is simple, repeatable and reproducible; however, it is insensitive to weak ligand-receptor interactions&lt;sup&gt;&lt;a href="#cite_note-Karchner2006-22"&gt;[22]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Farmahin2014-21"&gt;[21]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Nakai1995-26"&gt;[26]&lt;/a&gt;&lt;/sup&gt;.&lt;/p&gt;

&lt;h4&gt;Whole cell filtration binding assay&lt;/h4&gt;

&lt;p&gt;Dold and Greenlee&lt;sup&gt;&lt;a href="#cite_note-Dold1990-27"&gt;[27]&lt;/a&gt;&lt;/sup&gt; developed a method to detect specific binding of TCDD to whole mammalian cells in culture and was later modified by Farmahin et al.&lt;sup&gt;&lt;a href="#cite_note-Farmahin2014-21"&gt;[21]&lt;/a&gt;&lt;/sup&gt; for avian species. The cultured cells are incubated with radiolabeled TCDD with or without the presence of a competing ligand and filtered. The occupied protein adsorbs onto the filter and the radioactivity is measured to determine saturation binging and/or competitive binding. This assay is able to detect weak ligand-receptor interactions that are below the detection limit of the HAP assay&lt;sup&gt;&lt;a href="#cite_note-Farmahin2014-21"&gt;[21]&lt;/a&gt;&lt;/sup&gt;.&lt;/p&gt;

&lt;h3&gt;Protein-DNA Interaction Assays&lt;/h3&gt;

&lt;p&gt;The active AHR complexed with ARNT can be measured using protein-DNA interaction assays. Two methods are described in detail by Perez-Romero and Imperiale&lt;sup&gt;&lt;a href="#cite_note-Perez2007-28"&gt;[28]&lt;/a&gt;&lt;/sup&gt;. Chromatin immunoprecipitation measures the interaction of proteins with specific genomic regions &lt;em&gt;in vivo&lt;/em&gt;. It involves the treatment of cells with formaldehyde to crosslink neighboring protein-protein and protein-DNA molecules. Nuclear fractions are isolated, the genomic DNA is sheared, and nuclear lysates are used in immunoprecipitations with an antibody against the protein of interest. After reversal of the crosslinking, the associated DNA fragments are sequenced. Enrichment of specific DNA sequences represents regions on the genome that the protein of interest is associated with &lt;em&gt;in vivo&lt;/em&gt;. Electrophoretic mobility shift assay (EMSA) provides a rapid method to study DNA-binding protein interactions in vitro. This relies on the fact that complexes of protein and DNA migrate through a nondenaturing polyacrylamide gel more slowly than free DNA fragments. The protein-DNA complex components are then identified with appropriate antibodies. The EMSA assay was found to be consistent with the LRG assay in chicken hepatoma cells dosed with dioxin-like compounds&lt;sup&gt;&lt;a href="#cite_note-Heid2001-29"&gt;[29]&lt;/a&gt;&lt;/sup&gt;.&lt;/p&gt;

&lt;h3&gt;In silico Approaches&lt;/h3&gt;

&lt;p&gt;In silico homology modeling of the ligand binding domain of the AHR in combination with molecular docking simulations can provide valuable insight into the transactivation-potential of a diverse array of AHR ligands.&amp;nbsp; Such models have been developed for multiple AHR isoforms and ligands (high/low affinity, endogenous and synthetic, agonists and antagonists), and can accurately predict ligand potency based on their structure and physicochemical properties (Bonati et al 2017; Hirano et al 2015; Sovadinova et al 2006).&lt;/p&gt;
</measurement-methodology>
    <evidence-supporting-taxonomic-applicability>&lt;p&gt;The AHR structure has been shown to contribute to differences in species sensitivity to DLCs in several animal models. In 1976, a 10-fold difference was reported between two strains of mice (non-responsive DBA/2 mouse, and responsive C57BL/6 14 mouse) in CYP1A induction, lethality and teratogenicity following TCDD exposure&lt;sup&gt;&lt;a href="#cite_note-Poland1976-3"&gt;[3]&lt;/a&gt;&lt;/sup&gt;. This difference in dioxin sensitivity was later attributed to a single nucleotide polymorphism at position 375 (the equivalent position of amino acid residue 380 in chicken) in the AHR LBD&lt;sup&gt;&lt;a href="#cite_note-Ema1994-30"&gt;[30]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Poland1982-19"&gt;[19]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Poland1994-31"&gt;[31]&lt;/a&gt;&lt;/sup&gt;. Several other studies reported the importance of this amino acid in birds and mammals&lt;sup&gt;&lt;a href="#cite_note-Backlund2004-32"&gt;[32]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Ema1994-30"&gt;[30]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Karchner2006-22"&gt;[22]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Murray2005-33"&gt;[33]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Pandini2007-34"&gt;[34]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Pandini2009-35"&gt;[35]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Poland1994-31"&gt;[31]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Ramadoss2004-36"&gt;[36]&lt;/a&gt;&lt;/sup&gt;. It has also been shown that the amino acid at position 319 (equivalent to 324 in chicken) plays an important role in ligand-binding affinity to the AHR and transactivation ability of the AHR, due to its involvement in LBD cavity volume and its steric effect&lt;sup&gt;&lt;a href="#cite_note-Pandini2009-35"&gt;[35]&lt;/a&gt;&lt;/sup&gt;. Mutation at position 319 in the mouse eliminated AHR DNA binding&lt;sup&gt;&lt;a href="#cite_note-Pandini2009-35"&gt;[35]&lt;/a&gt;&lt;/sup&gt;.&lt;/p&gt;

&lt;p&gt;The first study that attempted to elucidate the role of avian AHR1 domains and key amino acids within avian AHR1 in avian differential sensitivity was performed by Karchner &lt;em&gt;et al.&lt;/em&gt;&lt;sup&gt;&lt;a href="#cite_note-Karchner2006-22"&gt;[22]&lt;/a&gt;&lt;/sup&gt;. Using chimeric AHR1 constructs combining three AHR1 domains (DBD, LBD and TAD) from the chicken (highly sensitive to DLC toxicity) and common tern (resistant to DLC toxicity), Karchner and colleagues&lt;sup&gt;&lt;a href="#cite_note-Karchner2006-22"&gt;[22]&lt;/a&gt;&lt;/sup&gt;, showed that amino acid differences within the LBD were responsible for differences in TCDD sensitivity between the chicken and common tern. More specifically, the amino acid residues found at positions 324 and 380 in the AHR1 LBD were associated with differences in TCDD binding affinity and transactivation between the chicken (Ile324_Ser380) and common tern (Val324_Ala380) receptors&lt;sup&gt;&lt;a href="#cite_note-Karchner2006-22"&gt;[22]&lt;/a&gt;&lt;/sup&gt;. Since the Karchner et al. (2006) study was conducted, the predicted AHR1 LBD amino acid sequences were been obtained for over 85 species of birds and 6 amino acid residues differed among species&lt;sup&gt;&lt;a href="#cite_note-Farmahin2013b-14"&gt;[14]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Head2008-37"&gt;[37]&lt;/a&gt;&lt;/sup&gt; . However, only the amino acids at positions 324 and 380 in the AHR1 LBD were associated with differences in DLC toxicity in ovo and AHR1-mediated gene expression in vitro&lt;sup&gt;&lt;a href="#cite_note-Farmahin2013b-14"&gt;[14]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Head2008-37"&gt;[37]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Manning2012-16"&gt;[16]&lt;/a&gt;&lt;/sup&gt;. These results indicate that avian species can be divided into one of three AHR1 types based on the amino acids found at positions 324 and 380 of the AHR1 LBD: type 1 (Ile324_Ser380), type 2 (Ile324_Ala380) and type 3 (Val324_Ala380)&lt;sup&gt;&lt;a href="#cite_note-Farmahin2013b-14"&gt;[14]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Head2008-37"&gt;[37]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Manning2012-16"&gt;[16]&lt;/a&gt;&lt;/sup&gt;.&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Little is known about differences in binding affinity of AhRs and how this relates to sensitivity in non-avian taxa.&lt;/li&gt;
	&lt;li&gt;Low binding affinity for DLCs of AhR1s of African clawed frog (&lt;em&gt;Xenopus laevis&lt;/em&gt;) and axolotl (&lt;em&gt;Ambystoma mexicanum&lt;/em&gt;) has been suggested as a mechanism for tolerance of these amphibians to DLCs (Lavine et al 2005; Shoots et al 2015).&lt;/li&gt;
	&lt;li&gt;Among reptiles, only AhRs of American alligator (&lt;em&gt;Alligator mississippiensis&lt;/em&gt;) have been investigated and little is known about the sensitivity of American alligator or other reptiles to DLCs (Oka et al 2016).&lt;/li&gt;
	&lt;li&gt;Among fishes, great differences in sensitivity to DLCs are known both for AhRs and for embryos among species that have been tested (Doering et al 2013; 2014).&lt;/li&gt;
	&lt;li&gt;Differences in binding affinity of the AhR2 have been demonstrated to explain differences in sensitivity to DLCs between sensitive and tolerant populations of Atlantic Tomcod (&lt;em&gt;Microgadus tomcod&lt;/em&gt;) (Wirgin et al 2011).
	&lt;ul&gt;
		&lt;li&gt;This was attributed to the rapid evolution of populations in highly contaminated areas of the Hudson River, resulting in a 6-base pair deletion in the AHR sequence (outside the LBD) and reduced ligand binding affinity, due to reduces AHR protein stability.&lt;/li&gt;
	&lt;/ul&gt;
	&lt;/li&gt;
	&lt;li&gt;Information is not yet available regarding whether differences in binding affinity of AhRs of fishes are predictive of differences in sensitivity of embryos, juveniles, or adults (Doering et al 2013).&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;The AhR is a very conserved and ancient protein (95) and the AhR is present &amp;nbsp;in human and mice (96&amp;ndash;98).&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;The AhR is present in human physiology and pathology. T&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;he AhR is highly expressed at several important physiological barriers such as the placenta, lung, gastrointestinal system, and liver in human (Wakx, Marinelli, Watanabe). &amp;nbsp;In these tissues, the AhR is involved in both detoxication processes involving xenobiotic metabolizing enzymes such as cytochromes P450, and in immune functions translating chemical signals into immune defence pathways (Marinelli, Stobbe). Moreover, it has a regulatory role in human dendritic cells and myelination (Kado, Shackleford).&lt;/span&gt;&lt;/span&gt; &lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;The lung constitutes another barrier exposed to components of air pollution such as particles and hydrocarbons (air pollution, cigarette smoke). The AhR detects such hydrocarbons and protects the pulmonary cells from their deleterious effects through metabolization.&lt;/span&gt;&lt;/span&gt; &lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;The regulatory effect on blood cells of the AhR, balancing different related cell types, can be extended to the megakaryocytes and their precursors; indeed, StemRegenin 1 (SR1), an antagonist of the AhR increases the human population of CD34+CD41low cells, a fraction of very efficient precursors of proplatelets (Bock).&lt;/span&gt;&lt;/span&gt; &lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;The occurrence of a nystagmus has been subsequently diagnosed in humans bearing a AhR mutation (Borovok).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;In human cancer, the AhR has either a pro or con tumor effect depending on the tissue, the ligand, and the duration of the activation (Zudaire, Chang, Litzenburg, Gramatzki, Lin, Wang). In human breast cancer, the AhR is thoughts to be responsible of its progression (Goode, Kanno, Optiz, Novikov, Hall, &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Subramaniam, Barhoover&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;). &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;In human mammary benign cells, Brooks et al. noted that a high level of AhR was associated with a modified cell cycle (with a 50% increase in population doubling time in cells expressing the AhR by more than 3-fold) and EMT including increased cell migration. Narasimnhan et al. found that suppression of the AhR pathway had a pro-tumorigenic effect in vitro (EMT, tumor migration) in triple negative breast cancer.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Many endogenous and exogenous ligands are present for the AhR in human (Optiz, Adachi, Schroeder, &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Rothhammer&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;). &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Indoles, such as indole-3-carbinol or one of its secondary metabolites, 3-3&amp;#39;- Diindolylmethane, are degradation products found in cruciferous vegetables and characterized as AhR ligands (Ema, Kall, Miller) they are also inducers of the human and rat CYP1A1 (Optiz). FICZ is the most potent AhR ligand known to date: it has a stronger affinity than TCDD for the human AhR (TCDD Kd=0.48 nM/FICZ Kd=0.07 nM) (Coumoul).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;
</evidence-supporting-taxonomic-applicability>
    <applicability>
      <sex>
        <evidence>High</evidence>
        <sex>Unspecific</sex>
      </sex>
      <life-stage>
        <evidence>High</evidence>
        <life-stage>Embryo</life-stage>
      </life-stage>
      <life-stage>
        <evidence>High</evidence>
        <life-stage>Development</life-stage>
      </life-stage>
      <life-stage>
        <evidence>High</evidence>
        <life-stage>All life stages</life-stage>
      </life-stage>
      <taxonomy taxonomy-id="ab767424-1286-466f-a43f-6630467eccc5">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="109ce903-310c-4030-80f5-fc444247f435">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="e3cbe271-c1f7-4f0b-acb4-bb8ff3c737de">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="d460d086-b9b4-4c4c-8dbc-e3ffe6c8d44e">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="f8570d25-a83d-45ec-9a91-ddc74459a135">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="905fad6d-2c9c-42a0-b683-1537a9dd6fb7">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="5ca49bb1-3efc-4115-b334-82e2761a586f">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="7f4f5ccb-4d94-4574-87e9-0dcfcfe92608">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="9df39eac-d707-4c00-b1ea-9a1505f20c77">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="325e3fb3-0e5a-42ce-b834-ffaa584f3490">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="a2e1100f-2c73-42ee-9356-2381f3f9de0d">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="ba982cc1-0376-4470-bed3-29bba8aceec4">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="b667fbe7-4be4-45d5-a707-316c7aaea8bc">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="b8753f15-9ab7-4425-9f65-b67236d6993f">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="ca1e44ab-6ba7-4ca2-9dab-f769adf983d9">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="44a12808-8bd9-48d3-9450-2b9e10e95068">
        <evidence>Not Specified</evidence>
      </taxonomy>
    </applicability>
    <biological-events>
      <biological-event object-id="a695a3c6-32e7-48ff-aa26-69581260df08" process-id="027addf6-122e-4553-8231-87946ff1d38b" action-id="858bfb7f-1f52-4390-9d28-4ea657198347"/>
      <biological-event object-id="a695a3c6-32e7-48ff-aa26-69581260df08" process-id="ef32cf4d-166e-4cb1-aeb1-2568a0c476f7" action-id="858bfb7f-1f52-4390-9d28-4ea657198347"/>
    </biological-events>
    <references>&lt;ol&gt;
	&lt;li&gt;&amp;uarr; &lt;sup&gt;&lt;a href="#cite_ref-Okey2007_1-0"&gt;1.0&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Okey2007_1-1"&gt;1.1&lt;/a&gt;&lt;/sup&gt; Okey, A. B. (2007). An aryl hydrocarbon receptor odyssey to the shores of toxicology: the Deichmann Lecture, International Congress of Toxicology-XI. &lt;em&gt;Toxicol.Sci.&lt;/em&gt; &lt;strong&gt;98&lt;/strong&gt;, 5-38.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Hoffman1991_2-0"&gt;&amp;uarr;&lt;/a&gt; Hoffman, E. C., Reyes, H., Chu, F. F., Sander, F., Conley, L. H., Brooks, B. A., and Hankinson, O. (1991). Cloning of a factor required for activity of the Ah (dioxin) receptor. &lt;em&gt;Science&lt;/em&gt; &lt;strong&gt;252&lt;/strong&gt;, 954-958.&lt;/li&gt;
	&lt;li&gt;&amp;uarr; &lt;sup&gt;&lt;a href="#cite_ref-Poland1976_3-0"&gt;3.0&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Poland1976_3-1"&gt;3.1&lt;/a&gt;&lt;/sup&gt; Poland, A., Glover, E., and Kende, A. S. (1976). Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. &lt;em&gt;J.Biol.Chem.&lt;/em&gt; &lt;strong&gt;251&lt;/strong&gt;, 4936-4946.&lt;/li&gt;
	&lt;li&gt;&amp;uarr; &lt;sup&gt;&lt;a href="#cite_ref-Gu2000_4-0"&gt;4.0&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Gu2000_4-1"&gt;4.1&lt;/a&gt;&lt;/sup&gt; Gu, Y. Z., Hogenesch, J. B., and Bradfield, C. A. (2000). The PAS superfamily: sensors of environmental and developmental signals. &lt;em&gt;Annu.Rev.Pharmacol.Toxicol.&lt;/em&gt; &lt;strong&gt;40&lt;/strong&gt;, 519-561.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Kewley2004_5-0"&gt;&amp;uarr;&lt;/a&gt; Kewley, R. J., Whitelaw, M. L., and Chapman-Smith, A. (2004). The mammalian basic helix-loop-helix/PAS family of transcriptional regulators. &lt;em&gt;Int.J.Biochem.Cell Biol.&lt;/em&gt; &lt;strong&gt;36&lt;/strong&gt;, 189-204.&lt;/li&gt;
	&lt;li&gt;&amp;uarr; &lt;sup&gt;&lt;a href="#cite_ref-Fujii2010_6-0"&gt;6.0&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Fujii2010_6-1"&gt;6.1&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Fujii2010_6-2"&gt;6.2&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Fujii2010_6-3"&gt;6.3&lt;/a&gt;&lt;/sup&gt; Fujii-Kuriyama, Y., and Kawajiri, K. (2010). Molecular mechanisms of the physiological functions of the aryl hydrocarbon (dioxin) receptor, a multifunctional regulator that senses and responds to environmental stimuli. &lt;em&gt;Proc.Jpn.Acad.Ser.B Phys.Biol.Sci.&lt;/em&gt; &lt;strong&gt;86&lt;/strong&gt;, 40-53.&lt;/li&gt;
	&lt;li&gt;&amp;uarr; &lt;sup&gt;&lt;a href="#cite_ref-Mimura2003_7-0"&gt;7.0&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Mimura2003_7-1"&gt;7.1&lt;/a&gt;&lt;/sup&gt; Mimura, J., and Fujii-Kuriyama, Y. (2003). Functional role of AhR in the expression of toxic effects by TCDD. &lt;em&gt;Biochimica et Biophysica Acta - General Subjects&lt;/em&gt; &lt;strong&gt;1619&lt;/strong&gt;, 263-268.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Giesy2006_8-0"&gt;&amp;uarr;&lt;/a&gt; Giesy, J. P., Kannan, K., Blankenship, A. L., Jones, P. D., and Newsted, J. L. (2006). Toxicology of PCBs and related compounds. In Endocrine Disruption Biological Bases for Health Effects in Wildlife and Humans (D. O. Norris, and J. A. Carr, Eds.), pp. 245-331. Oxford University Press, New York.&lt;/li&gt;
	&lt;li&gt;&amp;uarr; &lt;sup&gt;&lt;a href="#cite_ref-Safe1994_9-0"&gt;9.0&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Safe1994_9-1"&gt;9.1&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Safe1994_9-2"&gt;9.2&lt;/a&gt;&lt;/sup&gt; Safe, S. (1994). Polychlorinated biphenyls (PCBs): Environmental impact, biochemical and toxic responses, and implications for risk assessment. &lt;em&gt;Critical Reviews in Toxicology&lt;/em&gt; &lt;strong&gt;24&lt;/strong&gt;, 87-149.&lt;/li&gt;
	&lt;li&gt;&amp;uarr; &lt;sup&gt;&lt;a href="#cite_ref-Yasui2007_10-0"&gt;10.0&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Yasui2007_10-1"&gt;10.1&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Yasui2007_10-2"&gt;10.2&lt;/a&gt;&lt;/sup&gt; Yasui, T., Kim, E. Y., Iwata, H., Franks, D. G., Karchner, S. I., Hahn, M. E., and Tanabe, S. (2007). Functional characterization and evolutionary history of two aryl hydrocarbon receptor isoforms (AhR1 and AhR2) from avian species. &lt;em&gt;Toxicol.Sci&lt;/em&gt;. &lt;strong&gt;99&lt;/strong&gt;, 101-117.&lt;/li&gt;
	&lt;li&gt;&amp;uarr; &lt;sup&gt;&lt;a href="#cite_ref-Lee2009_11-0"&gt;11.0&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Lee2009_11-1"&gt;11.1&lt;/a&gt;&lt;/sup&gt; Lee, J. S., Kim, E. Y., and Iwata, H. (2009). Dioxin activation of CYP1A5 promoter/enhancer regions from two avian species, common cormorant (Phalacrocorax carbo) and chicken (Gallus gallus): association with aryl hydrocarbon receptor 1 and 2 isoforms. &lt;em&gt;Toxicol.Appl.Pharmacol&lt;/em&gt;. &lt;strong&gt;234&lt;/strong&gt;, 1-13.&lt;/li&gt;
	&lt;li&gt;&amp;uarr; &lt;sup&gt;&lt;a href="#cite_ref-Raucy2010_12-0"&gt;12.0&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Raucy2010_12-1"&gt;12.1&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Raucy2010_12-2"&gt;12.2&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Raucy2010_12-3"&gt;12.3&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Raucy2010_12-4"&gt;12.4&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Raucy2010_12-5"&gt;12.5&lt;/a&gt;&lt;/sup&gt; Raucy, J. L., and Lasker, J. M. (2010). Current in vitro high throughput screening approaches to assess nuclear receptor activation. &lt;em&gt;Curr. Drug Metab&lt;/em&gt; &lt;strong&gt;11&lt;/strong&gt; (9), 806-814.&lt;/li&gt;
	&lt;li&gt;&amp;uarr; &lt;sup&gt;&lt;a href="#cite_ref-Farmahin2012_13-0"&gt;13.0&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Farmahin2012_13-1"&gt;13.1&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Farmahin2012_13-2"&gt;13.2&lt;/a&gt;&lt;/sup&gt; Farmahin, R., Wu, D., Crump, D., Herv&amp;eacute;, J. C., Jones, S. P., Hahn, M. E., Karchner, S. I., Giesy, J. P., Bursian, S. J., Zwiernik, M. J., and Kennedy, S. W. (2012). Sequence and in vitro function of chicken, ring-necked pheasant, and Japanese quail AHR1 predict in vivo sensitivity to dioxins. Environ.Sci.Technol. 46, 2967-2975.&lt;/li&gt;
	&lt;li&gt;&amp;uarr; &lt;sup&gt;&lt;a href="#cite_ref-Farmahin2013b_14-0"&gt;14.0&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Farmahin2013b_14-1"&gt;14.1&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Farmahin2013b_14-2"&gt;14.2&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Farmahin2013b_14-3"&gt;14.3&lt;/a&gt;&lt;/sup&gt; Farmahin, R., Manning, G. E., Crump, D., Wu, D., Mundy, L. J., Jones, S. P., Hahn, M. E., Karchner, S. I., Giesy, J. P., Bursian, S. J., Zwiernik, M. J., Fredricks, T. B., and Kennedy, S. W. (2013b). Amino acid sequence of the ligand binding domain of the aryl hydrocarbon receptor 1 (AHR1) predicts sensitivity of wild birds to effects of dioxin-like compounds. Toxicol.Sci. 131, 139-152.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Fujisawa2012_15-0"&gt;&amp;uarr;&lt;/a&gt; Fujisawa, N., Ikenaka, Y., Kim, E. Y., Lee, J. S., Iwata, H., and Ishizuka, M. (2012). Molecular evidence predicts aryl hydrocarbon receptor ligand insensitivity in the peregrine falcon (Falco peregrines). European Journal of Wildlife Research 58, 167-175.&lt;/li&gt;
	&lt;li&gt;&amp;uarr; &lt;sup&gt;&lt;a href="#cite_ref-Manning2012_16-0"&gt;16.0&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Manning2012_16-1"&gt;16.1&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Manning2012_16-2"&gt;16.2&lt;/a&gt;&lt;/sup&gt; Manning, G. E., Farmahin, R., Crump, D., Jones, S. P., Klein, J., Konstantinov, A., Potter, D., and Kennedy, S. W. (2012). A luciferase reporter gene assay and aryl hydrocarbon receptor 1 genotype predict the embryolethality of polychlorinated biphenyls in avian species. Toxicol.Appl.Pharmacol. 263, 390-399.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Mol2012_17-0"&gt;&amp;uarr;&lt;/a&gt; Mol, T. L., Kim, E. Y., Ishibashi, H., and Iwata, H. (2012). In vitro transactivation potencies of black-footed albatross (Phoebastria nigripes) AHR1 and AHR2 by dioxins to predict CYP1A expression in the wild population. Environ.Sci.Technol. 46, 525-533.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Yueh2005_18-0"&gt;&amp;uarr;&lt;/a&gt; Yueh, M. F., Kawahara, M., and Raucy, J. (2005). Cell-based high-throughput bioassays to assess induction and inhibition of CYP1A enzymes. &lt;em&gt;Toxicol. In Vitro&lt;/em&gt; &lt;strong&gt;19&lt;/strong&gt; (2), 275-287.&lt;/li&gt;
	&lt;li&gt;&amp;uarr; &lt;sup&gt;&lt;a href="#cite_ref-Poland1982_19-0"&gt;19.0&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Poland1982_19-1"&gt;19.1&lt;/a&gt;&lt;/sup&gt; Poland, A., and Knutson, J. C. (1982). 2,3,7,8-tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanism of toxicity. &lt;em&gt;Annu. Rev. Pharmacol. Toxicol. &lt;/em&gt; &lt;strong&gt;22&lt;/strong&gt;, 517-554.&lt;/li&gt;
	&lt;li&gt;&amp;uarr; &lt;sup&gt;&lt;a href="#cite_ref-Hesterman2000_20-0"&gt;20.0&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Hesterman2000_20-1"&gt;20.1&lt;/a&gt;&lt;/sup&gt; Hestermann, E. V., Stegeman, J. J., and Hahn, M. E. (2000). Relative contributions of affinity and intrinsic efficacy to aryl hydrocarbon receptor ligand potency. &lt;em&gt;Toxicol. Appl. Pharmacol &lt;/em&gt; &lt;strong&gt;168&lt;/strong&gt; (2), 160-172.&lt;/li&gt;
	&lt;li&gt;&amp;uarr; &lt;sup&gt;&lt;a href="#cite_ref-Farmahin2014_21-0"&gt;21.0&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Farmahin2014_21-1"&gt;21.1&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Farmahin2014_21-2"&gt;21.2&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Farmahin2014_21-3"&gt;21.3&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Farmahin2014_21-4"&gt;21.4&lt;/a&gt;&lt;/sup&gt; Farmahin, R., Jones, S. P., Crump, D., Hahn, M. E., Giesy, J. P., Zwiernik, M. J., Bursian, S. J., and Kennedy, S. W. (2014). Species-specific relative AHR1 binding affinities of 2,3,4,7,8-pentachlorodibenzofuran explain avian species differences in its relative potency. &lt;em&gt;Comp Biochem. Physiol C. Toxicol. Pharmacol.&lt;/em&gt; &lt;strong&gt;161C&lt;/strong&gt;, 21-25.&lt;/li&gt;
	&lt;li&gt;&amp;uarr; &lt;sup&gt;&lt;a href="#cite_ref-Karchner2006_22-0"&gt;22.0&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Karchner2006_22-1"&gt;22.1&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Karchner2006_22-2"&gt;22.2&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Karchner2006_22-3"&gt;22.3&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Karchner2006_22-4"&gt;22.4&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Karchner2006_22-5"&gt;22.5&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Karchner2006_22-6"&gt;22.6&lt;/a&gt;&lt;/sup&gt; Karchner, S. I., Franks, D. G., Kennedy, S. W., and Hahn, M. E. (2006). The molecular basis for differential dioxin sensitivity in birds: Role of the aryl hydrocarbon receptor. &lt;em&gt;Proc. Natl. Acad. Sci. U. S. A&lt;/em&gt; &lt;strong&gt;103&lt;/strong&gt; (16), 6252-6257.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Lee2015_23-0"&gt;&amp;uarr;&lt;/a&gt; Lee, S., Shin, W. H., Hong, S., Kang, H., Jung, D., Yim, U. H., Shim, W. J., Khim, J. S., Seok, C., Giesy, J. P., and Choi, K. (2015). Measured and predicted affinities of binding and relative potencies to activate the AhR of PAHs and their alkylated analogues. &lt;em&gt;Chemosphere&lt;/em&gt; &lt;strong&gt;139&lt;/strong&gt;, 23-29.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Jones2003_24-0"&gt;&amp;uarr;&lt;/a&gt; Jones, S. A., Parks, D. J., and Kliewer, S. A. (2003). Cell-free ligand binding assays for nuclear receptors. &lt;em&gt;Methods Enzymol. &lt;/em&gt; &lt;strong&gt;364&lt;/strong&gt;, 53-71.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Gasiewicz1982_25-0"&gt;&amp;uarr;&lt;/a&gt; Gasiewicz, T. A., and Neal, R. A. (1982). The examination and quantitation of tissue cytosolic receptors for 2,3,7,8-tetrachlorodibenzo-p-dioxin using hydroxylapatite. &lt;em&gt;Anal. Biochem. &lt;/em&gt; &lt;strong&gt;124&lt;/strong&gt; (1), 1-11.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Nakai1995_26-0"&gt;&amp;uarr;&lt;/a&gt; Nakai, J. S., and Bunce, N. J. (1995). Characterization of the Ah receptor from human placental tissue. &lt;em&gt;J Biochem. Toxicol. &lt;/em&gt; &lt;strong&gt;10&lt;/strong&gt; (3), 151-159.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Dold1990_27-0"&gt;&amp;uarr;&lt;/a&gt; Dold, K. M., and Greenlee, W. F. (1990). Filtration assay for quantitation of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) specific binding to whole cells in culture. &lt;em&gt;Anal. Biochem. &lt;/em&gt; &lt;strong&gt;184&lt;/strong&gt; (1), 67-73.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Perez2007_28-0"&gt;&amp;uarr;&lt;/a&gt; Perez-Romero, P., and Imperiale, M. J. (2007). Assaying protein-DNA interactions in vivo and in vitro using chromatin immunoprecipitation and electrophoretic mobility shift assays. &lt;em&gt;Methods Mol. Med. &lt;/em&gt; &lt;strong&gt;131&lt;/strong&gt;, 123-139.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Heid2001_29-0"&gt;&amp;uarr;&lt;/a&gt; Heid, S. E., Walker, M. K., and Swanson, H. I. (2001). Correlation of cardiotoxicity mediated by halogenated aromatic hydrocarbons to aryl hydrocarbon receptor activation. &lt;em&gt;Toxicol. Sci&lt;/em&gt; &lt;strong&gt;61&lt;/strong&gt; (1), 187-196.&lt;/li&gt;
	&lt;li&gt;&amp;uarr; &lt;sup&gt;&lt;a href="#cite_ref-Ema1994_30-0"&gt;30.0&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Ema1994_30-1"&gt;30.1&lt;/a&gt;&lt;/sup&gt; Ema, M., Ohe, N., Suzuki, M., Mimura, J., Sogawa, K., Ikawa, S., and Fujii-Kuriyama, Y. (1994). Dioxin binding activities of polymorphic forms of mouse and human arylhydrocarbon receptors. J.Biol.Chem. 269, 27337-27343.&lt;/li&gt;
	&lt;li&gt;&amp;uarr; &lt;sup&gt;&lt;a href="#cite_ref-Poland1994_31-0"&gt;31.0&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Poland1994_31-1"&gt;31.1&lt;/a&gt;&lt;/sup&gt; Poland, A., Palen, D., and Glover, E. (1994). Analysis of the four alleles of the murine aryl hydrocarbon receptor. Mol.Pharmacol. 46, 915-921.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Backlund2004_32-0"&gt;&amp;uarr;&lt;/a&gt; Backlund, M., and Ingelman-Sundberg, M. (2004). Different structural requirements of the ligand binding domain of the aryl hydrocarbon receptor for high- and low-affinity ligand binding and receptor activation. Mol.Pharmacol. 65, 416-425.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Murray2005_33-0"&gt;&amp;uarr;&lt;/a&gt; Murray, I. A., Reen, R. K., Leathery, N., Ramadoss, P., Bonati, L., Gonzalez, F. J., Peters, J. M., and Perdew, G. H. (2005). Evidence that ligand binding is a key determinant of Ah receptor-mediated transcriptional activity. Arch.Biochem.Biophys. 442, 59-71.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Pandini2007_34-0"&gt;&amp;uarr;&lt;/a&gt; Pandini, A., Denison, M. S., Song, Y., Soshilov, A. A., and Bonati, L. (2007). Structural and functional characterization of the aryl hydrocarbon receptor ligand binding domain by homology modeling and mutational analysis. Biochemistry 46, 696-708.&lt;/li&gt;
	&lt;li&gt;&amp;uarr; &lt;sup&gt;&lt;a href="#cite_ref-Pandini2009_35-0"&gt;35.0&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Pandini2009_35-1"&gt;35.1&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Pandini2009_35-2"&gt;35.2&lt;/a&gt;&lt;/sup&gt; Pandini, A., Soshilov, A. A., Song, Y., Zhao, J., Bonati, L., and Denison, M. S. (2009). Detection of the TCDD binding-fingerprint within the Ah receptor ligand binding domain by structurally driven mutagenesis and functional analysis. Biochemistry 48, 5972-5983.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Ramadoss2004_36-0"&gt;&amp;uarr;&lt;/a&gt; Ramadoss, P., and Perdew, G. H. (2004). Use of 2-azido-3-[125I]iodo-7,8-dibromodibenzo-p-dioxin as a probe to determine the relative ligand affinity of human versus mouse aryl hydrocarbon receptor in cultured cells. Mol.Pharmacol. 66, 129-136.&lt;/li&gt;
	&lt;li&gt;&amp;uarr; &lt;sup&gt;&lt;a href="#cite_ref-Head2008_37-0"&gt;37.0&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Head2008_37-1"&gt;37.1&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Head2008_37-2"&gt;37.2&lt;/a&gt;&lt;/sup&gt; Head, J. A., Hahn, M. E., and Kennedy, S. W. (2008). Key amino acids in the aryl hydrocarbon receptor predict dioxin sensitivity in avian species. &lt;em&gt;Environ.Sci.Technol. &lt;/em&gt; &lt;strong&gt;42&lt;/strong&gt;, 7535-7541.&lt;/li&gt;
	&lt;li&gt;&amp;uarr; &lt;sup&gt;&lt;a href="#cite_ref-Denison2011_38-0"&gt;38.0&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Denison2011_38-1"&gt;38.1&lt;/a&gt;&lt;/sup&gt; Denison, M. S., Soshilov, A. A., He, G., DeGroot, D. E., and Zhao, B. (2011). Exactly the same but different: promiscuity and diversity in the molecular mechanisms of action of the aryl hydrocarbon (dioxin) receptor. &lt;em&gt;Toxicol.Sci.&lt;/em&gt; &lt;strong&gt;124&lt;/strong&gt;, 1-22.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Van1998_39-0"&gt;&amp;uarr;&lt;/a&gt; van den Berg, M., Birnbaum, L. S., Bosveld, A. T., Brunstr&amp;ouml;m, B., Cook, P., Feeley, M., Giesy, J. P., Hanberg, A., Hasegawa, R., Kennedy, S. W., Kubiak, T. J., Larsen, J. C., Van Leeuwen, F. X. R., Liem, A. K. D., Nolt, C., Peterson, R. E., Poellinger, L., Safe, S., Schrenk, D., Tillitt, D. E., Tysklind, M., Younes, M., W&amp;aelig;rn, F., and Zacharewski, T. R. (1998). Toxic equivalency factors (TEFs) for PCBs, PCDDs, PCDFs for humans and wildlife. &lt;em&gt;Environ.Health Perspect&lt;/em&gt;. &lt;strong&gt;106&lt;/strong&gt;, 775-792.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Cohen2011b_40-0"&gt;&amp;uarr;&lt;/a&gt; Cohen-Barnhouse, A. M., Zwiernik, M. J., Link, J. E., Fitzgerald, S. D., Kennedy, S. W., Herv&amp;eacute;, J. C., Giesy, J. P., Wiseman, S. B., Yang, Y., Jones, P. D., Wan, Y., Collins, B., Newsted, J. L., Kay, D. P., and Bursian, S. J. (2011b). Sensitivity of Japanese quail (Coturnix japonica), Common pheasant (Phasianus colchicus), and White Leghorn chicken (Gallus gallus domesticus) embryos to in ovo exposure to TCDD, PeCDF, and TCDF. &lt;em&gt;Toxicol.Sci.&lt;/em&gt; &lt;strong&gt;119&lt;/strong&gt;, 93-103.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Farmahin2013a_41-0"&gt;&amp;uarr;&lt;/a&gt; Farmahin, R., Crump, D., Jones, S. P., Mundy, L. J., and Kennedy, S. W. (2013a). Cytochrome P4501A induction in primary cultures of embryonic European starling hepatocytes exposed to TCDD, PeCDF and TCDF. &lt;em&gt;Ecotoxicology&lt;/em&gt; &lt;strong&gt;22&lt;/strong&gt;(4), 731-739.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Herve2010a_42-0"&gt;&amp;uarr;&lt;/a&gt; Herv&amp;eacute;, J. C., Crump, D., Jones, S. P., Mundy, L. J., Giesy, J. P., Zwiernik, M. J., Bursian, S. J., Jones, P. D., Wiseman, S. B., Wan, Y., and Kennedy, S. W. (2010a). Cytochrome P4501A induction by 2,3,7,8-tetrachlorodibenzo-p-dioxin and two chlorinated dibenzofurans in primary hepatocyte cultures of three avian species. &lt;em&gt;Toxicol. Sci.&lt;/em&gt; &lt;strong&gt;113&lt;/strong&gt;(2), 380-391.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Herve2010b_43-0"&gt;&amp;uarr;&lt;/a&gt; Herv&amp;eacute;, J. C., Crump, D. L., McLaren, K. K., Giesy, J. P., Zwiernik, M. J., Bursian, S. J., and Kennedy, S. W. (2010b). 2,3,4,7,8-pentachlorodibenzofuran is a more potent cytochrome P4501A inducer than 2,3,7,8-tetrachlorodibenzo-p-dioxin in herring gull hepatocyte cultures. &lt;em&gt;Environ. Toxicol. Chem.&lt;/em&gt; &lt;strong&gt;29&lt;/strong&gt;(9), 2088-2095.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Poland1973_44-0"&gt;&amp;uarr;&lt;/a&gt; Poland, A., and Glover, E. (1973). Studies on the mechanism of toxicity of the chlorinated dibenzo-p-dioxins. &lt;em&gt;Environ.Health Perspect&lt;/em&gt;. &lt;strong&gt;5&lt;/strong&gt;, 245-251.&lt;/li&gt;
	&lt;li&gt;&amp;uarr; &lt;sup&gt;&lt;a href="#cite_ref-McFarland1989_45-0"&gt;45.0&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-McFarland1989_45-1"&gt;45.1&lt;/a&gt;&lt;/sup&gt; McFarland, V. A., and Clarke, J. U. (1989). Environmental occurrence, abundance, and potential toxicity of polychlorinated biphenyl congeners: Considerations for a congener-specific analysis. &lt;em&gt;Environ.Health Perspect&lt;/em&gt;. &lt;strong&gt;81&lt;/strong&gt;, 225-239.&lt;/li&gt;
	&lt;li&gt;&amp;uarr; &lt;sup&gt;&lt;a href="#cite_ref-Omie2011_46-0"&gt;46.0&lt;/a&gt;&lt;/sup&gt; &lt;sup&gt;&lt;a href="#cite_ref-Omie2011_46-1"&gt;46.1&lt;/a&gt;&lt;/sup&gt; Omiecinski, C. J., Vanden Heuvel, J. P., Perdew, G. H., and Peters, J. M. (2011). Xenobiotic metabolism, disposition, and regulation by receptors: from biochemical phenomenon to predictors of major toxicities. &lt;em&gt;Toxicol.Sci.&lt;/em&gt; &lt;strong&gt;120&lt;/strong&gt; Suppl 1, S49-S75.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Swed2010_47-0"&gt;&amp;uarr;&lt;/a&gt; Swedenborg, E., and Pongratz, I. (2010). AhR and ARNT modulate ER signaling. &lt;em&gt;Toxicology&lt;/em&gt; &lt;strong&gt;268&lt;/strong&gt;, 132-138.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Diani2011_48-0"&gt;&amp;uarr;&lt;/a&gt; Diani-Moore, S., Ma, Y., Labitzke, E., Tao, H., David, W. J., Anderson, J., Chen, Q., Gross, S. S., and Rifkind, A. B. (2011). Discovery and biological characterization of 1-(1H-indol-3-yl)-9H-pyrido[3,4-b]indole as an aryl hydrocarbon receptor activator generated by photoactivation of tryptophan by sunlight. &lt;em&gt;Chem. Biol. Interact.&lt;/em&gt; &lt;strong&gt;193&lt;/strong&gt;(2), 119-128.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Wincent2012_49-0"&gt;&amp;uarr;&lt;/a&gt; Wincent, E., Bengtsson, J., Mohammadi, B. A., Alsberg, T., Luecke, S., Rannug, U., and Rannug, A. (2012). Inhibition of cytochrome P4501-dependent clearance of the endogenous agonist FICZ as a mechanism for activation of the aryl hydrocarbon receptor. &lt;em&gt;Proc. Natl. Acad. Sci. U. S. A&lt;/em&gt; &lt;strong&gt;109&lt;/strong&gt;(12), 4479-4484.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Baba2005_50-0"&gt;&amp;uarr;&lt;/a&gt; Baba, T., Mimura, J., Nakamura, N., Harada, N., Yamamoto, M., Morohashi, K., and Fujii-Kuriyama, Y. (2005). Intrinsic function of the aryl hydrocarbon (dioxin) receptor as a key factor in female reproduction. &lt;em&gt;Mol.Cell Biol&lt;/em&gt;. &lt;strong&gt;25&lt;/strong&gt;, 10040-10051.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Fernandez1995_51-0"&gt;&amp;uarr;&lt;/a&gt; Fernandez-Salguero, P. M., Pineau, T., Hilbert, D. M., McPhail, T., Lee, S. S., Kimura, S., Nebert, D. W., Rudikoff, S., Ward, J. M., and Gonzalez, F. J. (1995). Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. &lt;em&gt;Science&lt;/em&gt; &lt;strong&gt;268&lt;/strong&gt;, 722-726.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Ichihara2007_52-0"&gt;&amp;uarr;&lt;/a&gt; Ichihara, S., Yamada, Y., Ichihara, G., Nakajima, T., Li, P., Kondo, T., Gonzalez, F. J., and Murohara, T. (2007). A role for the aryl hydrocarbon receptor in regulation of ischemia-induced angiogenesis. &lt;em&gt;Arterioscler.Thromb.Vasc.Biol&lt;/em&gt;. &lt;strong&gt;27&lt;/strong&gt;, 1297-1304.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Lahvis2000_53-0"&gt;&amp;uarr;&lt;/a&gt; Lahvis, G. P., Lindell, S. L., Thomas, R. S., McCuskey, R. S., Murphy, C., Glover, E., Bentz, M., Southard, J., and Bradfield, C. A. (2000). Portosystemic shunting and persistent fetal vascular structures in aryl hydrocarbon receptor-deficient mice. &lt;em&gt;Proc.Natl.Acad.Sci U.S.A&lt;/em&gt; &lt;strong&gt;97&lt;/strong&gt;, 10442-10447.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Mimura1997_54-0"&gt;&amp;uarr;&lt;/a&gt; Mimura, J., Yamashita, K., Nakamura, K., Morita, M., Takagi, T. N., Nakao, K., Ema, M., Sogawa, K., Yasuda, M., Katsuki, M., and Fujii-Kuriyama, Y. (1997). Loss of teratogenic response to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice lacking the Ah (dioxin) receptor. &lt;em&gt;Genes Cells&lt;/em&gt; &lt;strong&gt;2&lt;/strong&gt;, 645-654.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Schmidt1996_55-0"&gt;&amp;uarr;&lt;/a&gt; Schmidt, J. V., Su, G. H., Reddy, J. K., Simon, M. C., and Bradfield, C. A. (1996). Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. &lt;em&gt;Proc.Natl.Acad.Sci U.S.A&lt;/em&gt; &lt;strong&gt;93&lt;/strong&gt;, 6731-6736.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Thack2002_56-0"&gt;&amp;uarr;&lt;/a&gt; Thackaberry, E. A., Gabaldon, D. M., Walker, M. K., and Smith, S. M. (2002). Aryl hydrocarbon receptor null mice develop cardiac hypertrophy and increased hypoxia-inducible factor-1alpha in the absence of cardiac hypoxia. &lt;em&gt;Cardiovasc.Toxicol.&lt;/em&gt; &lt;strong&gt;2&lt;/strong&gt;, 263-274.&lt;/li&gt;
	&lt;li&gt;&lt;a href="#cite_ref-Zhang2010_57-0"&gt;&amp;uarr;&lt;/a&gt; Zhang, N., Agbor, L. N., Scott, J. A., Zalobowski, T., Elased, K. M., Trujillo, A., Duke, M. S., Wolf, V., Walsh, M. T., Born, J. L., Felton, L. A., Wang, J., Wang, W., Kanagy, N. L., and Walker, M. K. (2010). An activated renin-angiotensin system maintains normal blood pressure in aryl hydrocarbon receptor heterozygous mice but not in null mice. &lt;em&gt;Biochem.Pharmacol.&lt;/em&gt; &lt;strong&gt;80&lt;/strong&gt;, 197-2040.&lt;/li&gt;
&lt;/ol&gt;

&lt;p&gt;Abnet, C.C.; Tanguay, R.L.; Heideman, W.; Peterson, R.E. 1999. Transactivation activity of human, zebrafish, and rainbow trout aryl hydrocarbon receptors expressed in COS-7 cells: Greater insight into species differences in toxic potency of polychlorinated dibenzo-p-dioxin, dibenzofuran, and biphenyl congeners. Toxicol. Appl. Pharmacol&lt;em&gt;.&lt;/em&gt; 159, 41-51.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Andreasen, E.A.; Tanguay, R.L.; Peterson, R.E.; Heideman, W. 2002. Identification of a critical amino acid in the aryl hydrocarbon receptor. J. Biol. Chem. 277 (15), 13210-13218.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Bak, S.M.; Lida, M.; Hirano, M.; Iwata, H.; Kim, E.Y. 2013. Potencies of red seabream AHR1- and AHR2-mediated transactivation by dioxins: implications of both AHRs in dioxin toxicity. Environ. Sci. Technol. 47 (6), 2877-2885.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Clark, B.W.; Matson, C.W.; Jung, D.; Di Giulio, R.T. 2010. AHR2 mediates cardiac teratogenesis of polycyclic aromatic hydrocarbons and PCB-126 in Atlantic killifish (&lt;em&gt;Fundulus heteroclitus&lt;/em&gt;). Aquat. Toxicol. 99, 232-240.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Doering, J.A.; Farmahin, R.; Wiseman, S.; Beitel, S.C.; Kennedy, S.W.; Giesy, J.P.; Hecker, M. 2015. Differences in activation of aryl hydrocarbon receptors of white sturgeon relative to lake sturgeon are predicted by identities of key amino acids in the ligand binding domain. Enviro. Sci. Technol. 49, 4681-4689.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Doering, J.A.; Farmahin, R.; Wiseman, S.; Kennedy, S.; Giesy J.P.; Hecker, M. 2014. Functionality of aryl hydrocarbon receptors (AhR1 and AhR2) of white sturgeon (Acipenser transmontanus) and implications for the risk assessment of dioxin-like compounds. Enviro. Sci. Technol. 48, 8219-8226.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Doering, J.A.; Giesy, J.P.; Wiseman, S.; Hecker, M. Predicting the sensitivity of fishes to dioxin-like compounds: possible role of the aryl hydrocarbon receptor (AhR) ligand binding domain. &lt;em&gt;Environ. Sci. Pollut. Res. Int.&lt;/em&gt; &lt;strong&gt;2013&lt;/strong&gt;, 20(3), 1219-1224.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Doering, J.A.; Wiseman, S; Beitel, S.C.; Giesy, J.P.; Hecker, M. 2014. Identification and expression of aryl hydrocarbon receptors (AhR1 and AhR2) provide insight in an evolutionary context regarding sensitivity of white sturgeon (&lt;em&gt;Acipenser transmontanus&lt;/em&gt;) to dioxin-like compounds. Aquat. Toxicol. 150, 27-35.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Duncan, D.M.; Burgess, E.A.; Duncan, I. 1998. Control of distal antennal identity and tarsal development in Drosophila by spineless-aristapedia, a homolog of the mammalian dioxin receptor. Genes Dev. 12, 1290-1303.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Eisner, B.K.; Doering, J.A.; Beitel, S.C.; Wiseman, S.; Raine, J.C.; Hecker, M. 2016. Cross-species comparison of relative potencies and relative sensitivities of fishes to dibenzo-p-dioxins, dibenzofurans, and polychlorinated biphenyls in vitro. Enviro. Toxicol. Chem. 35 (1), 173-181.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Emmons, R.B.; Duncan, D.; Estes, P.A.; Kiefel, P.; Mosher, J.T.; Sonnenfeld, M.; Ward, M.P.; Duncan, I.; Crews, S.T. 1999. The spineless-aristapedia and tango bHLH-PAS proteins interact to control antennal and tarsal development in Drosophila. Development. 126, 3937-3945.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Evans, B.R.; Karchner, S.I.; Franks, D.G.; Hahn, M.E. 2005. Duplicate aryl hydrocarbon receptor repressor genes (ahrr1 and ahrr2) in the zebrafish &lt;em&gt;Danio rerio&lt;/em&gt;: structure, function, evolution, and AHR-dependent regulation &lt;em&gt;in vivo&lt;/em&gt;. Arch. Biochem. Biophys. 441, 151-167.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Hahn, M.E. 2002. Aryl hydrocarbon receptors: diversity and evolution. Chemico-Biol. Interact. 141, 131-160.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Hahn, M.E.; Karchner, S.I.; Evans, B.R.; Franks, D.G.; Merson, R.R.; Lapseritis, J.M. 2006. Unexpected diversity of aryl hydrocarbon receptors in non-mammalian vertebrates: Insights from comparative genomics. J. Exp. Zool. A. Comp. Exp. Biol. 305, 693-706.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Hahn, M.E.; Poland, A.; Glover, E.; Stegeman, J.J. 1994. Photoaffinity labeling of the Ah receptor: phylogenetic survey of diverse vertebrate and invertebrate species. Arch. Biochem. Biophys. 310, 218-228.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Hansson, M.C.; Hahn, M.E. 2008. Functional properties of the four Atlantic salmon (&lt;em&gt;Salmo salar&lt;/em&gt;) aryl hydrocarbon receptor type 2 (AHR2) isoforms. Aquat. Toxicol. 86, 121-130.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Hansson, M.C.; Wittzell, H.; Persson, K.; von Schantz, T. 2004. Unprecedented genomic diversity of AhR1 and AhR2 genes in Atlantic salmon (&lt;em&gt;Salmo salar &lt;/em&gt;L.). Aquat. Toxicol. 68 (3), 219-232.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Karchner, S.I.; Franks, D.G.; Hahn, M.E. (2005). AHR1B, a new functional aryl hydrocarbon receptor in zebrafish: tandem arrangement of ahr1b and ahr2 genes. Biochem. J. 392 (1), 153-161.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Karchner, S.I.; Powell, W.H.; Hahn, M.E. 1999. Identification and functional characterization of two highly divergent aryl hydrocarbon receptors (AHR1 and AHR2) in the Teleost &lt;em&gt;Fundulus heteroclitus&lt;/em&gt;. Evidence for a novel subfamily of ligand-binding basic helix loop helix-Per-ARNT-Sim (bHLH-PAS) factors. J. Biol. Chem. 274, 33814-33824.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Lahvis, G.P.; Bradfield, C.A. 1998. Ahr null alleles: distinctive or different? Biochem. Pharmacol. 56, 781-787.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Lavine, J.A.; Rowatt, A.J.; Klimova, T.; Whitington, A.J.; Dengler, E.; Beck, C.; Powell, W.H. 2005. Aryl hydrocarbon receptors in the frog Xenopus laevis: two AhR1 paralogs exhibit low affinity for 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Toxicol. Sci. 88 (1), 60-72.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Oka, K.; Kohno, S.; Ohta, Y.; Guillette, L.J.; Iguchi, T.; Katsu, Y. (2016). Molecular cloning and characterization of the aryl hydrocarbon receptors and aryl hydrocarbon receptor nuclear translocators in the American alligator. Gen. Comp. Endo. 238, 13-22.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Pongratz, I.; Mason, G.G.; Poellinger, L. Dual roles of the 90-kDa heat shock protein hsp90 in modulating functional activities of the dioxin receptor. Evidence that the dioxin receptor functionally belongs to a subclass of nuclear receptors which require hsp90 both for ligand binding activity and repression of intrinsic DNA binding activity. J. Biol. Chem. 1992, 267 (19), 13728-13734&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Prasch, A.L.; Teraoka, H.; Carney, S.A.; Dong, W.; Hiraga, T.; Stegeman, J.J.; Heideman, W.; Peterson, R.E. 2003. Toxicol. Sci. Aryl hydrocarbon receptor 2 mediated 2,3,7,8-tetrachlorodibenzo-&lt;em&gt;p&lt;/em&gt;-dioxin developmental toxicity in zebrafish. 76 (1), 138-150.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Shoots, J.; Fraccalvieri, D.; Franks, D.G.; Denison, M.S.; Hahn, M.E.; Bonati, L.; Powell, W.H. 2015. An aryl hydrocarbon receptor from the salamander Ambystoma mexicanum exhibits low sensitivity to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Enviro. Sci. Technol&lt;em&gt;. &lt;/em&gt;49, 6993-7001.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Tanguay, R.L.; Abnet, C.C.; Heideman, W. Peterson, R.E. (1999). Cloning and characterization of the zebrafish (Danio rerio) aryl hydrocarbon receptor1. Biochimica et Biophysica Act 1444, 35-48.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Van den Berg, M.; Birnbaum, L.; Bosveld, A.T.C.; Brunstrom, B.; Cook, P.; Feeley, M.; Giesy, J.P.; Hanberg, A.; Hasegawa, R.; Kennedy, S.W.; Kubiak, T.; Larsen, J.C.; van Leeuwen, R.X.R.; Liem, A.K.D.; Nolt, C.; Peterson, R.E.; Poellinger, L.; Safe, S.; Schrenk, D.; Tillitt, D.; Tysklind, M.; Younes, M.; Waern, F.; Zacharewski, T. Toxic equivalency factors (TEFs) for PCBs, PCDDs, PECDFs for human and wildlife. Enviro. Hlth. Persp. &lt;strong&gt;1998&lt;/strong&gt;, 106, 775-792.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Van Tiem, L.A.; Di Giulio, R.T. 2011. AHR2 knockdown prevents PAH-mediated cardiac toxicity and XRE- and ARE-associated gene induction in zebrafish (&lt;em&gt;Danio rerio&lt;/em&gt;). Toxicol. Appl. Pharmacol. 254 (3), 280-287.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Whitlock, J.P.; Okino, S.T.; Dong, L.Q.; Ko, H.S.P.; Clarke Katzenberg, R.; Qiang, M.; Li, W. 1996. Induction of cytochrome P4501A1: a model for analyzing mammalian gene transcription. Faseb. J. 10, 809-818.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Wirgin, I.; Roy, N.K.; Loftus, M.; Chambers, R.C.; Franks, D.G.; Hahn, M.E. 2011. Mechanistic basis of resistance to PCBs in Atlantic tomcod from the Hudson River. Science. 331, 1322-1324.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Yamauchi, M.; Kim, E.Y.; Iwata, H.; Shima, Y.; Tanabe, S. Toxic effects of 2,3,7,8-tetrachlorodibenzo-&lt;em&gt;p&lt;/em&gt;-dioxin (TCDD) in developing red seabream (&lt;em&gt;Pagrus major&lt;/em&gt;) embryos: an association of morphological deformities with AHR1, AHR2 and CYP1A expressions. &lt;em&gt;Aquat. Toxicol.&lt;/em&gt; &lt;strong&gt;2006&lt;/strong&gt;, 16, 166-179.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Yasui, T.; Kim, E.Y.; Iawata, H.; Franks, D.G.; Karchner, S.I.; Hahn, M.E.; Tanabe, S. 2007. Functional characterization and evolutionary history of two aryl hydrocarbon receptor isoforms (AhR1 and AhR2) from avian species. Toxicol. Sci. 99 (1), 101-117.&lt;/p&gt;

&lt;div&gt;Hirano, M.; Hwang, JH; Park, HJ; Bak, SM; Iwata, H. and Kim, EY (2015) In Silico Analysis of the Interaction of Avian Aryl Hydrocarbon Receptors and Dioxins to Decipher Isoform-, Ligand-, and Species-Specific Activations.&lt;cite&gt; Environmental Science &amp;amp; Technology&lt;/cite&gt; &lt;strong&gt;49 &lt;/strong&gt;(6): 3795-3804.DOI: 10.1021/es505733f&lt;/div&gt;

&lt;div&gt;&amp;nbsp;&lt;/div&gt;

&lt;p&gt;Bonati, L.; Corrada, D.; Tagliabue, S.G.; Motta, S. (2017) Molecular modeling of the AhR structure and interactions can shed light on ligand-dependent activation and transformation mechanisms. &lt;em&gt;Current Opinion in Toxicology &lt;/em&gt;&lt;strong&gt;2&lt;/strong&gt;: 42-49. https://doi.org/10.1016/j.cotox.2017.01.011.&lt;/p&gt;

&lt;p&gt;Sovadinov&amp;aacute;, I. , Bl&amp;aacute;ha, L. , Jano&amp;scaron;ek, J. , Hilscherov&amp;aacute;, K. , Giesy, J. P., Jones, P. D. and Holoubek, I. (2006), Cytotoxicity and aryl hydrocarbon receptor‐mediated activity of N‐heterocyclic polycyclic aromatic hydrocarbons: Structure‐activity relationships. &lt;em&gt;Environmental Toxicology and Chemistry&lt;/em&gt;, &lt;strong&gt;25&lt;/strong&gt;: 1291-1297. doi:&lt;a href="https://doi.org/10.1897/05-388R.1"&gt;10.1897/05-388R.1&lt;/a&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Wakx A, Nedder M, Tomkiewicz-Raulet C, Dalmasso J, Chissey A, et al. 2018. Expression,&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Localization, and Activity of the Aryl Hydrocarbon Receptor in the Human Placenta. Int J Mol Sci. 19(12)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Ema M, Ohe N, Suzuki M, Mimura J, Sogawa K, et al. 1994. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Dioxin binding activities of polymorphic forms of mouse and human arylhydrocarbon receptors.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Kall MA, Vang O, Clausen J. 1996. Effects of dietary broccoli on human in vivo drug metabolizing enzymes:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;evaluation of caffeine, oestrone and chlorzoxazone metabolism. Carcinogenesis. 17(4):793&amp;ndash;99&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Miller CA. 1997. Expression of the human aryl hydrocarbon receptor complex in yeast. Activation of transcription by indole compounds. J. Biol. Chem. 272(52):32824&amp;ndash;29&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, et al. 2011. An endogenous tumour promoting ligand of the human aryl hydrocarbon receptor. Nature. 478(7368):197&amp;ndash;203&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Adachi J, Mori Y, Matsui S, Takigami H, Fujino J, et al. 2001. Indirubin and indigo are potent aryl hydrocarbon receptor ligands present in human urine. J. Biol. Chem. 276(34):31475&amp;ndash;78&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Marinelli L, Martin-Gallausiaux C, Bourhis J-M, B.guet-Crespel F, Blotti.re HM, Lapaque N. 2019. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Identification of the novel role of butyrate as AhR ligand in human intestinal epithelial cells. Sci&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Rep. 9(1):643&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Stobbe-Maicherski N, Wolff S, Wolff C, Abel J, Sydlik U, et al. 2013. The interleukin-6-type cytokine oncostatin M induces aryl hydrocarbon receptor expression in a STAT3-dependent manner in human HepG2 hepatoma cells. FEBS J. 280(24):6681&amp;ndash;90&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Kado S, Chang WLW, Chi AN, Wolny M, Shepherd DM, Vogel CFA. 2017. Aryl hydrocarbon receptor signaling modifies Toll-like receptor-regulated responses in human dendritic cells. Arch Toxicol. 91(5):2209&amp;ndash;21&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Bock KW. 2019. Human AHR functions in vascular tissue: Pro- and anti-inflammatory responses of AHR agonists in atherosclerosis. Biochem Pharmacol. 159:116&amp;ndash;20&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Schroeder JC, Dinatale BC, Murray IA, Flaveny CA, Liu Q, et al. 2010. The uremic toxin 3- indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. Biochemistry. 49(2):393&amp;ndash;400&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Watanabe I, Tatebe J, Namba S, Koizumi M, Yamazaki J, Morita T. 2013. Activation of aryl hydrocarbon receptor mediates indoxyl sulfate-induced monocyte chemoattractant protein-1 expression in human umbilical vein endothelial cells. Circ J. 77(1):224&amp;ndash;30&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Shackleford G, Sampathkumar NK, Hichor M, Weill L, Meffre D, et al. 2018. Involvement of Aryl hydrocarbon receptor in myelination and in human nerve sheath tumorigenesis. Proc Natl Acad Sci U S 115(6):E1319&amp;ndash;28&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Zudaire E, Cuesta N, Murty V, Woodson K, Adams L, et al. 2008. The aryl hydrocarbon receptor repressor is a putative tumor suppressor gene in multiple human cancers. J Clin Invest. 118(2):640&amp;ndash;50&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Goode GD, Ballard BR, Manning HC, Freeman ML, Kang Y, Eltom SE. 2013. Knockdown of aberrantly upregulated aryl hydrocarbon receptor reduces tumor growth and metastasis of MDA-MB- 231 human breast cancer cell line. Int J Cancer. 133(12):2769&amp;ndash;80&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Chang JT, Chang H, Chen P-H, Lin S-L, Lin P. 2007. Requirement of aryl hydrocarbon receptor overexpression for CYP1B1 up-regulation and cell growth in human lung adenocarcinomas. Clin Cancer&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Res. 13(1):38&amp;ndash;45&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Kanno Y, Takane Y, Izawa T, Nakahama T, Inouye Y. 2006. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;The inhibitory effect of aryl hydrocarbon receptor repressor (AhRR) on the growth of human breast cancer MCF-7 cells. Biol Pharm Bull. 29(6):1254&amp;ndash;57&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Goode G, Pratap S, Eltom SE. 2014. Depletion of the aryl hydrocarbon receptor in MDA-MB- 231 human breast cancer cells altered the expression of genes in key regulatory pathways of cancer. PLoS One. 9(6):e100103&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Opitz CA, Litzenburger UM, Sahm F, Ott M, Tritschler I, et al. 2011. An endogenous tumour promoting ligand of the human aryl hydrocarbon receptor. Nature. 478(7368):197&amp;ndash;203&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Novikov O, Wang Z, Stanford EA, Parks AJ, Ramirez-Cardenas A, et al. 2016. An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer Cells. Mol Pharmacol. 90(5):674&amp;ndash;88&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Litzenburger UM, Opitz CA, Sahm F, Rauschenbach KJ, Trump S, et al. 2014. Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget. 5(4):1038&amp;ndash;51&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Hall JM, Barhoover MA, Kazmin D, McDonnell DP, Greenlee WF, Thomas RS. 2010. Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation. Mol Endocrinol. 24(2):359&amp;ndash;69&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Gramatzki D, Pantazis G, Schittenhelm J, Tabatabai G, K.hle C, et al. 2009. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells. Oncogene. 28(28):2593&amp;ndash;2605&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Subramaniam V, Ace O, Prud&amp;rsquo;homme GJ, Jothy S. 2011. Tranilast treatment decreases cell growth, migration and inhibits colony formation of human breast cancer cells. Exp Mol Pathol. 90(1):116&amp;ndash;22&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Rothhammer V, Borucki DM, Kenison JE, Hewson P, Wang Z, et al. 2018. Detection of aryl hydrocarbon receptor agonists in human samples. Sci Rep. 8(1):4970&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Lin P, Chang H, Tsai W-T, Wu M-H, Liao Y-S, et al. 2003. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Overexpression of aryl hydrocarbon receptor in human lung carcinomas. Toxicol Pathol. 31(1):22&amp;ndash;30&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Barhoover MA, Hall JM, Greenlee WF, Thomas RS. 2010. Aryl hydrocarbon receptor regulates cell cycle progression in human breast cancer cells via a functional interaction with cyclin-dependent kinase 4. Mol Pharmacol. 77(2):195&amp;ndash;201&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Wang K, Li Y, Jiang Y-Z, Dai C-F, Patankar MS, et al. 2013. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;An endogenous aryl hydrocarbon receptor ligand inhibits proliferation and migration of human ovarian cancer cells. Cancer Lett. 340(1):63&amp;ndash;71&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Aptos,sans-serif"&gt;&lt;span style="font-size:10.0pt"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;Borovok N, Weiss C, Sharkia R, Reichenstein M, Wissinger B, et al. 2020. Gene and Protein Expression in Subjects With a Nystagmus-Associated AHR Mutation. Front Genet. 11:582796&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;&lt;span style="font-size:14px"&gt;Harper PA, Riddick DS, Okey AB. Regulating the regulator: factors that control levels and activity of the aryl hydrocarbon receptor. Biochem Pharmacol. 2006;72(3):267-79.&lt;/span&gt;&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;&lt;span style="font-size:14px"&gt;Wright EJ, De Castro KP, Joshi AD, Elferink CJ. Canonical and non-canonical aryl hydrocarbon receptor signaling pathways. Curr Opin Toxicol. 2017;2:87-92.&lt;/span&gt;&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&lt;em&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;&lt;span style="font-size:14px"&gt;Hern&amp;aacute;ndez-Ochoa I, Karman BN, Flaws JA. The role of the aryl hydrocarbon receptor in the female reproductive system. Biochem Pharmacol. 2009;77(4):547-59.&lt;/span&gt;&lt;/span&gt;&lt;/em&gt;&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;&lt;br /&gt;
&amp;nbsp;&lt;/p&gt;
</references>
    <source>AOPWiki</source>
    <creation-timestamp>2016-11-29T18:41:22</creation-timestamp>
    <last-modification-timestamp>2025-05-31T07:56:20</last-modification-timestamp>
  </key-event>
  <key-event id="677c3fa3-ea71-44fd-bd59-6740716305fb">
    <title>increase, Preeclampsia</title>
    <short-name>increase, Preeclampsia</short-name>
    <biological-organization-level>Individual</biological-organization-level>
    <description></description>
    <measurement-methodology></measurement-methodology>
    <evidence-supporting-taxonomic-applicability></evidence-supporting-taxonomic-applicability>
    <applicability>
    </applicability>
    <references></references>
    <source>AOPWiki</source>
    <creation-timestamp>2021-05-31T10:58:27</creation-timestamp>
    <last-modification-timestamp>2021-05-31T10:58:27</last-modification-timestamp>
  </key-event>
  <key-event id="42b06a4d-5fe7-4f2b-8e56-047be78a1a2a">
    <title>Increase, COX-2 expression</title>
    <short-name>Increase, COX-2 expression</short-name>
    <biological-organization-level>Molecular</biological-organization-level>
    <description>&lt;p&gt;&lt;strong&gt;COX Pathway:&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;&lt;a href="https://aopwiki.org/system/dragonfly/production/2017/05/08/7vmvnr8r73_COX_pathway.pdf"&gt;https://aopwiki.org/system/dragonfly/production/2017/05/08/7vmvnr8r73_COX_pathway.pdf&lt;/a&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Prostaglandin-endoperoxide synthase (PTGS; KEGG ID E.C. 1.14.99.1) is an enzyme that has two catalytic sites.&lt;/li&gt;
	&lt;li&gt;Cyclooxygenase site (COX) catalyzes conversion of arachidonic acid into endoperoxide prostaglandin G2 (&lt;a href="https://aopwiki.org/wiki/index.php?title=Simmons_et_al.,_2004&amp;amp;action=edit&amp;amp;redlink=1" title="Simmons et al., 2004 (page does not exist)"&gt;Simmons et al 2004&lt;/a&gt;).&lt;/li&gt;
	&lt;li&gt;Peroxidase active site converts PGG2 to PGH2 (KEGG reactions 1599, 1590). PGH2 is a precursor for synthesis of other prostaglandins (PGEs, PGFs), prostacyclin, and thromboxanes (Simmons et al 2004; Botting &amp;amp; Botting 2011).&lt;/li&gt;
	&lt;li&gt;There are two isoforms, COX-1 and COX-2&lt;/li&gt;
	&lt;li&gt;COX-2 is inducible by certain chemical exposures, inflammation, during discrete stages of gamete maturation, and more (Green et al 2012).&lt;/li&gt;
	&lt;li&gt;However, COX biology is complex and important details of the pathway remain unknown (Grosser 2006).&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;COX Cardiovascular Roles:&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Prostaglandins which are catalyzed by COX and have roles in cellular homeostasis and in promoting inflammatory responses (Chien et al 2015; Smith et al 2000; Tilley et al 2001; Vane et al 1994).&lt;/li&gt;
	&lt;li&gt;Significant&amp;nbsp;evidence suggests a link between COX-2 mediated inflammatory responses and progression of alterations in&amp;nbsp;cardiovascular development and function in murine&amp;nbsp;models, humans, and zebrafish (&lt;em&gt;Danio rerio&lt;/em&gt;)&amp;nbsp;(Delgado et al 2004; Gullestad &amp;amp; Aukrust 2005; Hocherl et al 2002; Huang et al 2007; Wong et al 1998 ).&lt;/li&gt;
	&lt;li&gt;However, the precise mechanism by which prostaglandins produce alterations in cardiovascular development have not been clearly elucidated (Hocherl &amp;amp; Dreher 2002).&lt;/li&gt;
&lt;/ul&gt;
</description>
    <measurement-methodology>&lt;ul&gt;
	&lt;li&gt;COX-2 can be&amp;nbsp;measured as abundance of transcript by use of quantitative real-time polymerase chain reaction (q-RT PCR). Transcript abundance of COX-2 has been measured in whole embryos of fishes (Dong et al 2010; Huang et al 2007; Teraoka et al 2008; 2014) and&amp;nbsp;embryonic hepatic and&amp;nbsp;cardiac tissue of birds (Fujisawa et al 2014).&lt;/li&gt;
	&lt;li&gt;COX-2 could be measured by use of ELISA or Western Blot, but commercial kits are not currently available for fishes or birds.&lt;/li&gt;
&lt;/ul&gt;
</measurement-methodology>
    <evidence-supporting-taxonomic-applicability>&lt;p&gt;&lt;strong&gt;COX-2 Structure and Function:&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;There is a high level of conservation of COX-2, as well as its function, especially across vertebrates (Havird et al 2008; 2015), indicating that numerous vertebrate taxa might be susceptible to up-regulation in COX-2.&lt;/li&gt;
	&lt;li&gt;Typically, teleost fish genomes contain more than one COX-2 gene, likely a result of genome duplication after divergence of teleosts from tetrapods (Ishikawa et al 2007; Havird et al 2015). In zebrafish there are two isoforms,&amp;nbsp;COX-2a and COX-2b (Teraoka et al 2014).&lt;/li&gt;
	&lt;li&gt;In invertebrates, COX is found in most crustaceans, the majority of molluscs, but only in specific lineages within Cnidaria and Annelida. COX genes are not found in Hemichordata, Echinodermata, or Platyhelminthes. Insecta COX genes lack in homology, but might function as COX enzymes based on structural analyses (Havird et al 2015).&lt;/li&gt;
&lt;/ul&gt;
</evidence-supporting-taxonomic-applicability>
    <cell-term>
      <source-id>CL:0000255</source-id>
      <source>CL</source>
      <name>eukaryotic cell</name>
    </cell-term>
    <applicability>
      <sex>
        <evidence>High</evidence>
        <sex>Unspecific</sex>
      </sex>
      <life-stage>
        <evidence>High</evidence>
        <life-stage>Embryo</life-stage>
      </life-stage>
      <taxonomy taxonomy-id="cfd455a8-25ff-4287-9ff1-c9f6c99224c5">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="40a96606-3ba7-4743-a401-22460d1b3c4b">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="109ce903-310c-4030-80f5-fc444247f435">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="ba982cc1-0376-4470-bed3-29bba8aceec4">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="b8753f15-9ab7-4425-9f65-b67236d6993f">
        <evidence>Moderate</evidence>
      </taxonomy>
    </applicability>
    <biological-events>
      <biological-event object-id="ba198f4b-e042-407e-855c-f8842dbe1afd" process-id="2a9e9810-90f5-4a87-beee-31a21d9535dc" action-id="858bfb7f-1f52-4390-9d28-4ea657198347"/>
    </biological-events>
    <references>&lt;p&gt;Bacchi, S., Palumbo, P., Sponta, A., &amp;amp; Coppolino, M. F. (2012). Clinical pharmacology of non-steroidal anti-inflammatory drugs: a review. Anti-Inflammatory &amp;amp; Anti-Allergy Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Inflammatory and Anti-Allergy Agents), 11(1), 52-64.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Botting, R. M., &amp;amp; Botting, J. H. (2011). C14 Non-steroidal anti-inflammatory drugs. In Principles of Immunopharmacology (pp. 573-584). Birkh&amp;auml;user Basel.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Chien, P.; Lin, C.; Hsiao, L.; Yang, C. (2015). c-SRC/Pyk2/EGFR/PI3K/Akt/CREB-activated pathway contributes to human cardiomyocyte hypertrophy: Role of COX-2 induction. Mol. Cell. Endocrin. 409. 59-72.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Chandrasekharan, N. V., Dai, H., Roos, K. L. T., Evanson, N. K., Tomsik, J., Elton, T. S., &amp;amp; Simmons, D. L. (2002). COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proceedings of the National Academy of Sciences,99(21), 13926-13931.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Crofford, L.J. (1997). COX-1 and COX-2 tissue expression: implications and predictions. J. Rheumatol. Suppl. 49, 15-90.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Degner, S.C.; Kemp, M.Q.; Hockings, J.K.; Romagnolo, D.F. (2007). Cyclooxygenase-2 promoter activation by the aromatic hydrocarbon receptor in breast cancer MCF-7 cells: Repressive effects of conjugated linoleic acid. Nutri. Canc. 56 (2), 248-257.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Delgado R.; Newar, M.; Zewail, A.; Kar, B.; Vaughn, W.; Wu, K.; Aleksic, N,; Sivasubramanian, N.; McKay, K.; Mann, D. (2004). Cyclooxygenase-2 inhibitor treatment improves left ventricle function and mortality in a murine model of doxorubicin-induced heart failure. Circulation. 109, 1428-1433.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Dong, W.; Matsumura, F.; Kullman, S.W. (2010). TCDD induced pericardial edema and relative COX-2 expression in medaka (Oryzias latipes) embryos. Toxicol. Sci. 118 (1), 213-223.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Fujisaw, N.; Nakayama, S.M.M.; Ikenaka, Y.; Ishizuka, M. 2014. TCDD-induced chick cardiotoxicity is abolished by a selective cyclooxygenase-2 (COX-2) inhibitor NS398. Arch. Toxicol. 88, 1739-1748.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Gullestad, L.; Aukrust, P. (2005). Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am. J. Cardiol. 95, 17C-23C; discussion 38C-40C.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Havird, J. C., Kocot, K. M., Brannock, P. M., Cannon, J. T., Waits, D. S., Weese, D. A., ... &amp;amp; Halanych, K. M. (2015). Reconstruction of Cyclooxygenase Evolution in Animals Suggests Variable, Lineage-Specific Duplications, and Homologs with Low Sequence Identity. Journal of molecular evolution, 1-16.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Havird, J. C., Miyamoto, M. M., Choe, K. P., &amp;amp; Evans, D. H. (2008). Gene duplications and losses within the cyclooxygenase family of teleosts and other chordates. Molecular biology and evolution, 25(11), 2349-2359.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Hocherl, K.; Dreher, F.; Kurtz, A.; Bucher, M. (2002). Cyclooxygenase-2 inhibition attenuates liposaccaride-induced cardiovascular failure. Hypertension. 40, 947-953.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Huang, C.; Chen, P., Huang, C.; Yu J. (2007). Aristolochic acid induces heart failure in zebrafish embryos that is mediated by inflammation. Toxicol, Sci. 100 (2), 486-494.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Ishikawa, T. O., Griffin, K. J., Banerjee, U., &amp;amp; Herschman, H. R. (2007). The zebrafish genome contains two inducible, functional cyclooxygenase-2 genes.Biochemical and biophysical research communications, 352(1), 181-187.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Jonsson, M.E.; Kubota, A.; Timme-Laragy, A.R.; Woodin, B.; Stegeman, J.J. (2012). Ahr2-dependence of PCB126 effects on the swim bladder in relation to expression of CYP1 and cox-2 genes in developing zebrafish. Toxicol. Appl. Pharmacol. 265 (2), 166-174.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Picot, D.; Loll, P.J.; Garavito, R.M. (1994). The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature. 367 (6460), 243-290.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Simmons, D. L., Botting, R. M., &amp;amp; Hla, T. (2004). Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacological reviews,56(3), 387-437.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology.&amp;nbsp;Annu Rev Biochem&lt;em&gt;.&amp;nbsp;&lt;/em&gt;2000;&amp;nbsp;69:&amp;nbsp;145&amp;ndash;182.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Streicher, J.M.; Kamei, K.; Ishikawa, T.; Herschman, H.; Wang, Y. (2010). Compensatory hypertrophy induced by ventricular cardiomyocyte specific COX-2 expression in mice. J. Mol. Cell. Cardiol. 49 (1), 88-94.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Teraoka, H.; Kubota, A.; Kawai, Y.; Hiraga, T. (2008). Prostanoid signaling mediates circulation failure caused by TCDD in developing zebrafish. Interdis. Studies Environ. Chem. Biol. Resp. Chem. Pollut. 61-80.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Teraoka, H.; Okuno, Y.; Nijoukubo, D.; Yamakoshi, A.; Peterson, R.E.; Stegeman, J.J.; Kitazawa, T.; Hiraga, T.; Kubota, A. (2014). Involvement of COX2-thromboxane pathway in TCDD-induced precardiac edema in developing zebrafish. Aquat. Toxicol. 154, 19-25.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes.&amp;nbsp;J Clin Invest&lt;em&gt;.&amp;nbsp;&lt;/em&gt;2001;&amp;nbsp;108:&amp;nbsp;15&amp;ndash;23.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Vane JR, Mitchell JA, Appleton I, Tomlinson A, Bishop-Bailey D, Croxtall J, Willoughby DA. Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation.&amp;nbsp;Proc Natl Acad Sci U S A&lt;em&gt;.&amp;nbsp;&lt;/em&gt;1994;91:&amp;nbsp;2046&amp;ndash;2050.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Wong, S.; Fukuchi, M.; Melnyk, P.; Rodger, I.; Giaid, A. (1998). Induction of cyclooxygenase-2 and activation of nuclear factor-kappaB in myocardium of patients with congestive heart failure. Circulation, 98, 100-103.&lt;/p&gt;
</references>
    <source>AOPWiki</source>
    <creation-timestamp>2017-02-09T14:35:07</creation-timestamp>
    <last-modification-timestamp>2018-03-20T16:33:23</last-modification-timestamp>
  </key-event>
  <key-event id="79d28b81-b1b9-4c08-9beb-b50733211cdb">
    <title>reduced production, VEGF</title>
    <short-name>reduced production, VEGF</short-name>
    <biological-organization-level>Cellular</biological-organization-level>
    <description>&lt;p&gt;Vascular endothelial growth factors (VEGFs) are a family of homodimeric glycoproteins that stimulate vasculogenesis and angiogenesis in various tissues&lt;sup&gt;[1]&lt;/sup&gt;.&amp;nbsp; They play vital roles in fetal development and increased oxygen supply in response to tissue injury and hypoxic stress&lt;sup&gt;[1,2]&lt;/sup&gt;.&amp;nbsp; VEGFs signal through cell surface receptor tyrosine kinases: VEGFR-1,&amp;nbsp;VEGFR-2 and&amp;nbsp;VEGFR-3 (Figure 1), which play critical roles in haematopoietic cell development, vascular endothelial cell development and lymphatic endothelial cell development, respectively&lt;sup&gt;[3]&lt;/sup&gt;.&amp;nbsp; The mammalian VEGF-A family has been extensively studied, and includes multiple splice variants, with VEGF&lt;sub&gt;165&lt;/sub&gt; being the most abundantly expressed&lt;sup&gt;[1]&lt;/sup&gt;.&amp;nbsp;&amp;nbsp;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;&lt;img alt="" class="mw-mmv-dialog-is-open mw-mmv-final-image png" src="https://upload.wikimedia.org/wikipedia/commons/c/c8/VEGF_receptors.png" /&gt;&lt;/p&gt;

&lt;p&gt;Figure 1: VEGF family members and their respective receptors (H&amp;auml;ggstr&amp;ouml;m, Mikael (2014). &amp;quot;&lt;a class="external text" href="https://en.wikiversity.org/wiki/WikiJournal_of_Medicine/Medical_gallery_of_Mikael_H%C3%A4ggstr%C3%B6m_2014"&gt;Medical gallery of Mikael H&amp;auml;ggstr&amp;ouml;m 2014&lt;/a&gt;&amp;quot;. &lt;em&gt;WikiJournal of Medicine&lt;/em&gt; &lt;strong&gt;1&lt;/strong&gt; (2). &lt;a class="extiw" href="https://en.wikipedia.org/wiki/Digital_object_identifier" title="w:Digital object identifier"&gt;DOI&lt;/a&gt;:&lt;a class="external text" href="https://doi.org/10.15347/wjm/2014.008" rel="nofollow"&gt;10.15347/wjm/2014.008&lt;/a&gt;. &lt;a class="extiw" href="https://en.wikipedia.org/wiki/International_Standard_Serial_Number" title="en:International Standard Serial Number"&gt;ISSN&lt;/a&gt; &lt;a class="external text" href="http://www.worldcat.org/issn/2002-4436" rel="nofollow"&gt;2002-4436&lt;/a&gt;. &lt;a class="external text" href="https://creativecommons.org/publicdomain/zero/1.0/deed.en" rel="nofollow"&gt;Public Domain&lt;/a&gt;. Retrieved 24/05/2017)&lt;br /&gt;
&amp;nbsp;&lt;/p&gt;
</description>
    <measurement-methodology>&lt;p&gt;&lt;em&gt;Methods that have been previously reviewed and approved by a recognized authority should be included in the Overview section above. All other methods, including those well established in the published literature, should be described here. Consider the following criteria when describing each method: 1. Is the assay fit for purpose? 2. Is the assay directly or indirectly (i.e. a surrogate) related to a key event relevant to the final adverse effect in question? 3. Is the assay repeatable? 4. Is the assay reproducible? &lt;/em&gt;&lt;/p&gt;

&lt;p&gt;VEGF protein can be measured by enzyme-linked immunosorbent assay (Ivnitski-Steele et al. (2005), immunihistochemistry or western blot (Li et al. 2016).&lt;/p&gt;

&lt;p&gt;VEGF gene expression, which is directly correlated with protein levels, can be measured by quantitative real-time polymerase chain reaction (QPCR) (Medford et al. 2009).&lt;/p&gt;
</measurement-methodology>
    <evidence-supporting-taxonomic-applicability>&lt;p&gt;VEGF proteins have been isolated and&amp;nbsp;characterized in multiple species including mammals&lt;sup&gt;[1,2,4]&lt;/sup&gt;, chicken&lt;sup&gt;[4]&lt;/sup&gt;, Japanese quail&lt;sup&gt;[6]&lt;/sup&gt;, &lt;em&gt;Xenopus laevis&lt;/em&gt;&lt;sup&gt;[7]&lt;/sup&gt; and zebrafish&lt;sup&gt;[4,5,7]&lt;/sup&gt;; VEGF&lt;sub&gt;165&lt;/sub&gt; in particular is highly conserved among species with &amp;gt;95% homology between the human transcript and bovine, ovine and murine variants&lt;sup&gt;[1]&lt;/sup&gt;.&amp;nbsp; The avian and amphibian VEGF proteins are highly homologous to the mammalian VEGFs, wheres the fish homologue is less similar&lt;sup&gt;[7]&lt;/sup&gt;. Invertebrates, such as &lt;em&gt;C. elegans&lt;/em&gt; and &lt;em&gt;Drosophila&lt;/em&gt; also contain a VEGFR-like receptor&lt;sup&gt;[7]&lt;/sup&gt;.&lt;/p&gt;
</evidence-supporting-taxonomic-applicability>
    <cell-term>
      <source-id>CL:0000566</source-id>
      <source>CL</source>
      <name>angioblastic mesenchymal cell</name>
    </cell-term>
    <applicability>
      <sex>
        <evidence>High</evidence>
        <sex>Unspecific</sex>
      </sex>
      <life-stage>
        <evidence>High</evidence>
        <life-stage>Embryo</life-stage>
      </life-stage>
      <life-stage>
        <evidence>High</evidence>
        <life-stage>Development</life-stage>
      </life-stage>
      <life-stage>
        <evidence>High</evidence>
        <life-stage>Adult</life-stage>
      </life-stage>
      <taxonomy taxonomy-id="0924b029-7b44-4e61-92f9-cdaba5fd44d5">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="42a83725-7234-4b5b-b126-4651c3467c4c">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="f5c6c9e8-9327-462a-9035-4c7eb6f1eb01">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="6a5b376b-edcc-4703-a928-322458d212ae">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="7f4f5ccb-4d94-4574-87e9-0dcfcfe92608">
        <evidence>High</evidence>
      </taxonomy>
    </applicability>
    <biological-events>
      <biological-event object-id="ad466b20-827e-4c6c-9492-c1178dd8756f" process-id="2a9e9810-90f5-4a87-beee-31a21d9535dc" action-id="daf07ded-b29b-4e00-9e44-8a8de58b3293"/>
      <biological-event object-id="ad466b20-827e-4c6c-9492-c1178dd8756f" process-id="5a290a1e-c8f5-4939-9c70-924dda1ea517" action-id="daf07ded-b29b-4e00-9e44-8a8de58b3293"/>
    </biological-events>
    <references>&lt;p&gt;&lt;br /&gt;
1. Cecilia Y. Cheung (1997) Vascular Endothelial Growth Factor: Possible Role in Fetal Development and Placental Function. &lt;em&gt;J Soc Gynecol Invest. &lt;/em&gt;&lt;strong&gt;4&lt;/strong&gt;: 169-77&lt;/p&gt;

&lt;p&gt;2. &lt;span style="font-family:calibri,sans-serif; font-size:11.0pt"&gt;Ahluwalia, A., and Tarnawski, A. S. (2012). Critical role of hypoxia sensor--HIF-1alpha in VEGF gene activation. Implications for angiogenesis and tissue injury healing. &lt;em&gt;Curr. Med. Chem.&lt;/em&gt; &lt;strong&gt;19&lt;/strong&gt;(1), 90-97.&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-family:calibri,sans-serif; font-size:11.0pt"&gt;3. &lt;/span&gt;Holmes, K., Roberts, O. L., Thomas, A. M., and Cross, M. J. (2007). Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition. &lt;em&gt;Cell Signal.&lt;/em&gt; &lt;strong&gt;19&lt;/strong&gt;(10), 2003-2012.&lt;/p&gt;

&lt;p&gt;4. Ivnitski-Steele, I. D., Friggens, M., Chavez, M., and Walker, M. K. (2005). 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) inhibition of coronary vasculogenesis is mediated, in part, by reduced responsiveness to endogenous angiogenic stimuli, including vascular endothelial growth factor A (VEGF-A). Birth Defects Res. A Clin Mol. Teratol. 73(6), 440-446.&lt;/p&gt;

&lt;p&gt;5. Zhu, D., Fang Y., Gao, &amp;nbsp;K., Shen, J., Zhong, T.P., and Li, &amp;nbsp;F. (2017) Vegfa Impacts Early Myocardium Development in Zebrafish. &lt;em&gt;Int J Mol Sci. &lt;/em&gt;&lt;strong&gt;18&lt;/strong&gt;(2): 444.&lt;/p&gt;

&lt;p&gt;6. Eichmann, A., Marcelle, C., Breant, C., and Le Douarin, N.M. (1996). Molecular cloning of Quek 1 and 2, two quail vascular endothelial growth factor (VEGF) receptor-like molecules. &lt;em&gt;Gene&lt;/em&gt; &lt;strong&gt;174&lt;/strong&gt;, 3&amp;ndash;8.&lt;/p&gt;

&lt;p&gt;7. Masabumi Shibuya (2002) Vascular Endothelial Growth Factor Receptor Family Genes: When Did the Three Genes Phylogenetically Segregate? &lt;em&gt;Biol. Chem.&lt;/em&gt;, &lt;strong&gt;383&lt;/strong&gt;: 1573 &amp;ndash; 1579.&lt;/p&gt;

&lt;p&gt;8. Li, X.; Liu, X.; Guo, H.; Zhao, Z.; Li, Y.S. and Chen, G. (2016) The significance of the increased expression of phosphorylated MeCP2 in the membranes from patients with proliferative diabetic retinopathy. &lt;em&gt;Scientific Reports, &lt;/em&gt;volume 6, Article&amp;nbsp;number:&amp;nbsp;32850. 10.1038/srep32850&lt;/p&gt;

&lt;p&gt;9. Medford, A. R., Douglas, S. K., Godinho, S. I., Uppington, K. M., Armstrong, L., Gillespie, K. M., van Zyl, B., Tetley, T.D., Ibrahim, N.B.N. and Millar, A. B. (2009). Vascular Endothelial Growth Factor (VEGF) isoform expression and activity in human and murine lung injury. &lt;em&gt;Respiratory Research&lt;/em&gt;, &lt;strong&gt;10&lt;/strong&gt;(1), 27. http://doi.org/10.1186/1465-9921-10-27&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;
</references>
    <source>AOPWiki</source>
    <creation-timestamp>2016-11-29T18:41:28</creation-timestamp>
    <last-modification-timestamp>2018-03-28T11:48:00</last-modification-timestamp>
  </key-event>
  <key-event id="9c2a2b45-4f79-4a6e-b978-76aa8b123221">
    <title>Altered, Cardiovascular development/function</title>
    <short-name>Altered, Cardiovascular development/function</short-name>
    <biological-organization-level>Organ</biological-organization-level>
    <description>&lt;p&gt;This key event applies to the disruption of cardiogenesis early enough in embryogenesis to result in gross morphological alterations leading to reduced cardiac function.&lt;/p&gt;
</description>
    <measurement-methodology>&lt;p&gt;Altered cardiovascular development/function can be measured in numerous ways:&lt;/p&gt;

&lt;p&gt;1) As blood flow in the mesencephalic vein by use of time-lapse recording using a digital video camera (Teraoka et al 2008;&amp;nbsp;2014). Blood flow is measured as the number of red blood cells passing the mesencephalic vein per second (Teraoka et al 2008; 2014). This method is described in detail by Teraoka et al (2002). However, some studies have assessed blood flow through visualized scoring techniques by use of a microscope as (1) same rate&amp;nbsp;as control, (2) slower rate than control, or (3) no flow (Henry et al 1997).&lt;/p&gt;

&lt;p&gt;2) As heart area, pericardial edema area, or yolk sac edema area quantified with&amp;nbsp;area analysis by use of a microscope linked digital camera and conventional image software&amp;nbsp;(Dong et al 2010; Teraoka et al 2008; 2014; Yamauchi et al 2006). Images at the same magnification are used to obtain the&amp;nbsp;area measured as number of pixels (Teraoka et al 2008; 2014). This method can use either live individuals or histologic samples. This method is described in detail by Teraoka et al (2003).&lt;/p&gt;

&lt;p&gt;3) As basic physical measurements such as heart weight, heart aspect ratio (horizontal length versus vertical length), heart weight to body weight ratio (Fujisawa et al 2014).&lt;/p&gt;

&lt;p&gt;4) As incidence of malformation&amp;nbsp;measured as percent occurrence among individuals (Buckler et al 2015; Dong et al 2010; Park et al 2014; Yamauchi et al 2006).This method is described in detail by Dong et al (2010).&lt;/p&gt;

&lt;p&gt;5) As heartbeat rate measured by direct observation by use of a microscope (Park et al 2014). This method is described in detail by Park et al (2014).&lt;/p&gt;
</measurement-methodology>
    <evidence-supporting-taxonomic-applicability>&lt;ul&gt;
	&lt;li&gt;Some form of cardiovascular system is present in members of the clade Bilateria (Bishopric 2005). This clade includes most animal phyla, except for sponges (Porifera), jellyfishes and corals (Cnidaria), placozoans (Placozoa), and comb jellies (Ctenophora).&lt;/li&gt;
	&lt;li&gt;Differences in cardiovascular systems are present among taxa. Vertebrates have closed circulatory systems, while some invertebrate taxa have open circulatory systems (Kardong 2006).&lt;/li&gt;
&lt;/ul&gt;
</evidence-supporting-taxonomic-applicability>
    <organ-term>
      <source-id>UBERON:0000948</source-id>
      <source>UBERON</source>
      <name>heart</name>
    </organ-term>
    <applicability>
      <sex>
        <evidence>High</evidence>
        <sex>Unspecific</sex>
      </sex>
      <life-stage>
        <evidence>High</evidence>
        <life-stage>Embryo</life-stage>
      </life-stage>
      <taxonomy taxonomy-id="3677faa1-063d-42d3-8e25-00291c6359cf">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="3787a1aa-da69-47ff-926a-93ba5ba9626e">
        <evidence>High</evidence>
      </taxonomy>
    </applicability>
    <biological-events>
      <biological-event process-id="0ca3ec48-d6fb-4d7e-8ef9-8ac3bb71af6e" action-id="40170979-dec4-42d2-93fa-9785e9edd1e8"/>
      <biological-event object-id="c3dab278-d35a-43a5-a603-8db06423794a" process-id="f391422c-9e8d-417e-ae6e-348871e9938c" action-id="d174c842-9881-4c5e-a044-9c0b40492c6f"/>
    </biological-events>
    <references>&lt;p&gt;&lt;br /&gt;
1. Carro, T., Dean, K., and Ottinger, M. A. (2013a). Effects of an environmentally relevant polychlorinated biphenyl (PCB) mixture on embryonic survival and cardiac development in the domestic chicken. Environ. Toxicol. Chem. 23(6), 1325-1331.&lt;/p&gt;

&lt;p&gt;2. Carro, T., Taneyhill, L. A., and Ottinger, M. A. (2013b). The effects of an environmentally relevant 58 congener polychlorinated biphenyl (PCB) mixture on cardiac development in the chick embryo. Environ. Toxicol. Chem.&lt;/p&gt;

&lt;p&gt;3. DeWitt, J. C., Millsap, D. S., Yeager, R. L., Heise, S. S., Sparks, D. W., and Henshel, D. S. (2006). External heart deformities in passerine birds exposed to environmental mixtures of polychlorinated biphenyls during development. Environ. Toxicol. Chem. 25(2), 541-551.&lt;/p&gt;

&lt;p&gt;4. Heid, S. E., Walker, M. K., and Swanson, H. I. (2001). Correlation of cardiotoxicity mediated by halogenated aromatic hydrocarbons to aryl hydrocarbon receptor activation. Toxicol. Sci 61(1), 187-196.&lt;/p&gt;

&lt;p&gt;5. Walker, M. K., and Catron, T. F. (2000). Characterization of cardiotoxicity induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin and related chemicals during early chick embryo development. Toxicol. Appl. Pharmacol. 167(3), 210-221.&lt;/p&gt;

&lt;p&gt;6. Walker, M. K., Pollenz, R. S., and Smith, S. M. (1997). Expression of the aryl hydrocarbon receptor (AhR) and AhR nuclear translocator during chick cardiogenesis is consistent with 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced heart defects. Toxicol. Appl. Pharmacol. 143(2), 407-419.&lt;/p&gt;

&lt;p&gt;7. Kopf, P. G., and Walker, M. K. (2009). Overview of developmental heart defects by dioxins, PCBs, and pesticides. J. Environ. Sci. Health C. Environ. Carcinog. Ecotoxicol. Rev. 27(4), 276-285.&lt;/p&gt;

&lt;p&gt;Bishopric, N.H. (2005). Evolution of the heart from bacteria to man. Ann. N. Y. Acad. Sci. 1047, 13-29.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Buckler J.; Candrl, J.S.; McKee, M.J.; Papoulias, D.M.; Tillitt, D.E.; Galat, D.L. Sensitivity of shovelnose sturgeon (&lt;em&gt;Scaphirhynchus platorynchus&lt;/em&gt;) and pallid sturgeon (&lt;em&gt;S. albus&lt;/em&gt;) early life stages to PCB-126 and 2,3,7,8-TCDD exposure. &lt;em&gt;Enviro. Toxicol. Chem. &lt;/em&gt;&lt;strong&gt;2015&lt;/strong&gt;, 34(6), 1417-1424.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Carney, S.A.; Prasch, A.L.; Heideman, W.; Peterson, R.E. 2006. Understanding dioxin developmental toxicity using the zebrafish model. Birth Defects Research. A. 76, 7-18.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Cohen-Barnhouse, A.M.; Zwiernik, M.J.; Link, J.E.; Fitzgerald, S.D.; Kennedy, S.W.; Herve, J.C.; Giesy, J.P.; Wiseman, S.; Yang, Y.; Jones, P.D.; Yi, W.; Collins, B.; Newsted, J.L.; Kay, D.; Bursian, S.J. 2011. Sensitivity of Japanese quail (&lt;em&gt;Coturnix japonica&lt;/em&gt;), common pheasant (&lt;em&gt;Phasianus colchicus&lt;/em&gt;), and white leghorn chicken (&lt;em&gt;Gallus gallus domesticus&lt;/em&gt;) embryos to &lt;em&gt;in ovo&lt;/em&gt; exposure to TCDD, PeCDF, and TCDF. Toxicol. Sci. 119, 93-102.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Elonen, G.E.; Spehar, R.L.; Holcombe, G.W.; Johnson, R.D.; Fernandez, J.D.; Erickson, R.J.; Tietge, J.E.; Cook, P.M. Comparative toxicity of 2,3,7,8-tetrachlorodibenzo-&lt;em&gt;p&lt;/em&gt;-dioxin to seven freshwater fish species during early life-stage development.&lt;em&gt; Enviro. Toxico. Chem. &lt;/em&gt;&lt;strong&gt;1998&lt;/strong&gt;, 17, 472-483.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Goldstone, H.M.H.; Stegeman, J.J. (2008). Molecular mechanisms of 2,3,7,8-tetrachlorodibenzo-p-dioxin cardiovascular embryotoxicity. Drug. Metab. Rev. 38, 261-289.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Heid, S.E.; Walker, M.K.; Swanson, H.I. (2001). Correlation of cardiotoxicity mediated by halogenated aromatic hydrocarbons to aryl hydrocarbon receptor activation. Toxicol. Sci. 61 (1), 187-196.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Huang, L.; Wang, C.; Zhang, Y.; Li, J.; Zhong, Y.; Zhou, Y.; Chen, Y.; Zuo, Z. (2012). Benzo[a]pyrene exposure influences the cardiac development and the expression of cardiovascular relative genes in zebrafish (Daniorerio) embryos. Chemosphere. 87 (4), 369-375.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Johnson, R.D.; Tietge, J.E.; Jensen, K.M.; Fernandez, J.D.; Linnum, A.L.; Lothenbach, D.B.; Holcombe, G.W.; Cook, P.M.; Christ, S.A.; Lattier, D.L.; Gordon, D.A. Toxicity of 2,3,7,8-tetrachlorodibenzo-&lt;em&gt;p&lt;/em&gt;-dioxin to early life stage brooke trout (&lt;em&gt;Salvelinus fontinalis&lt;/em&gt;) following parental dietary exposure. &lt;em&gt;Enviro. Toxicol. Chem.&lt;/em&gt; &lt;strong&gt;1998&lt;/strong&gt;, 17 (12), 2408-2421.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Kardong, K.V. (2006). Vertebrates: comparative anatomy, function, evolution. McGraw-Hill Higher Eduction. Boston, USA.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Lemly, A.D. (2002). Symptoms and implications of selenium toxicity in fish: the Belews Lake case example. Aquat. Toxicol. 57 (1-2), 39-49.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Park, Y.J.; Lee, M.J.; Kim, H.R.; Chung, K.H.; Oh, S.M. Developmental toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in artificially fertilized crucian carp (Carassius auratus) embryo. &lt;em&gt;Sci. Totl. Enviro.&lt;/em&gt; &lt;strong&gt;2014&lt;/strong&gt;, 491-492, 271-278.&lt;/p&gt;

&lt;p&gt;Teraoka, H.; Dong, W.; Hiraga, T. (2003). Zebrafish as a novel experimental model for development toxicology. Congenit. Anom. 43, 123-132.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Teraoka, T.; Dong, W.; Ogawa, S.; Tsukiyama, S.; Okuhara, Y.; Niiyama, M.; Ueno, N.; Peterson, R.E. (2002). 2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity in the zebrafish embryo: Altered regional blood flow and impaired lower jaw development. Toxicol. Sci. 65, 192-199.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Tillitt, D.E.; Buckler, J.A.; Nicks, D.K.; Candrl, J.S.; Claunch, R.A.; Gale, R.W.; Puglis, H.J.; Little, E.E.; Linbo, T.L.; Baker, M. Sensitivity of lake sturgeon (Acipenser fulvescens) early life stages to 2,3,7,8-tetrachlorodibenzo-p-dioxin and 3,3&amp;rsquo;,4,4&amp;rsquo;,5-pentachlorobiphenyl. 2015. Enviro. Toxicol. Chem. DOI: 10.1002/etc.3614.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Toomey, B.H.; Bello, S.; Hahn, M.E.; Cantrell, S.; Wright, P.; Tillitt, D.; Di Giulio, R.T. TCDD induces apoptotic cell death and cytochrome P4501A expression in developing &lt;em&gt;Fundulus heteroclitus&lt;/em&gt; embryos. &lt;em&gt;Aquat. Toxicol.&lt;/em&gt; &lt;strong&gt;2001&lt;/strong&gt;, 53, 127-138.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Walker, M.K.; Spitsbergen, J.M.; Olson, J.R.; Peterson, R.E. 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD) toxicity during early life stage development of lake trout (&lt;em&gt;Salvelinus namaycush&lt;/em&gt;). &lt;em&gt;Canad. J. Fisheries Aqua. Sci.&lt;/em&gt; &lt;strong&gt;1991&lt;/strong&gt;, 48, 875-883.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Yamauchi, M.; Kim, E.Y.; Iwata, H.; Shima, Y.; Tanabe, S. Toxic effects of 2,3,7,8-tetrachlorodibenzo-&lt;em&gt;p&lt;/em&gt;-dioxin (TCDD) in developing red seabream (&lt;em&gt;Pagrus major&lt;/em&gt;) embryos: an association of morphological deformities with AHR1, AHR2 and CYP1A expressions. &lt;em&gt;Aquat. Toxicol.&lt;/em&gt; &lt;strong&gt;2006&lt;/strong&gt;, 16, 166-179.&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;Zabel, E.W; Cook, P.M.; Peterson, R.E. Toxic equivalency factors of polychlorinated dibenzo-p-dioxin, dibenzofuran and biphenyl congeners based on early-life stage mortality in rainbow trout (Oncorhynchus mykiss). Aquat Toxicol. &lt;strong&gt;1995&lt;/strong&gt;. 31, 315-328.&lt;/p&gt;
</references>
    <source>AOPWiki</source>
    <creation-timestamp>2016-11-29T18:41:24</creation-timestamp>
    <last-modification-timestamp>2017-09-16T10:14:36</last-modification-timestamp>
  </key-event>
  <key-event id="d75c9f09-3f16-4627-84f5-60ef45c1f533">
    <title>Decreased trophoblast invasion/migration</title>
    <short-name>Cellular dysfunction (human placenta trophoblast cells) </short-name>
    <biological-organization-level>Cellular</biological-organization-level>
    <description></description>
    <measurement-methodology></measurement-methodology>
    <evidence-supporting-taxonomic-applicability></evidence-supporting-taxonomic-applicability>
    <applicability>
    </applicability>
    <references></references>
    <source>AOPWiki</source>
    <creation-timestamp>2023-02-07T12:27:36</creation-timestamp>
    <last-modification-timestamp>2026-11-17T01:45:37</last-modification-timestamp>
  </key-event>
  <key-event id="e648f918-6b20-4147-9b56-01a68955b349">
    <title>Increase, Prostaglandin E2 concentration</title>
    <short-name>Increase, Prostaglandin E2 concentration</short-name>
    <biological-organization-level>Tissue</biological-organization-level>
    <description></description>
    <measurement-methodology></measurement-methodology>
    <evidence-supporting-taxonomic-applicability></evidence-supporting-taxonomic-applicability>
    <applicability>
    </applicability>
    <references></references>
    <source>AOPWiki</source>
    <creation-timestamp>2026-11-17T00:27:31</creation-timestamp>
    <last-modification-timestamp>2026-11-17T01:44:03</last-modification-timestamp>
  </key-event>
  <key-event id="f47cf8c7-2e96-426f-8d68-5ccc30c16368">
    <title>Decreased, PPAR-gamma activation</title>
    <short-name>Decreased, PPAR-gamma activation</short-name>
    <biological-organization-level>Molecular</biological-organization-level>
    <description>&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;The Peroxisome Proliferator-Activated Receptors (PPAR) family of genes involved in regulation of lipid metabolism and energy pathways (Desvergne and Wahli 1999, Hihi et al. 2002, Ahmed et al. 2007).&amp;nbsp; Fatty acids stimulate the expression of PPAR genes, which initiate a variety of cellular responses focused on lipid metabolism, but also inflammation and apoptosis pathways.&amp;nbsp; Decreases in PPAR-gamma expression are associated with disruption of adipocyte differentiation and glucose homeostasis.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
</description>
    <measurement-methodology>&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;Peroxisome proliferation-activated receptors are investigated by changes in gene expression and protein levels.&amp;nbsp; X-ray crystallography can be used to determine molecular structure. &amp;nbsp;Effects of PPAR gamma on expression of downstream genes can be investigating using metabolomics and RT-qPCR approaches.&amp;nbsp; &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
</measurement-methodology>
    <evidence-supporting-taxonomic-applicability>&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="background-color:white"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;&lt;span style="font-family:&amp;quot;Calibri&amp;quot;,sans-serif"&gt;&lt;span style="color:#212529"&gt;Life Stage:&amp;nbsp;All life stages.&amp;nbsp; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="background-color:white"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;&lt;span style="font-family:&amp;quot;Calibri&amp;quot;,sans-serif"&gt;&lt;span style="color:#212529"&gt;Sex: Applies to both males and females.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="background-color:white"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;&lt;span style="font-family:&amp;quot;Calibri&amp;quot;,sans-serif"&gt;&lt;span style="color:#212529"&gt;Taxonomic:&amp;nbsp;Appears to be present broadly, with representative studies in mammals.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
</evidence-supporting-taxonomic-applicability>
    <cell-term>
      <source-id>CL:0000182</source-id>
      <source>CL</source>
      <name>hepatocyte</name>
    </cell-term>
    <applicability>
      <sex>
        <evidence>Not Specified</evidence>
        <sex>Unspecific</sex>
      </sex>
      <life-stage>
        <evidence>Not Specified</evidence>
        <life-stage>All life stages</life-stage>
      </life-stage>
      <taxonomy taxonomy-id="b8753f15-9ab7-4425-9f65-b67236d6993f">
        <evidence>Not Specified</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="ba982cc1-0376-4470-bed3-29bba8aceec4">
        <evidence>Not Specified</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="b667fbe7-4be4-45d5-a707-316c7aaea8bc">
        <evidence>Not Specified</evidence>
      </taxonomy>
    </applicability>
    <biological-events>
      <biological-event object-id="5711cde6-e0e9-46b5-9762-6eec54ba7b96" process-id="2dd85acd-9c86-4210-b0f9-7659276b58b9" action-id="daf07ded-b29b-4e00-9e44-8a8de58b3293"/>
    </biological-events>
    <references>&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;Ahmed, W., Ziouzenkova, O., Brown, J. Devchand, P. Francis, S., Kadakia, M., Kanda, T., Orasanu, G., Sharlach, M., Zandbergen, F., and Plutzky, J.&amp;nbsp; 2007. &amp;nbsp;PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?&amp;nbsp; Journal of Internal Medicine 262: 184-198.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;Desvergne, B. and Wahli, W. 1999. &amp;nbsp;Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine Reviews 20(5): 649-688.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;Hihi, A.K., Michalik, L., Wahli, W. 2002. PPARs: transcriptional effectors of fatty acids and their derivatives. Cellular and Molecular Life Sciences 59: 790-798.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
</references>
    <source>AOPWiki</source>
    <creation-timestamp>2016-11-29T18:41:23</creation-timestamp>
    <last-modification-timestamp>2023-10-30T09:07:07</last-modification-timestamp>
  </key-event>
  <key-event id="9fe06144-feee-45d3-95ba-e88bfd50610b">
    <title>Increase, Extracellular matrix deposition</title>
    <short-name>Increase, ECM deposition</short-name>
    <biological-organization-level>Tissue</biological-organization-level>
    <description>&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;ECM is a macromolecular structure that provides physical support to tissues and is essential for organ function. The composition of ECM is tissue specific and consists mainly of fibrous proteins, glycoproteins, and proteoglycans. The ECM in lung is compartmentalised to basement membrane and the interstitial space. Fibroblasts found in the interstitial space are the main sources of ECM in lung (White, 2015). Altered composition of ECM is observed in several lung diseases of inflammatory origin in humans including chronic obstructive pulmonary disease, asthma and idiopathic lung fibrosis. The composition and architecture of the ECM determines 1) the open sites of attachment that are available to cells, 2) the mechanical properties of the ECM and 3) the mechanical loading (breathing) experienced by the cells. Thus, changes in the ECM composition during the exaggerated wound healing process determines if an organism commits to fibrotic process or completes the wound healing (&lt;span style="color:red"&gt;Blaauboer et al., 2014&lt;/span&gt;).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;strong&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;&lt;em&gt;&lt;span style="color:red"&gt;Evidence for its perturbation in the context of pulmonary fibrosis:&lt;/span&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;&lt;u&gt;&lt;strong&gt;In lung fibrosis&lt;/strong&gt;&lt;/u&gt;, an exaggerated amount of ECM is distributed in the alveolar parenchyma in a non-heterogenous manner, leading to lower spirometry readings implying occlusion of alveolar regions and reduced gas exchange. Collagen 1 and Collagen III are suggested to be the main components of the ECM in the thickened alveolar septa in fibrosis with other constituents such as fibronectin, elastin and tenacin C (Zhang et al., 1994; Hinz, 2006; Kuhn &amp;amp; McDonald, 1991; Crabb et al., 2006; Bensadoun et al., 1996; Klingberg et al., 2012; McKleroy et al., 2013). It is suggested that ECM composition dramatically changes during the fibrotic process. The early fibrotic process is characterised by collagen III deposition and collagen 1 predominates the later stages of the fibrosis. Excessive collagen production by myofibroblasts is necessary for the development of fibrosis (scarred tissue), with established areas of scar formation containing almost exclusively Type I collagen (Bateman et al., 1981; McKleroy et al., 2013; Zhang et al., 1994). Studies have demonstrated that while total collagen increases in IPF, there is also a shift toward the less elastic type I collagen, which contributes to the stiffness of the scar tissue within the lung (Nimni, 1983; Rozin et al., 2005; McKleroy et al., 2013).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;The fibrotic ECM contains characteristic accumulation of fibroblasts and myofibroblasts, which are the major contributors of ECM synthesised. The proliferation of fibroblasts and their differentiation into myofibroblasts is, in turn, guided by the composition and structure of the ECM. For example, &lt;span style="color:red"&gt;s&lt;/span&gt;tudies have demonstrated that cytokines secreted in response to inflammation are capable of activating fibroblasts, and that these changes could cause alterations in the fibroblasts that lead to excessive proliferation and ECM deposition (Sivakumar et al., 2012; Wynn, 2011).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&lt;span style="font-size:11pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="color:#000000"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="color:red"&gt;&lt;u&gt;In liver fibrosis,&lt;/u&gt;&amp;nbsp;extracellular matrix (ECM) deposition is a critical hallmark. It represents the accumulation of fibrotic scar tissue due to excessive synthesis and reduced degradation of ECM components (e.g., collagen types I and III) (&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="background-color:yellow"&gt;&lt;span style="color:red"&gt;PMID:&amp;nbsp;34685739&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="color:red"&gt;). This deposition disrupts liver architecture and impairs function.&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:11pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="color:#000000"&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="color:red"&gt;ECM deposition is considered a highly essential event for liver fibrosis progression because it marks the transition from reversible inflammation to irreversible fibrosis, it correlates with disease severity and progression to cirrhosis (&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="background-color:yellow"&gt;&lt;span style="color:red"&gt;PMID:&amp;nbsp;34685739&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="color:red"&gt;).&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="color:red"&gt;Experimental evidence often supports the essentiality, such as fibrosis models showing reduced ECM deposition when specific pathways (e.g., TGF-&amp;beta; or integrin signaling) are inhibited (&lt;span style="background-color:yellow"&gt;PMID:&amp;nbsp;31362006&lt;/span&gt;). ECM deposition is a measurable KE using histological, biochemical, and imaging methods (e.g., Masson&amp;rsquo;s trichrome staining, hydroxyproline content, or MRI elastography, Red sirius).&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p style="text-align:justify"&gt;&amp;nbsp;&lt;/p&gt;

&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;&lt;span style="color:#000000"&gt;&lt;em&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="color:red"&gt;Caligiuri A, Gentilini A, Pastore M, Gitto S, Marra F. Cellular and Molecular Mechanisms Underlying Liver Fibrosis Regression.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/em&gt;&lt;strong&gt;&lt;em&gt;&amp;nbsp;&lt;/em&gt;&lt;/strong&gt;&lt;em&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="color:red"&gt;Cells. 2021 Oct 15;10(10):2759. doi: 10.3390/cells10102759. PMID: 34685739; PMCID: PMC8534788.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="font-family:&amp;quot;Times New Roman&amp;quot;,serif"&gt;&lt;span style="color:#000000"&gt;&lt;em&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="color:red"&gt;Fan W, Liu T, Chen W, Hammad S, Longerich T, Hausser I, Fu Y, Li N, He Y, Liu C, Zhang Y, Lian Q, Zhao X, Yan C, Li L, Yi C, Ling Z, Ma L, Zhao X, Xu H, Wang P, Cong M, You H, Liu Z, Wang Y, Chen J, Li D, Hui L, Dooley S, Hou J, Jia J, Sun B. ECM1 Prevents Activation of Transforming Growth Factor&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/em&gt;&lt;strong&gt;&lt;em&gt;&amp;nbsp;&lt;/em&gt;&lt;/strong&gt;&lt;em&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="color:red"&gt;&amp;beta;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/em&gt;&lt;em&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="color:red"&gt;, Hepatic Stellate Cells, and Fibrogenesis in Mice.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/em&gt;&lt;strong&gt;&lt;em&gt;&amp;nbsp;&lt;/em&gt;&lt;/strong&gt;&lt;em&gt;&lt;strong&gt;&lt;span style="font-size:10pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="color:red"&gt;Gastroenterology. 2019 Nov;157(5):1352-1367.e13. doi: 10.1053/j.gastro.2019.07.036. Epub 2019 Jul 27. PMID: 31362006.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/strong&gt;&lt;/em&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
</description>
    <measurement-methodology>&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;&lt;strong&gt;&lt;em&gt;&lt;span style="color:red"&gt;qRT-PCR, Immunosorbant assays, and immunohistochemistry:&lt;/span&gt;&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;The qRT-PCR, ELISA, and immunohistochemistry are routinely used to assess the levels of protein and mRNA levels. The various genes and proteins that are assessed include, collagen I, collagen III, elastin and tenacin C. Histological staining with stains such as Masson Trichrome, Picro-sirius red are used to identify the tissue/cellular distribution of collagen, which can be quantified using morphometric analysis both in vivo and in vitro. The assays are routinely used and are quantitative.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;&lt;strong&gt;&lt;em&gt;Sircol Collagen Assay for collagen quantification:&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;The Serius dye has been used for many decades to detect collagen in histology samples. The Serius Red F3BA selectively binds to collagen and the signal can be read at 540 nm (Chen &amp;amp; Raghunath, 2009; Nikota et al., 2017).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;&lt;strong&gt;&lt;em&gt;Hydroxyproline assay:&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;Hydroxyproline is a non-proteinogenic amino acid formed by the prolyl-4-hydroxylase. Hydroxyproline is only found in collagen and thus, it serves as a direct measure of the amount of collagen present in cells or tissues. Colorimetric methods are readily available and have been extensively used to quantify collagen using this assay (Chen &amp;amp; Raghunath, 2009; Nikota et al., 2017).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;&lt;strong&gt;&lt;em&gt;&lt;span style="color:red"&gt;Ex vivo and in vitro models of ECM deposition:&lt;/span&gt;&lt;/em&gt;&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;&lt;span style="color:red"&gt;No models currently exist which allow for in vitro assessment of ECM deposition. Using single, or co-cultures containing fibroblasts, the production of soluble ECM components can be assessed after exposure to a stressor of interest using either ELISA or qRT-PCR experiments as a proxy.&amp;nbsp; &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
</measurement-methodology>
    <evidence-supporting-taxonomic-applicability></evidence-supporting-taxonomic-applicability>
    <applicability>
    </applicability>
    <references>&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;1. Bateman, E., Turner-Warwick, M. and Adelmann-Grill, B. (1981). Immunohistochemical study of collagen types in human foetal lung and fibrotic lung disease. Thorax, 36(9), pp.645-653.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;2. Bensadoun, E., Burke, A., Hogg, J. and Roberts, C. (1996). Proteoglycan deposition in pulmonary fibrosis. American Journal of Respiratory and Critical Care Medicine, 154(6), pp.1819-1828.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;3. Blaauboer M et al. Extracellular matrix proteins: A positive feedback loop in lung fibrosis. Matrix Biology, 2014, 34, 170-178&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;4. Chen, C. and Raghunath, M. (2009). Focus on collagen: in vitro systems to study fibrogenesis and antifibrosis _ state of the art. Fibrogenesis &amp;amp; Tissue Repair, 2(1).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;5. Crabb, R., Chau, E., Decoteau, D. and Hubel, A. (2006). Microstructural Characteristics of Extracellular Matrix Produced by Stromal Fibroblasts. Annals of Biomedical Engineering, 34(10), pp.1615-1627.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;6. HINZ, B. (2006). Masters and servants of the force: The role of matrix adhesions in myofibroblast force perception and transmission. European Journal of Cell Biology, 85(3-4), pp.175-181.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;7. Kuhn C, McDonald JA. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol. 1991;138(5):1257&amp;ndash;1265.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;8. Klingberg, F., Hinz, B. and White, E. (2012). The myofibroblast matrix: implications for tissue repair and fibrosis. The Journal of Pathology, 229(2), pp.298-309.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;9. McKleroy, W., Lee, T. and Atabai, K. (2013). Always cleave up your mess: targeting collagen degradation to treat tissue fibrosis. American Journal of Physiology-Lung Cellular and Molecular Physiology, 304(11), pp.L709-L721.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;10. Nikota, J., Banville, A., Goodwin, L., Wu, D., Williams, A., Yauk, C., Wallin, H., Vogel, U. and Halappanavar, S. (2017). Stat-6 signaling pathway and not Interleukin-1 mediates multi-walled carbon nanotube-induced lung fibrosis in mice: insights from an adverse outcome pathway framework. Particle and Fibre Toxicology, 14(1).&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;11. Nimni, M. (1983). Collagen: Structure, function, and metabolism in normal and fibrotic tissues. Seminars in Arthritis and Rheumatism, 13(1), pp.1-86.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;12. Rozin, G., Gomes, M., Parra, E., Kairalla, R., de Carvalho, C. and Capelozzi, V. (2005). Collagen and elastic system in the remodelling process of major types of idiopathic interstitial pneumonias (IIP). Histopathology, 46(4), pp.413-421.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;13. Sivakumar, P., Ntolios, P., Jenkins, G. and Laurent, G. (2012). Into the matrix. Current Opinion in Pulmonary Medicine, 18(5), pp.462-469.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;14. White, E. (2015). Lung Extracellular Matrix and Fibroblast Function. Annals of the American Thoracic Society, 12(Supplement 1), pp.S30- S33. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;15. Wynn, T. (2011). Integrating mechanisms of pulmonary fibrosis. The Journal of Experimental Medicine, 208(7), pp.1339-1350.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:16px"&gt;&lt;span style="font-family:Arial,Helvetica,sans-serif"&gt;16. Zhang K, Rekhter MD, Gordon D, Phan SH. Myofibroblasts and their role in lung collagen gene expression during pulmonary fibrosis. A combined immunohistochemical and in situ hybridization study. Am J Pathol. 1994;145(1):114&amp;ndash;125&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
</references>
    <source>AOPWiki</source>
    <creation-timestamp>2018-01-05T13:12:18</creation-timestamp>
    <last-modification-timestamp>2026-02-10T04:44:20</last-modification-timestamp>
  </key-event>
  <key-event id="16d77181-0da9-49c3-af36-4ff08e983c43">
    <title>Decreased, MMP</title>
    <short-name>Decreased, MMP</short-name>
    <biological-organization-level>Cellular</biological-organization-level>
    <description></description>
    <measurement-methodology></measurement-methodology>
    <evidence-supporting-taxonomic-applicability></evidence-supporting-taxonomic-applicability>
    <applicability>
    </applicability>
    <references></references>
    <source>AOPWiki</source>
    <creation-timestamp>2026-11-17T01:23:42</creation-timestamp>
    <last-modification-timestamp>2026-11-17T01:23:42</last-modification-timestamp>
  </key-event>
  <key-event id="542e80fe-a3ac-47ad-8f95-c441419980bf">
    <title>increase, placental insufficiency</title>
    <short-name>increase, placental insufficiency</short-name>
    <biological-organization-level>Organ</biological-organization-level>
    <description></description>
    <measurement-methodology></measurement-methodology>
    <evidence-supporting-taxonomic-applicability></evidence-supporting-taxonomic-applicability>
    <applicability>
    </applicability>
    <references></references>
    <source>AOPWiki</source>
    <creation-timestamp>2021-05-31T10:54:29</creation-timestamp>
    <last-modification-timestamp>2021-05-31T10:54:29</last-modification-timestamp>
  </key-event>
  <key-event-relationship id="c2408ddd-80ae-4fcf-98e2-b9b2af63cb30">
    <title>
      <upstream-id>19a51ece-bc2e-4475-9636-2797e76dd4c4</upstream-id>
      <downstream-id>42b06a4d-5fe7-4f2b-8e56-047be78a1a2a</downstream-id>
    </title>
    <description></description>
    <evidence-collection-strategy/>
    <weight-of-evidence>
      <value></value>
      <biological-plausibility></biological-plausibility>
      <emperical-support-linkage></emperical-support-linkage>
      <uncertainties-or-inconsistencies></uncertainties-or-inconsistencies>
    </weight-of-evidence>
    <known-modulating-factors/>
    <quantitative-understanding>
      <description></description>
      <response-response-relationship/>
      <time-scale/>
      <feedforward-feedback-loops/>
    </quantitative-understanding>
    <applicability>
    </applicability>
    <evidence-supporting-taxonomic-applicability></evidence-supporting-taxonomic-applicability>
    <references></references>
    <source>AOPWiki</source>
    <creation-timestamp>2026-11-17T01:34:14</creation-timestamp>
    <last-modification-timestamp>2026-11-17T01:34:14</last-modification-timestamp>
  </key-event-relationship>
  <key-event-relationship id="a773ada8-f0ba-4ce6-adca-ff35a68684ea">
    <title>
      <upstream-id>42b06a4d-5fe7-4f2b-8e56-047be78a1a2a</upstream-id>
      <downstream-id>e648f918-6b20-4147-9b56-01a68955b349</downstream-id>
    </title>
    <description></description>
    <evidence-collection-strategy/>
    <weight-of-evidence>
      <value></value>
      <biological-plausibility></biological-plausibility>
      <emperical-support-linkage></emperical-support-linkage>
      <uncertainties-or-inconsistencies></uncertainties-or-inconsistencies>
    </weight-of-evidence>
    <known-modulating-factors/>
    <quantitative-understanding>
      <description></description>
      <response-response-relationship/>
      <time-scale/>
      <feedforward-feedback-loops/>
    </quantitative-understanding>
    <applicability>
    </applicability>
    <evidence-supporting-taxonomic-applicability></evidence-supporting-taxonomic-applicability>
    <references></references>
    <source>AOPWiki</source>
    <creation-timestamp>2026-11-17T01:26:26</creation-timestamp>
    <last-modification-timestamp>2026-11-17T01:26:26</last-modification-timestamp>
  </key-event-relationship>
  <key-event-relationship id="5c2e36e0-ebd1-43f9-8803-c00fcd3e3251">
    <title>
      <upstream-id>42b06a4d-5fe7-4f2b-8e56-047be78a1a2a</upstream-id>
      <downstream-id>9c2a2b45-4f79-4a6e-b978-76aa8b123221</downstream-id>
    </title>
    <description>&lt;ul&gt;
	&lt;li&gt;The precise role that COX-2 plays in altered cardiovascular development/function has not been investigated. However, the prostaglandin synthesis pathway, of which COX-2 is a rate limiting step, is known to have roles in development of the heart (Dong et al 2010; Huang et al 2007; Teraoka et al 2008; 2014).&lt;/li&gt;
&lt;/ul&gt;
</description>
    <evidence-collection-strategy/>
    <weight-of-evidence>
      <value></value>
      <biological-plausibility>&lt;ul&gt;
	&lt;li&gt;The prostaglandin synthesis pathway, of which COX-2 is a rate limiting step, is known to have roles in development of the heart and therefore altered levels of expression of COX-2 could be expected to result in altered development of the heart.&lt;/li&gt;
&lt;/ul&gt;
</biological-plausibility>
      <emperical-support-linkage>&lt;ul&gt;
	&lt;li&gt;Blocking induction of COX-2 through knockdown of COX-2 or through selective antagonists of COX-2 &amp;nbsp;in zebrafish, Japanese medaka (&lt;em&gt;Oryzias latipes&lt;/em&gt;), and chicken (&lt;em&gt;Gallus gallus&lt;/em&gt;)&amp;nbsp;prevents alteration in cardiovascular development and function by 2,3,7,8-TCDD, including prevention of pericardial edema, changes in heart size, and reduction in blood blow (Dong et al 2010; Teraoka et al 2008; 2014).&lt;/li&gt;
	&lt;li&gt;Knockdown of and selective antagonists of thromboxane A synthase 1 (CYP5A), which is down-stream of COX-2 in the prostaglandin synthesis pathway, prevents alteration in cardiovascular development and function by 2,3,7,8-TCDD&amp;nbsp;(Teraoka et al 2008).&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;&lt;strong&gt;COX-2 Cardiovascular Development Roles:&lt;/strong&gt;&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Transgenic mice (&lt;em&gt;Mus musculus&lt;/em&gt;) that over express COX-2 display altered cardiac remodeling&amp;nbsp;that results in cardiomyocyte hypertrophy&amp;nbsp;(Streicher et al 2010). However, significantly impaired cardiac function was not observed in the strain of transgenic mice investigated in this study (Streicher et al 2010).&lt;/li&gt;
	&lt;li&gt;Embryos of zebrafish (&lt;em&gt;Danio rerio&lt;/em&gt;) exposed to the COX-2 inducers, aristolochic acid and doxorubicin, develop hypertrophy of the heart, disorganization of cardiomyocytes, and loss of endocardium (Huang et al 2007). These&amp;nbsp;effects result&amp;nbsp;in reduced function of the heart and eventually cause death in zebrafish (Huang et al 2007).&lt;/li&gt;
	&lt;li&gt;COX-2 has also been demonstrated&amp;nbsp;to have roles in cardiovascular development in humans, chicken (&lt;em&gt;Gallus gallus&lt;/em&gt;), and Japanese medaka (&lt;em&gt;Oryzias latipes&lt;/em&gt;) (Fujisawa et al 2014; Gullestad &amp;amp; Aukrust 2005; Hocherl et al 2002; Huang et al 2007; Wong et al 1998).&amp;nbsp;&lt;/li&gt;
&lt;/ul&gt;
</emperical-support-linkage>
      <uncertainties-or-inconsistencies>&lt;ul&gt;
	&lt;li&gt;Intermediary steps between increased expression of COX-2 and altered heart development and function have not been investigated.&lt;/li&gt;
	&lt;li&gt;The precise role of COX-2 and the prostaglandin synthesis pathway in early development of the heart is not known.&lt;/li&gt;
&lt;/ul&gt;
</uncertainties-or-inconsistencies>
    </weight-of-evidence>
    <known-modulating-factors></known-modulating-factors>
    <quantitative-understanding>
      <description>&lt;ul&gt;
	&lt;li&gt;There is an R&lt;sup&gt;2&lt;/sup&gt; of 0.84 between relative COX-2 mRNA and altered heart development measured as pericardial area in embryos of Japanese medaka exposed to the COX-2 inducer, 2,3,7,8-teterachlorodibenzo-p-dioxin (TCDD) (Dong et al 2010).&lt;/li&gt;
&lt;/ul&gt;
</description>
      <response-response-relationship></response-response-relationship>
      <time-scale></time-scale>
      <feedforward-feedback-loops></feedforward-feedback-loops>
    </quantitative-understanding>
    <applicability>
      <sex>
        <evidence>High</evidence>
        <sex>Unspecific</sex>
      </sex>
      <life-stage>
        <evidence>High</evidence>
        <life-stage>Embryo</life-stage>
      </life-stage>
      <life-stage>
        <evidence>High</evidence>
        <life-stage>Development</life-stage>
      </life-stage>
      <taxonomy taxonomy-id="cfd455a8-25ff-4287-9ff1-c9f6c99224c5">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="40a96606-3ba7-4743-a401-22460d1b3c4b">
        <evidence>High</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="109ce903-310c-4030-80f5-fc444247f435">
        <evidence>High</evidence>
      </taxonomy>
    </applicability>
    <evidence-supporting-taxonomic-applicability>&lt;ul&gt;
	&lt;li&gt;Links between induction of COX-2 and alteration of cardiovascular development and function has only been demonstrated in zebrafish, Japanese medaka, and chicken (Dong et al 2010; Teraoka et al 2008; 2014).&lt;/li&gt;
	&lt;li&gt;However, it is acknowledged that this key event relationship could be applicable to all vertebrate taxa and some invertebrate taxa based on presence of COX-2 genes and a cardiovascular system.&lt;/li&gt;
&lt;/ul&gt;
</evidence-supporting-taxonomic-applicability>
    <references>&lt;p&gt;Dong, W.; Matsumura, F.; Kullman, S.W. (2010). TCDD induced pericardial edema and relative COX-2 expression in medaka (Oryzias latipes) embryos. Toxicol. Sci. 118 (1), 213-223.&lt;/p&gt;

&lt;p&gt;Fujisaw, N.; Nakayama, S.M.M.; Ikenaka, Y.; Ishizuka, M. 2014. TCDD-induced chick cardiotoxicity is abolished by a selective cyclooxygenase-2 (COX-2) inhibitor NS398. Arch. Toxicol. 88, 1739-1748.&lt;/p&gt;

&lt;p&gt;Huang, C.C.; Chen, P.C.; Huang, C.W.; Yu, J. (2007). Aristolochic acid induces heart failure in zebrafish embryos that is mediated by inflammation. Toxicol. Sci. 100, 486-494.&lt;/p&gt;

&lt;p&gt;Teraoka, H.; Kubota, A.; Kawai, Y.; Hiraga, T. (2008). Prostanoid signaling mediates circulation failure caused by TCDD in developing zebrafish. Interdis. Studies Environ. Chem. Biol. Resp. Chem. Pollut. 61-80.&lt;/p&gt;

&lt;p&gt;Teraoka, H.; Okuno, Y.; Nijoukubo, D.; Yamakoshi, A.; Peterson, R.E.; Stegeman, J.J.; Kitazawa, T.; Hiraga, T.; Kubota, A. (2014). Involvement of COX2-thromboxane pathway in TCDD-induced precardiac edema in developing zebrafish. Aquat. Toxicol. 154, 19-25.&lt;/p&gt;
</references>
    <source>AOPWiki</source>
    <creation-timestamp>2017-02-09T14:40:36</creation-timestamp>
    <last-modification-timestamp>2018-03-28T13:24:19</last-modification-timestamp>
  </key-event-relationship>
  <key-event-relationship id="6ecc4cdf-ae77-4d74-8fc5-82421b608a20">
    <title>
      <upstream-id>e648f918-6b20-4147-9b56-01a68955b349</upstream-id>
      <downstream-id>f47cf8c7-2e96-426f-8d68-5ccc30c16368</downstream-id>
    </title>
    <description></description>
    <evidence-collection-strategy/>
    <weight-of-evidence>
      <value></value>
      <biological-plausibility></biological-plausibility>
      <emperical-support-linkage></emperical-support-linkage>
      <uncertainties-or-inconsistencies></uncertainties-or-inconsistencies>
    </weight-of-evidence>
    <known-modulating-factors/>
    <quantitative-understanding>
      <description></description>
      <response-response-relationship/>
      <time-scale/>
      <feedforward-feedback-loops/>
    </quantitative-understanding>
    <applicability>
    </applicability>
    <evidence-supporting-taxonomic-applicability></evidence-supporting-taxonomic-applicability>
    <references></references>
    <source>AOPWiki</source>
    <creation-timestamp>2026-11-17T02:03:28</creation-timestamp>
    <last-modification-timestamp>2026-11-17T02:03:28</last-modification-timestamp>
  </key-event-relationship>
  <key-event-relationship id="d13b2d46-5240-41ea-9bd4-9a542cba8a07">
    <title>
      <upstream-id>f47cf8c7-2e96-426f-8d68-5ccc30c16368</upstream-id>
      <downstream-id>16d77181-0da9-49c3-af36-4ff08e983c43</downstream-id>
    </title>
    <description></description>
    <evidence-collection-strategy/>
    <weight-of-evidence>
      <value></value>
      <biological-plausibility></biological-plausibility>
      <emperical-support-linkage></emperical-support-linkage>
      <uncertainties-or-inconsistencies></uncertainties-or-inconsistencies>
    </weight-of-evidence>
    <known-modulating-factors/>
    <quantitative-understanding>
      <description></description>
      <response-response-relationship/>
      <time-scale/>
      <feedforward-feedback-loops/>
    </quantitative-understanding>
    <applicability>
    </applicability>
    <evidence-supporting-taxonomic-applicability></evidence-supporting-taxonomic-applicability>
    <references></references>
    <source>AOPWiki</source>
    <creation-timestamp>2026-11-17T01:31:53</creation-timestamp>
    <last-modification-timestamp>2026-11-17T01:31:53</last-modification-timestamp>
  </key-event-relationship>
  <key-event-relationship id="863e523f-7cba-4728-b9ab-3638ed4ee297">
    <title>
      <upstream-id>16d77181-0da9-49c3-af36-4ff08e983c43</upstream-id>
      <downstream-id>9fe06144-feee-45d3-95ba-e88bfd50610b</downstream-id>
    </title>
    <description></description>
    <evidence-collection-strategy/>
    <weight-of-evidence>
      <value></value>
      <biological-plausibility></biological-plausibility>
      <emperical-support-linkage></emperical-support-linkage>
      <uncertainties-or-inconsistencies></uncertainties-or-inconsistencies>
    </weight-of-evidence>
    <known-modulating-factors/>
    <quantitative-understanding>
      <description></description>
      <response-response-relationship/>
      <time-scale/>
      <feedforward-feedback-loops/>
    </quantitative-understanding>
    <applicability>
    </applicability>
    <evidence-supporting-taxonomic-applicability></evidence-supporting-taxonomic-applicability>
    <references></references>
    <source>AOPWiki</source>
    <creation-timestamp>2026-11-17T01:32:13</creation-timestamp>
    <last-modification-timestamp>2026-11-17T01:32:13</last-modification-timestamp>
  </key-event-relationship>
  <key-event-relationship id="5f566a42-e69a-4bba-b889-cd321435e40c">
    <title>
      <upstream-id>9fe06144-feee-45d3-95ba-e88bfd50610b</upstream-id>
      <downstream-id>d75c9f09-3f16-4627-84f5-60ef45c1f533</downstream-id>
    </title>
    <description></description>
    <evidence-collection-strategy/>
    <weight-of-evidence>
      <value></value>
      <biological-plausibility></biological-plausibility>
      <emperical-support-linkage></emperical-support-linkage>
      <uncertainties-or-inconsistencies></uncertainties-or-inconsistencies>
    </weight-of-evidence>
    <known-modulating-factors/>
    <quantitative-understanding>
      <description></description>
      <response-response-relationship/>
      <time-scale/>
      <feedforward-feedback-loops/>
    </quantitative-understanding>
    <applicability>
    </applicability>
    <evidence-supporting-taxonomic-applicability></evidence-supporting-taxonomic-applicability>
    <references></references>
    <source>AOPWiki</source>
    <creation-timestamp>2026-11-17T01:32:26</creation-timestamp>
    <last-modification-timestamp>2026-11-17T01:32:26</last-modification-timestamp>
  </key-event-relationship>
  <key-event-relationship id="35a215e1-fe63-42c3-9198-ff89a5dba322">
    <title>
      <upstream-id>d75c9f09-3f16-4627-84f5-60ef45c1f533</upstream-id>
      <downstream-id>542e80fe-a3ac-47ad-8f95-c441419980bf</downstream-id>
    </title>
    <description></description>
    <evidence-collection-strategy/>
    <weight-of-evidence>
      <value></value>
      <biological-plausibility></biological-plausibility>
      <emperical-support-linkage></emperical-support-linkage>
      <uncertainties-or-inconsistencies></uncertainties-or-inconsistencies>
    </weight-of-evidence>
    <known-modulating-factors/>
    <quantitative-understanding>
      <description></description>
      <response-response-relationship/>
      <time-scale/>
      <feedforward-feedback-loops/>
    </quantitative-understanding>
    <applicability>
    </applicability>
    <evidence-supporting-taxonomic-applicability></evidence-supporting-taxonomic-applicability>
    <references></references>
    <source>AOPWiki</source>
    <creation-timestamp>2026-11-17T01:57:36</creation-timestamp>
    <last-modification-timestamp>2026-11-17T01:57:36</last-modification-timestamp>
  </key-event-relationship>
  <key-event-relationship id="f9cd9abf-466b-4cb9-8465-e35ff6341fb9">
    <title>
      <upstream-id>542e80fe-a3ac-47ad-8f95-c441419980bf</upstream-id>
      <downstream-id>79d28b81-b1b9-4c08-9beb-b50733211cdb</downstream-id>
    </title>
    <description></description>
    <evidence-collection-strategy/>
    <weight-of-evidence>
      <value></value>
      <biological-plausibility></biological-plausibility>
      <emperical-support-linkage></emperical-support-linkage>
      <uncertainties-or-inconsistencies></uncertainties-or-inconsistencies>
    </weight-of-evidence>
    <known-modulating-factors/>
    <quantitative-understanding>
      <description></description>
      <response-response-relationship/>
      <time-scale/>
      <feedforward-feedback-loops/>
    </quantitative-understanding>
    <applicability>
    </applicability>
    <evidence-supporting-taxonomic-applicability></evidence-supporting-taxonomic-applicability>
    <references></references>
    <source>AOPWiki</source>
    <creation-timestamp>2026-11-17T02:00:35</creation-timestamp>
    <last-modification-timestamp>2026-11-17T02:00:35</last-modification-timestamp>
  </key-event-relationship>
  <key-event-relationship id="37579c2a-5f32-4b6a-afb9-5024ced61a47">
    <title>
      <upstream-id>79d28b81-b1b9-4c08-9beb-b50733211cdb</upstream-id>
      <downstream-id>9c2a2b45-4f79-4a6e-b978-76aa8b123221</downstream-id>
    </title>
    <description></description>
    <evidence-collection-strategy/>
    <weight-of-evidence>
      <value></value>
      <biological-plausibility></biological-plausibility>
      <emperical-support-linkage></emperical-support-linkage>
      <uncertainties-or-inconsistencies></uncertainties-or-inconsistencies>
    </weight-of-evidence>
    <known-modulating-factors/>
    <quantitative-understanding>
      <description></description>
      <response-response-relationship/>
      <time-scale/>
      <feedforward-feedback-loops/>
    </quantitative-understanding>
    <applicability>
    </applicability>
    <evidence-supporting-taxonomic-applicability></evidence-supporting-taxonomic-applicability>
    <references></references>
    <source>AOPWiki</source>
    <creation-timestamp>2026-11-17T02:04:14</creation-timestamp>
    <last-modification-timestamp>2026-11-17T02:04:14</last-modification-timestamp>
  </key-event-relationship>
  <key-event-relationship id="77bc8620-64a9-49e8-81a7-da371805038d">
    <title>
      <upstream-id>79d28b81-b1b9-4c08-9beb-b50733211cdb</upstream-id>
      <downstream-id>677c3fa3-ea71-44fd-bd59-6740716305fb</downstream-id>
    </title>
    <description></description>
    <evidence-collection-strategy/>
    <weight-of-evidence>
      <value></value>
      <biological-plausibility></biological-plausibility>
      <emperical-support-linkage></emperical-support-linkage>
      <uncertainties-or-inconsistencies></uncertainties-or-inconsistencies>
    </weight-of-evidence>
    <known-modulating-factors/>
    <quantitative-understanding>
      <description></description>
      <response-response-relationship/>
      <time-scale/>
      <feedforward-feedback-loops/>
    </quantitative-understanding>
    <applicability>
    </applicability>
    <evidence-supporting-taxonomic-applicability></evidence-supporting-taxonomic-applicability>
    <references></references>
    <source>AOPWiki</source>
    <creation-timestamp>2026-11-17T01:37:44</creation-timestamp>
    <last-modification-timestamp>2026-11-17T01:37:44</last-modification-timestamp>
  </key-event-relationship>
  <key-event-relationship id="3c6355c8-8c6f-4e8b-bd88-2c450a586e8b">
    <title>
      <upstream-id>9c2a2b45-4f79-4a6e-b978-76aa8b123221</upstream-id>
      <downstream-id>677c3fa3-ea71-44fd-bd59-6740716305fb</downstream-id>
    </title>
    <description></description>
    <evidence-collection-strategy/>
    <weight-of-evidence>
      <value></value>
      <biological-plausibility></biological-plausibility>
      <emperical-support-linkage></emperical-support-linkage>
      <uncertainties-or-inconsistencies></uncertainties-or-inconsistencies>
    </weight-of-evidence>
    <known-modulating-factors/>
    <quantitative-understanding>
      <description></description>
      <response-response-relationship/>
      <time-scale/>
      <feedforward-feedback-loops/>
    </quantitative-understanding>
    <applicability>
    </applicability>
    <evidence-supporting-taxonomic-applicability></evidence-supporting-taxonomic-applicability>
    <references></references>
    <source>AOPWiki</source>
    <creation-timestamp>2026-11-17T01:33:08</creation-timestamp>
    <last-modification-timestamp>2026-11-17T01:33:08</last-modification-timestamp>
  </key-event-relationship>
  <aop id="eb852705-6668-4e0e-971e-ee891fb5c9be">
    <title>Activation of aryl hydrocarbon receptor (AhR) leading to preeclampsia via COX-2/PPAR-gamma-mediated trophoblast dysfunction</title>
    <short-name>AhR activation leading to preeclampsia via COX-2/PPAR-gamma-mediated dysfunction</short-name>
    <point-of-contact>YuCheng Nien</point-of-contact>
    <authors>&lt;p&gt;YuCheng Nien.&lt;br /&gt;
Department of Obstetrics, Gynecology &amp;amp; Women&amp;#39;s Health, Taichung Veterans General Hospital, Taichung, Taiwan.&lt;/p&gt;
</authors>
    <coaches>
    </coaches>
    <external_links>
    </external_links>
    <status>
      <wiki-license>All rights reserved</wiki-license>
    </status>
    <oecd-project/>
    <handbook-version>2.8</handbook-version>
    <abstract>&lt;p&gt;Preeclampsia (PE) is a severe pregnancy-specific hypertensive disorder affecting 3-5% of pregnancies globally and is a leading cause of maternal and perinatal morbidity and mortality, with significantly elevated risk and clinical severity among women with diabetes. This Adverse Outcome Pathway (AOP) was initiated to elucidate the mechanistic linkage between diabetic hyperglycemia and exacerbated PE pathology via the aryl hydrocarbon receptor (AhR) signaling axis. Under hyperglycemic conditions, non-enzymatic glycoxidation and lipid peroxidation promote the accumulation of &lt;em&gt;N&lt;/em&gt;-&amp;epsilon;-carboxymethyllysine (CML), which acts as a stressor to trigger the Molecular Initiating Event (MIE): Activation, AhR (Event 18) in placental trophoblasts and endothelial cells. Aberrant AhR activation subsequently induces Increase, COX-2 expression (Event 1269) and Increase, Prostaglandin E2 concentration (Event 2466). Excessive PGE2 signaling leads to Decreased, PPAR-gamma activation (Event 233), which in turn drives Decreased, MMP (Event 2467) activity and Increase, Extracellular matrix deposition (Event 1501) within the placental microenvironment. Together, matrix remodeling arrest and excessive ECM accumulation result in Decreased trophoblast invasion/migration (Event 2103), impairing uterine spiral artery remodeling and leading to placental insufficiency (Event 1892) and hypoxia. Placental ischemia subsequently triggers the release of anti-angiogenic factors, resulting in reduced production, VEGF (Event 948) and Altered, Cardiovascular development/function (Event 317)&amp;mdash;manifesting as widespread maternal vascular endothelial dysfunction and vasoconstriction&amp;mdash;which ultimately culminate in the Adverse Outcome (AO) of increase, Preeclampsia (Event 1893). Overall, the biological plausibility of this pathway is supported by moderate-to-strong empirical evidence from diabetic vascular/renal models demonstrating CML&amp;ndash;AhR&amp;ndash;COX-2/PGE2 signaling, alongside established roles of PPAR-&amp;gamma;, MMPs, and VEGF in placentation. However, major knowledge gaps remain regarding quantitative CML thresholds in early human gestation and direct causal confirmation of the AhR&amp;ndash;COX-2/PGE2&amp;ndash;PPAR-&amp;gamma; cascade at the human maternal-fetal interface. Scientifically and regulatorily, this AOP provides an organizing framework for identifying early predictive biomarkers, evaluating developmental and reproductive toxicity (DART) of AhR ligands, and guiding targeted preventive interventions for high-risk diabetic pregnancies.&lt;/p&gt;
</abstract>
    <background>&lt;p&gt;&lt;span style="font-size:12.0pt"&gt;Pregnant women with preexisting diabetes or gestational diabetes mellitus face a substantially elevated risk of developing severe PE and preterm birth. This Adverse Outcome Pathway (AOP) was developed to address a critical mechanistic question: &lt;em&gt;How does a diabetic hyperglycemic microenvironment disrupt trophoblast invasion, angiogenic balance, and uterine spiral artery remodeling, thereby exacerbating the clinical severity of preeclampsia?&lt;/em&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p&gt;&lt;span style="font-size:12.0pt"&gt;The primary objectives of developing this AOP are to&lt;/span&gt;&lt;br /&gt;
&lt;span style="font-size:12pt"&gt;1. Document specialized placental and vascular biology: Synthesize cross-disciplinary evidence connecting diabetic nephropathic/vascular mechanisms (CML&amp;ndash;AhR&amp;ndash;COX-2/PGE2 signaling) with PPAR-&amp;gamma; downregulation, MMP suppression, extracellular matrix (ECM) remodeling, and placental angiogenesis (VEGF).&lt;/span&gt;&lt;br /&gt;
&lt;span style="font-size:12.0pt"&gt;2. E&lt;span style="font-size:12pt"&gt;stablish the biological relevance of upstream molecular and cellular assays (e.g., serum CML-modified peptides, AhR activation, COX-2/PGE2 levels, PPAR-&amp;gamma; activity, MMP-2/MMP-9 expression, and VEGF production) alongside clinical angiogenic biomarkers (sFlt-1/PlGF ratio) to guide early risk stratification and targeted therapeutic interventions for high-risk diabetic pregnancies.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
</background>
    <development-strategy>&lt;p&gt;&lt;span style="font-size:12pt"&gt;This Adverse Outcome Pathway (AOP) was developed using a cross-disease translational strategy, bridging well-characterized clinical pathology at the Adverse Outcome (AO) end with mechanistic molecular toxicology at the Molecular Initiating Event (MIE) end:&lt;/span&gt;&lt;/p&gt;

&lt;ol&gt;
	&lt;li&gt;&lt;span style="font-size:12pt"&gt;Cross-Organ Mechanistic Extrapolation (Diabetic Nephropathy to Placenta): To explain the high clinical incidence and severity of PE in pregnancies complicated by diabetes mellitus or gestational diabetes mellitus (GDM), we extrapolated a validated diabetic vascular/renal mechanism (Lee et al., 2016), in which hyperglycemia-derived &lt;em&gt;N&lt;/em&gt;-&amp;epsilon;-carboxymethyllysine (CML) activates AhR (Event 18) to upregulate COX-2 (Event 1269) and PGE2 (Event 2466), driving extracellular matrix (ECM) deposition (Event 1501) and inflammatory cell infiltration.&lt;/span&gt;&lt;/li&gt;
	&lt;li&gt;&lt;span style="font-size:12pt"&gt;Placental Microenvironment Integration: We bridged the upstream inflammatory axis (Events 1269 and 2466) to downstream trophoblast and vascular dysfunction (Events 2103, 948, and 317) through PPAR-&amp;gamma; inactivation (Event 233) and MMP downregulation (Event 2467), integrating pregnancy-specific regulatory networks.&lt;/span&gt;&lt;/li&gt;
&lt;/ol&gt;
</development-strategy>
    <molecular-initiating-event key-event-id="19a51ece-bc2e-4475-9636-2797e76dd4c4">
      <evidence-supporting-chemical-initiation>&lt;p&gt;The AHR can be activated by several structurally diverse chemicals, but binds preferentially to planar halogenated aromatic hydrocarbons and polycyclic aromatic hydrocarbons. Dioxin-like compounds (DLCs), which include polychlorinated dibenzo-p-dioxins (PCDDs), polychlorinated dibenzofurans (PCDFs) and certain polychlorinated biphenyls (PCBs), are among the most potent AHR ligands&lt;sup&gt;&lt;a href="#cite_note-Denison2011-38"&gt;[38]&lt;/a&gt;&lt;/sup&gt;. Only a subset of PCDD, PCDF and PCB congeners has been shown to bind to the AHR and cause toxic effects to those elicited by TCDD. Until recently, TCDD was considered to be the most potent DLC in birds&lt;sup&gt;&lt;a href="#cite_note-Van1998-39"&gt;[39]&lt;/a&gt;&lt;/sup&gt;; however, recent reports indicate that 2,3,4,7,8-pentachlorodibenzofuran (PeCDF) is more potent than TCDD in some species of birds.&lt;sup&gt;&lt;a href="#cite_note-Cohen2011b-40"&gt;[40]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Farmahin2012-13"&gt;[13]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Farmahin2013a-41"&gt;[41]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Farmahin2014-21"&gt;[21]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Herve2010a-42"&gt;[42]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Herve2010b-43"&gt;[43]&lt;/a&gt;&lt;/sup&gt; When screened for their ability to induce aryl hydrocarbon hydroxylase (AHH) activity, dioxins with chlorine atoms at a minimum of three out of the four lateral ring positions, and with at least one non-chlorinated ring position are the most active&lt;sup&gt;&lt;a href="#cite_note-Poland1973-44"&gt;[44]&lt;/a&gt;&lt;/sup&gt;. Of the dioxin-like PCBs, non-ortho congeners are the most toxicologically active, while mono-ortho PCBs are generally less potent&lt;sup&gt;&lt;a href="#cite_note-McFarland1989-45"&gt;[45]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Safe1994-9"&gt;[9]&lt;/a&gt;&lt;/sup&gt;. Chlorine substitution at ortho positions increases the energetic costs of assuming the coplanar conformation required for binding to the AHR &lt;sup&gt;&lt;a href="#cite_note-McFarland1989-45"&gt;[45]&lt;/a&gt;&lt;/sup&gt;. Thus, a smaller proportion of mono-ortho PCB molecules are able to bind to the AHR and elicit toxic effects, resulting in reduced potency of these congeners. Other PCB congeners, such as di-ortho substituted PCBs, are very weak AHR agonists and do not likely contribute to dioxin-like effects &lt;sup&gt;&lt;a href="#cite_note-Safe1994-9"&gt;[9]&lt;/a&gt;&lt;/sup&gt;.&lt;/p&gt;

&lt;ul&gt;
	&lt;li&gt;Contrary to studies of birds and mammals, even the most potent mono-ortho PCBs bind to AhRs of fishes with very low affinity, if at all (Abnet et al 1999; Doering et al 2014; 2015; Eisner et al 2016; Van den Berg et al 1998).&lt;/li&gt;
&lt;/ul&gt;

&lt;p&gt;The role of the AHR in mediating the toxic effects of planar hydrophobic contaminants has been well studied, however the endogenous role of the AHR is less clear &lt;sup&gt;&lt;a href="#cite_note-Okey2007-1"&gt;[1]&lt;/a&gt;&lt;/sup&gt;. Some endogenous and natural substances, including prostaglandin PGG2 and the tryptophan derivatives indole-3-carbinol, 6-formylindolo[3,2-b]carbazole (FICZ) and kynurenic acid can bind to and activate the AHR. &lt;sup&gt;&lt;a href="#cite_note-Fujii2010-6"&gt;[6]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Omie2011-46"&gt;[46]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Swed2010-47"&gt;[47]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Diani2011-48"&gt;[48]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Wincent2012-49"&gt;[49]&lt;/a&gt;&lt;/sup&gt; The AHR is thought to have important endogenous roles in reproduction, liver and heart development, cardiovascular function, immune function and cell cycle regulation &lt;sup&gt;&lt;a href="#cite_note-Baba2005-50"&gt;[50]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Denison2011-38"&gt;[38]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Fernandez1995-51"&gt;[51]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Ichihara2007-52"&gt;[52]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Lahvis2000-53"&gt;[53]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Mimura1997-54"&gt;[54]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Omie2011-46"&gt;[46]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Schmidt1996-55"&gt;[55]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Thack2002-56"&gt;[56]&lt;/a&gt;&lt;/sup&gt;&lt;sup&gt;&lt;a href="#cite_note-Zhang2010-57"&gt;[57]&lt;/a&gt;&lt;/sup&gt; and activation of the AHR by DLCs may therefore adversely affect these processes.&lt;/p&gt;
</evidence-supporting-chemical-initiation>
    </molecular-initiating-event>
    <key-events>
      <key-event key-event-id="42b06a4d-5fe7-4f2b-8e56-047be78a1a2a"/>
      <key-event key-event-id="e648f918-6b20-4147-9b56-01a68955b349"/>
      <key-event key-event-id="f47cf8c7-2e96-426f-8d68-5ccc30c16368"/>
      <key-event key-event-id="16d77181-0da9-49c3-af36-4ff08e983c43"/>
      <key-event key-event-id="9fe06144-feee-45d3-95ba-e88bfd50610b"/>
      <key-event key-event-id="d75c9f09-3f16-4627-84f5-60ef45c1f533"/>
      <key-event key-event-id="542e80fe-a3ac-47ad-8f95-c441419980bf"/>
      <key-event key-event-id="79d28b81-b1b9-4c08-9beb-b50733211cdb"/>
      <key-event key-event-id="9c2a2b45-4f79-4a6e-b978-76aa8b123221"/>
    </key-events>
    <adverse-outcome key-event-id="677c3fa3-ea71-44fd-bd59-6740716305fb">
      <examples/>
    </adverse-outcome>
    <key-event-relationships>
      <relationship id="c2408ddd-80ae-4fcf-98e2-b9b2af63cb30">
        <adjacency>adjacent</adjacency>
        <quantitative-understanding-value>High</quantitative-understanding-value>
        <evidence>High</evidence>
      </relationship>
      <relationship id="a773ada8-f0ba-4ce6-adca-ff35a68684ea">
        <adjacency>adjacent</adjacency>
        <quantitative-understanding-value>High</quantitative-understanding-value>
        <evidence>High</evidence>
      </relationship>
      <relationship id="5c2e36e0-ebd1-43f9-8803-c00fcd3e3251">
        <adjacency>adjacent</adjacency>
        <quantitative-understanding-value>Moderate</quantitative-understanding-value>
        <evidence>Moderate</evidence>
      </relationship>
      <relationship id="6ecc4cdf-ae77-4d74-8fc5-82421b608a20">
        <adjacency>adjacent</adjacency>
        <quantitative-understanding-value>Moderate</quantitative-understanding-value>
        <evidence>Moderate</evidence>
      </relationship>
      <relationship id="d13b2d46-5240-41ea-9bd4-9a542cba8a07">
        <adjacency>adjacent</adjacency>
        <quantitative-understanding-value>High</quantitative-understanding-value>
        <evidence>High</evidence>
      </relationship>
      <relationship id="863e523f-7cba-4728-b9ab-3638ed4ee297">
        <adjacency>adjacent</adjacency>
        <quantitative-understanding-value>Moderate</quantitative-understanding-value>
        <evidence>Moderate</evidence>
      </relationship>
      <relationship id="5f566a42-e69a-4bba-b889-cd321435e40c">
        <adjacency>adjacent</adjacency>
        <quantitative-understanding-value>Moderate</quantitative-understanding-value>
        <evidence>Moderate</evidence>
      </relationship>
      <relationship id="35a215e1-fe63-42c3-9198-ff89a5dba322">
        <adjacency>adjacent</adjacency>
        <quantitative-understanding-value>High</quantitative-understanding-value>
        <evidence>High</evidence>
      </relationship>
      <relationship id="f9cd9abf-466b-4cb9-8465-e35ff6341fb9">
        <adjacency>adjacent</adjacency>
        <quantitative-understanding-value>High</quantitative-understanding-value>
        <evidence>High</evidence>
      </relationship>
      <relationship id="37579c2a-5f32-4b6a-afb9-5024ced61a47">
        <adjacency>adjacent</adjacency>
        <quantitative-understanding-value>High</quantitative-understanding-value>
        <evidence>High</evidence>
      </relationship>
      <relationship id="77bc8620-64a9-49e8-81a7-da371805038d">
        <adjacency>adjacent</adjacency>
        <quantitative-understanding-value>High</quantitative-understanding-value>
        <evidence>High</evidence>
      </relationship>
      <relationship id="3c6355c8-8c6f-4e8b-bd88-2c450a586e8b">
        <adjacency>adjacent</adjacency>
        <quantitative-understanding-value>High</quantitative-understanding-value>
        <evidence>High</evidence>
      </relationship>
    </key-event-relationships>
    <applicability>
      <sex>
        <evidence>Moderate</evidence>
        <sex>Female</sex>
      </sex>
      <life-stage>
        <evidence>Moderate</evidence>
        <life-stage>Pregnancy</life-stage>
      </life-stage>
      <taxonomy taxonomy-id="b8753f15-9ab7-4425-9f65-b67236d6993f">
        <evidence>Moderate</evidence>
      </taxonomy>
      <taxonomy taxonomy-id="ba982cc1-0376-4470-bed3-29bba8aceec4">
        <evidence>Moderate</evidence>
      </taxonomy>
    </applicability>
    <overall-assessment>
      <description>&lt;table cellspacing="0" class="Table" style="border-collapse:collapse; width:100.0%"&gt;
	&lt;tbody&gt;
		&lt;tr&gt;
			&lt;td colspan="2" style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:1px solid black; vertical-align:top; width:100%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&amp;nbsp;Support for Biological Plausibility of KERs&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:28%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;MIE =&amp;gt; KE1: Activation, AhR leads to Increase, COX-2 expression&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:71%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Biological Plausibility of the MIE =&amp;gt; KE1 is high.&lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Rationale:&amp;nbsp; Ligand-bound aryl hydrocarbon receptor (AhR) undergoes conformational activation and translocates into the nucleus, where it heterodimerizes with the AhR nuclear translocator (ARNT). The resulting AhR/ARNT transcription factor complex specifically binds to xenobiotic response elements (XREs/DREs) located within the promoter region of the PTGS2 gene (encoding cyclooxygenase-2, COX-2). This genomic binding recruits transcriptional coactivators to directly drive COX-2 mRNA synthesis and protein expression. (Lee et al. (2016); Vogel et al. (2007))&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:28%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;KE1 =&amp;gt; KE2: Increase, COX-2 expression leads to Increase, Prostaglandin E2 concentration&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:71%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Biological Plausibility of the KE1 =&amp;gt; KE2 is high. &lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Rationale:&amp;nbsp; Cyclooxygenase-2 (COX-2) functions as the rate-limiting enzyme converting membrane arachidonic acid into prostaglandin H2 (PGH2). PGH2 is subsequently isomerized to prostaglandin E2 (PGE2) via terminal microsomal prostaglandin E synthase-1 (mPGES-1). Elevated COX-2 protein level directly leads to a stoichiometric increase in PGE2 synthesis and extracellular secretion. (Lee et al. (2016); Li et al. (2015))&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:28%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;KE2 =&amp;gt; KE3: Increase, Prostaglandin E2 concentration leads to Decreased, PPAR-gamma activation&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:71%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Biological Plausibility of the KE2 =&amp;gt; KE3 is high. &lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Rationale:&amp;nbsp; Extracellular PGE2 binds to G-protein coupled E-prostanoid receptors (EP2/EP4) on trophoblasts, activating intracellular cAMP/PKA and ERK1/2-MAPK kinase cascades. This signals inhibitory phosphorylation at serine residues within the N-terminal or ligand-binding domain of peroxisome proliferator-activated receptor gamma (PPAR-gamma), suppressing its nuclear translocation and DNA-binding activity. (Jia et al. (2022))&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:28%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;KE3 =&amp;gt; KE4: Decreased, PPAR-gamma activation leads to Decreased, MMP&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:71%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Biological Plausibility of the KE3 =&amp;gt; KE4 is high. &lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Rationale: &amp;nbsp;Active PPAR-gamma&amp;nbsp;functions as an essential positive transcriptional regulator of matrix metalloproteinases (&lt;em&gt;MMP2 &lt;/em&gt;and&amp;nbsp;&lt;em&gt;MMP9&lt;/em&gt;) by binding to peroxisome proliferator response elements (PPREs) in their promoter regions. Suppression of PPAR-gamma&amp;nbsp;activity abolishes this baseline transactivation and alters the MMP/TIMP stoichiometric balance, markedly reducing proMMP-2/9 expression and enzymatic cleavage. (Jia et al. (2022); Kobara et al. (2013))&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:28%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;KE4 =&amp;gt; KE5: Decreased, MMP leads to Increase, ECM deposition&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:71%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Biological Plausibility of the KE4 =&amp;gt; KE5 is high.&lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Rationale: &amp;nbsp;MMP-2 and MMP-9 (type IV collagenases) are key endopeptidases responsible for degrading structural extracellular matrix (ECM) components, including Type IV collagen, fibronectin, and laminin. Suppression of MMP gelatinase activity arrests matrix degradation and turnover, leading to pericellular accumulation of structural matrix proteins and tissue fibrosis. (Lee et al. (2016); Bautista-Bautista et al. (2024))&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:28%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;KE5 =&amp;gt; KE6: Increase, ECM deposition leads to Cellular dysfunction (human placenta trophoblast cells)&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:71%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Biological Plausibility of the KE 5 =&amp;gt; KE6 is high.&lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Rationale:&amp;nbsp; Excessive ECM deposition increases spatial biomechanical stiffness and creates dense physical barriers within the maternal decidua. Dense matrix physical constraints combined with altered integrin mechanotransduction physically restrict extravillous trophoblast (EVT) motility and invasion toward maternal spiral arteries. (Jiang et al. (2013); Tossetta et al. (2019))&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:28%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;KE6 =&amp;gt; KE7: Cellular dysfunction (human placenta trophoblast cells) leads to increase, placental insufficiency&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:71%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Biological Plausibility of the KE6 =&amp;gt; KE7 is high. &lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Rationale:&amp;nbsp; Impaired EVT invasion prevents endovascular replacement of maternal subplacental uterine spiral artery endothelial and smooth muscle layers. Unremodeled spiral arteries remain high-resistance, low-flow vessels, causing chronic uteroplacental hypoperfusion, severe ischemia, and severe placental insufficiency. (Zhao et al. (2023/2025); Khankin et al. (2010))&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:28%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;KE7 =&amp;gt; KE8: increase, placental insufficiency leads to reduced production, VEGF&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:71%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Biological Plausibility of the KE7 =&amp;gt; KE8 is high. &lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Rationale: &amp;nbsp;Ischemic and hypoxic syncytiotrophoblasts hypersecrete soluble fms-like tyrosine kinase-1 (sFlt-1). Secreted sFlt-1 functions as a high-affinity decoy receptor that binds and sequesters free vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), dramatically reducing bioavailable circulating free VEGF levels. (Rana et al. (2019); AHA Organoid Model (2025))&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:28%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;KE8 =&amp;gt; KE9: reduced production, VEGF leads to Altered, Cardiovascular development/function&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:71%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Biological Plausibility of the KE8 =&amp;gt; KE9 is high. &lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Rationale:&amp;nbsp; Free VEGF is mandatory for maintaining endothelial cell survival, fenestration integrity, and eNOS-mediated nitric oxide (NO) production. Depletion of free VEGF causes systemic endothelial injury, eNOS uncoupling, impaired vasorelaxation, and Endothelin-1 (ET-1) upregulation, triggering systemic arterial vasospasm. (Li et al. (2020); Zhou et al. (2019))&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:28%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;KE9 =&amp;gt; AO: Altered, Cardiovascular development/function leads to increase, Preeclampsia&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:71%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Biological Plausibility of the KE 9=&amp;gt; AO is high. &lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Rationale: &amp;nbsp;Systemic arterial vasospasm elevates total peripheral resistance, directly causing maternal gestational hypertension. Glomerular endotheliosis and podocyte injury disrupt the renal filtration barrier, causing proteinuria and fulfilling clinical criteria for Preeclampsia. (Roberts et al. (2021); Jiang et al. (2025))&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
	&lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;table cellspacing="0" class="Table" style="border-collapse:collapse"&gt;
	&lt;tbody&gt;
		&lt;tr&gt;
			&lt;td colspan="2" style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:1px solid black; vertical-align:top; width:396px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&amp;nbsp;Support for essentiality of KEs&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:179px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;MIE: Activation, AhR&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:217px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Essentiality of the MIE is high.&lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Rationale for Essentiality of the MIE in the AOP:&amp;nbsp; Genetic deletion of AhR (AhR -/-), siRNA-mediated AhR knockdown, or pharmacological inhibition using specific AhR antagonists (e.g., CH223191, biseugenol, or&amp;nbsp;alpha-naphthoflavone) completely abolishes CML- or ligand-induced COX-2 upregulation. (Lee et al. (2016); Vogel et al. (2007))&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:179px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;KE1: &lt;span style="background-color:white"&gt;Increase, COX-2 expression&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:217px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Essentiality of the KE1 is high.&lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Rationale for Essentiality of the KE1 in the AOP:&amp;nbsp; Pharmacological inhibition of COX-2 using selective inhibitors (e.g., celecoxib, indomethacin, or low-dose aspirin) or COX-2 gene silencing directly blocks downstream PGE2 production and prevents its autocrine/paracrine accumulation. (Lee et al. (2016); Li et al. (2015))&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:179px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;KE2: &lt;span style="background-color:white"&gt;Increase, Prostaglandin E2 concentration&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:217px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Essentiality of the KE2 is high.&lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Rationale for Essentiality of the KE2 in the AOP: &amp;nbsp;Blocking upstream AhR/COX-2 signaling, neutralizing extracellular PGE2 with specific antibodies, or antagonizing EP2/EP4 receptors fully rescues PPAR-gamma&amp;nbsp;nuclear localization and transcriptional transactivation. (Jia et al. (2022))&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:179px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;KE3: &lt;span style="background-color:white"&gt;Decreased, PPAR-gamma activation&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:217px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Essentiality of the KE3 is high.&lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Rationale for Essentiality of the KE3 in the AOP: Administration of synthetic PPAR-gamma&amp;nbsp;agonists (e.g., rosiglitazone or pioglitazone) directly restores MMP-2 and MMP-9 expression and gelatinase activity, overcoming upstream PGE2-mediated suppression. (Jia et al. (2022); Kobara et al. (2013))&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:179px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;KE4: &lt;span style="background-color:white"&gt;Decreased, MMP&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:217px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Essentiality of the KE4 is high.&lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Rationale for Essentiality of the KE4 in the AOP: Restoring MMP activity via PPAR-gamma&amp;nbsp;agonists or upstream AhR/COX-2 inhibition prevents excessive matrix deposition; conversely, broad-spectrum MMP inhibitors induce rapid, uncontrolled ECM accumulation. (Lee et al. (2016); Bautista-Bautista et al. (2024))&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:179px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;KE5: &lt;span style="background-color:white"&gt;Increase, ECM deposition&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:217px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Essentiality of the KE5 is high.&lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Rationale for Essentiality of the KE5 in the AOP: Enzymatic degradation of excess matrix components or preventing upstream AhR-driven ECM overproduction restores EVT invasion depth in Matrigel and Transwell invasion assays. (Jiang et al. (2013); Tossetta et al. (2019))&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:179px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;KE6: &lt;span style="background-color:white"&gt;Cellular dysfunction (human placenta trophoblast cells)&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:217px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Essentiality of the KE6 is high.&lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Rationale for Essentiality of the KE6 in the AOP: Reversing trophoblast invasion failure or blocking upstream AhR/COX-2 pathobiology restores endovascular spiral artery transformation and improves uteroplacental blood perfusion in animal models. (Zhao et al. (2023/2025); Khankin et al. (2010))&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:179px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;KE7: &lt;span style="background-color:white"&gt;placental insufficiency&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:217px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Essentiality of the KE7 is high.&lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Rationale for Essentiality of the KE7 in the AOP: Administration of sFlt-1 neutralizing antibodies, recombinant VEGF165, or relieving placental ischemia (via upstream pathway inhibition) directly restores bioavailable free VEGF concentrations. (Rana et al. (2019); AHA Organoid Model (2025))&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:179px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;KE8: &lt;span style="background-color:white"&gt;reduced production, VEGF&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:217px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Essentiality of the KE8 is high.&lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Rationale for Essentiality of the KE8 in the AOP: Exogenous VEGF supplementation or sFlt-1 antagonism restores endothelial eNOS activation and normalizes endothelium-dependent vasodilation in isolated maternal resistance arteries. (Li et al. (2020); Zhou et al. (2019))&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:179px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;KE9: &lt;span style="background-color:white"&gt;Altered, Cardiovascular development/function&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:217px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Essentiality of the KE9 is high.&lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Rationale for Essentiality of the KE9 in the AOP: Upstream blockade of the MIE (AhR antagonism) or early KEs (COX-2 inhibition via low-dose aspirin, PPAR-gamma activation, or sFlt-1 neutralization) prevents or significantly attenuates gestational hypertension and proteinuria. (Roberts et al. (2021); Jiang et al. (2025))&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
	&lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;
</description>
      <applicability>&lt;p&gt;The AOP660 applies to &lt;em&gt;Homo sapiens&amp;nbsp;&lt;/em&gt;(human), pregnancy, and female.&lt;/p&gt;
</applicability>
      <key-event-essentiality-summary>&lt;table cellspacing="0" class="Table" style="border-collapse:collapse"&gt;
	&lt;tbody&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:1px solid black; vertical-align:top; width:139px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;Event&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:1px solid black; vertical-align:top; width:154px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;Direct Evidence&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:1px solid black; vertical-align:top; width:130px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;Indirect Evidence&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:139px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;MIE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:154px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;***&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:130px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;***&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:139px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;KE1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:154px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;***&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:130px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;***&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:139px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;KE2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:154px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;**&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:130px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;***&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:139px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;KE3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:154px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;***&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:130px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;***&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:139px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;KE4&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:154px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;***&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:130px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;**&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:139px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;KE5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:154px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;**&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:130px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;***&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:139px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;KE6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:154px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;***&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:130px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;***&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:139px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;KE7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:154px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;***&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:130px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;***&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:139px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;KE8&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:154px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;***&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:130px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;***&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:139px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;KE9 &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:154px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;***&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:130px"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="color:black"&gt;***&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
	&lt;/tbody&gt;
&lt;/table&gt;
</key-event-essentiality-summary>
      <weight-of-evidence-summary>&lt;table cellspacing="0" class="Table" style="border-collapse:collapse; width:100.0%"&gt;
	&lt;tbody&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:1px solid black; vertical-align:top; width:32%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;MIE =&amp;gt; KE1&lt;/span&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt; : Activation, AhR leads to Increase, COX-2 expression&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:1px solid black; vertical-align:top; width:67%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;Empirical Support of the MIE =&amp;gt; KE1 is high.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;Rationale:&amp;nbsp;In diabetic mesangial cells and human placental/endothelial models, exposure to advanced glycation end-products (CML) or dioxin-like compounds triggers AhR nuclear translocation followed by a time- and concentration-dependent elevation of COX-2 expression. This response is completely absent in AhR-deficient models. (Lee et al. (2016); Vogel et al. (2007))&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:32%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;KE1 =&amp;gt; KE2&lt;/span&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt; : Increase, COX-2 expression leads to Increase, Prostaglandin E2 concentration&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:67%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;Empirical Support of the KE1 =&amp;gt; KE2 is high. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;Rationale:&amp;nbsp;Quantitative assays in human trophoblasts, endothelial cells, and diabetic renal tissues demonstrate that COX-2 protein expression directly correlates with extracellular PGE2 concentrations in cell culture supernatants and tissue homgenates. (Lee et al. (2016); Li et al. (2015))&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:32%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;KE2 =&amp;gt; KE3&lt;/span&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt; : Increase, Prostaglandin E2 concentration leads to Decreased, PPAR-gamma activation&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:67%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;Empirical Support of the KE2 =&amp;gt; KE3 is moderate.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;Rationale:&amp;nbsp;Treatment of human extravillous trophoblasts (EVTs) or vascular cells with exogenous PGE2 induces dose-dependent inhibition of PPAR-gamma&amp;nbsp;reporter gene activity and reduces nuclear PPAR-gamma&amp;nbsp;protein levels, mimicking pathology observed in preeclamptic placentas. (Jia et al. (2022))&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:32%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;KE3 =&amp;gt; KE4&lt;/span&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt; : Decreased, PPAR-gamma activation leads to Decreased, MMP&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:67%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;Empirical Support of the KE3 =&amp;gt; KE4 is high. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;Rationale:&amp;nbsp;siRNA-mediated PPAR-gamma&amp;nbsp;knockdown or pharmacological inhibition with GW9662 markedly reduces MMP-2/9 mRNA expression and gelatinase zymography activity in human HTR-8/SVneo trophoblast cells and extra-placental membranes. (Jia et al. (2022); Kobara et al. (2013))&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:32%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;KE4 =&amp;gt; KE5&lt;/span&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt; : Decreased, MMP leads to Increase, ECM deposition&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:67%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;Empirical Support of the KE4 =&amp;gt; KE5 is high. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;Rationale:&amp;nbsp;In diabetic tissue models and human decidual cultures, reduced MMP-9 gelatinase activity quantitatively correlates with significant increases in Type IV collagen and Fibronectin deposition. (Lee et al. (2016); Bautista-Bautista et al. (2024))&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:32%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;KE5 =&amp;gt; KE6&lt;/span&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt; : Increase, ECM deposition leads to Cellular dysfunction (human placenta trophoblast cells)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:67%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;Empirical Support of the KE5 =&amp;gt; KE6 is moderate.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;Rationale:&amp;nbsp;Increased ECM substrate stiffness and dense Fibronectin/Collagen matrices significantly decrease HTR-8/SVneo migration speed and invasion capacity in vitro. (Jiang et al. (2013); Tossetta et al. (2019))&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:32%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;KE6 =&amp;gt; KE7&lt;/span&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt; : Cellular dysfunction (human placenta trophoblast cells) leads to increase, placental insufficiency&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:67%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;Empirical Support of the KE 6 =&amp;gt; KE7 is high. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;Rationale:&amp;nbsp;Histopathological analysis of preeclamptic placentas consistently reveals shallow EVT invasion and unremodeled spiral arteries, directly correlating with reduced Doppler uteroplacental perfusion parameters. (Zhao et al. (2023/2025); Khankin et al. (2010))&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:32%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;KE7 =&amp;gt; KE8&lt;/span&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt; : increase, placental insufficiency leads to reduced production, VEGF&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:67%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;Empirical Support of the KE7 =&amp;gt; KE8 is high. Rationale:&amp;nbsp;In clinical preeclampsia cohorts and Reduced Uteroplacental Perfusion Pressure (RUPP) animal models, placental hypoxia directly drives a surge in serum sFlt-1 accompanied by a reciprocal collapse in bioavailable free VEGF. (Rana et al. (2019); AHA Organoid Model (2025))&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:32%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;KE8 =&amp;gt; KE9&lt;/span&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt; : reduced production, VEGF leads to Altered, Cardiovascular development/function&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:67%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;Empirical Support of the KE8 =&amp;gt; KE9 is high. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;Rationale:&amp;nbsp;Exogenous sFlt-1 infusion in pregnant rodents induces systemic endothelial cell swelling, blunted vasodilation responses, and acute systemic vasoconstriction. (Li et al. (2020); Zhou et al. (2019))&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td style="border-bottom:1px solid black; border-left:1px solid black; border-right:1px solid black; border-top:none; vertical-align:top; width:32%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;KE9 =&amp;gt; AO&lt;/span&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt; : Altered, Cardiovascular development/function leads to increase, Preeclampsia&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td style="border-bottom:1px solid black; border-left:none; border-right:1px solid black; border-top:none; vertical-align:top; width:67%"&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;Empirical Support of the KE9 =&amp;gt; AO is high.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;span style="font-family:Calibri,sans-serif"&gt;&lt;span style="font-family:&amp;quot;Arial&amp;quot;,sans-serif"&gt;Rationale:&amp;nbsp;Clinical trials and animal models demonstrate that reversing endothelial dysfunction directly alleviates hypertension and renal pathology, preventing progression to clinical Preeclampsia. (Roberts et al. (2021); Jiang et al. (2025))&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
	&lt;/tbody&gt;
&lt;/table&gt;

&lt;p&gt;&amp;nbsp;&lt;/p&gt;
</weight-of-evidence-summary>
      <known-modulating-factors>&lt;table class="Table"&gt;
	&lt;tbody&gt;
		&lt;tr&gt;
			&lt;td&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Modulating Factor (MF)&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Influence or Outcome&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;KER(s) involved&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Pre-existing Diabetes / GDM&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Chronic hyperglycemia, advanced glycation end-product (N(6)-Carboxymethyllysine, CML) accumulation, significantly increases MIE activation sensitivity, accelerates the COX-2/PGE2 inflammatory cascade.&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;MIE/ KE1/ KE2 &lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;IDO1 Activity &amp;amp; Endogenous Ligands&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Tryptophan metabolites (Kynurenine, ITE) maintains homeostatic maternal-fetal immune tolerance; exposure to xenobiotics suppresses IDO1, disrupting physiological AhR protective signaling.&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;MIE&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Genetic Polymorphisms (&lt;em&gt;AHR&lt;/em&gt; Variants)&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;&lt;em&gt;AHR&lt;/em&gt; rs713150G minor allele variant drives differential placental AhR expression; clinically identified as a protective genetic factor against preeclampsia susceptibility.&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;MIE&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Low-Dose Aspirin Prophylaxis&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Cyclooxygenase (COX) inhibitor initiated prior to 16 weeks of gestation blunts downstream pro-inflammatory prostaglandin (PGE2) surges, effectively reducing preeclampsia incidence in high-risk pregnancies&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;KE1/ KE2 &lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
		&lt;tr&gt;
			&lt;td&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Exogenous AhR Modulators &amp;amp; Toxins&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;Dioxin-like compounds (TCDD) and Benzo[a]pyrene (B(a)P) exacerbate sFlt-1 hypersecretion and ECM accumulation.&lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
			&lt;td&gt;
			&lt;p&gt;&lt;span style="font-size:12pt"&gt;MIE/ KE5/ KE8 &lt;/span&gt;&lt;/p&gt;
			&lt;/td&gt;
		&lt;/tr&gt;
	&lt;/tbody&gt;
&lt;/table&gt;
</known-modulating-factors>
      <quantitative-considerations>&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="color:#000000"&gt;&lt;span style="color:black"&gt;The quantitative understanding of AOP 660 is currently categorized overall as&amp;nbsp;&lt;/span&gt;&lt;strong&gt;Moderate&lt;/strong&gt;, defined by a distinct temporal and scale-dependent hierarchy across biological levels of organization. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="color:#000000"&gt;&lt;span style="color:black"&gt;Upstream key events spanning the Molecular Initiating Event (MIE, AhR activation) to KE2 (PGE2 elevation) exhibit robust semi-quantitative dose- and time-response relationships in vitro within acute timeframes (hours to 48 h). In this early phase, chronic accumulation of&amp;nbsp;&lt;/span&gt;&lt;em&gt;N&lt;/em&gt;-&amp;epsilon;-carboxymethyllysine (CML) under hyperglycemic stress eventually overcomes homeostatic negative feedback clearance driven by CYP1A1/CYP1A2 enzymes. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="color:#000000"&gt;&lt;span style="color:black"&gt;Midstream cell- and tissue-level events (KE3 to KE6: PGE2&amp;ndash;PPAR-&lt;/span&gt;gamma&amp;nbsp;&lt;span style="color:black"&gt;repression, MMP-2/9 suppression, and ECM over-deposition) display moderate quantitative predictability; while specific PGE2 threshold concentrations and matrix stiffness values correlate directly with reduced extravillous trophoblast invasion in human explant models, quantitative inter-individual microenvironmental variations remain. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="color:#000000"&gt;&lt;span style="color:black"&gt;Conversely, downstream systemic events leading to the Adverse Outcome (KE7 to AO: placental insufficiency, sFlt-1/PlGF ratio surge, endothelial vasospasm, and preeclampsia) possess&amp;nbsp;&lt;/span&gt;&lt;strong&gt;High&lt;/strong&gt;&amp;nbsp;quantitative predictive validity spanning weeks across gestation (weeks 12&amp;ndash;20 to clinical presentation). Clinically validated biomarkers, particularly circulating sFlt-1/PlGF ratio thresholds (e.g., cutoffs of &amp;gt;38 or &amp;gt;85), reliably predict impending preeclampsia onset within 1 to 4 weeks. &lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="color:#000000"&gt;&lt;span style="color:black"&gt;Future incorporation of multi-scale toxicokinetic-toxicodynamic (TKTD) computational models will bridge early upstream CML-AhR threshold concentrations directly with downstream systemic vascular risks, advancing this framework into a fully quantitative risk-assessment tool for high-risk diabetic pregnancies.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
</quantitative-considerations>
    </overall-assessment>
    <potential-applications>&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="color:#000000"&gt;Based on the weight-of-evidence (WoE) evaluation&amp;mdash;supported by strong biological plausibility, moderate empirical evidence, and evolving quantitative predictability&amp;mdash;this Adverse Outcome Pathway (AOP) serves as a robust mechanistic framework for hypothesis generation, early biomarker discovery, and screening-level hazard identification:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;ol&gt;
	&lt;li&gt;&lt;span style="color:black"&gt;Early Risk Stratification &amp;amp; Biomarker Discovery:&amp;nbsp;By mechanistic bridging of diabetic hyperglycemia to placental vascular pathology, upstream and mid-stream Key Events&amp;mdash;including maternal serum &lt;em&gt;N&lt;/em&gt;-&amp;epsilon;-carboxymethyllysine (CML), AhR activation (MIE, Event 18), COX-2/PGE2 elevation (Events 1269 &amp;amp; 2466), and MMP-2/9 suppression (Event 2467)&amp;mdash;provide a panel of early-gestation mechanistic biomarkers. These complement established mid-to-late gestation angiogenic markers (such as the sFlt-1/PlGF ratio) to enable earlier risk stratification for preeclampsia (Event 1893) in pregnancies complicated by diabetes or GDM.&lt;/span&gt;&lt;/li&gt;
	&lt;li&gt;&lt;span style="color:black"&gt;DART Hazard Assessment &amp;amp; Chemical Grouping :&amp;nbsp;As AhR activation is a shared MIE across multiple toxicological networks, this AOP provides a biological rationale for screening exogenous AhR agonists and modulators (e.g., environmental dioxin-like pollutants or pharmaceuticals) for placenta- and vascular-mediated developmental and reproductive toxicity (DART). It directly informs chemical profiling and Integrated Approaches to Testing and Assessment (IATA) using human first-trimester trophoblast (HTR-8/SVneo) and endothelial (HUVEC) assays.&lt;/span&gt;&lt;/li&gt;
	&lt;li&gt;&lt;span style="color:black"&gt;Targeted Therapeutic Interventions:&amp;nbsp;Mapping this intermediate signaling cascade uncovers pharmacological targets beyond conventional low-dose aspirin prophylaxis. Specifically, attenuating aberrant AhR hyperactivation, restoring PPAR-gamma transactivation (Event 233), or modulating PGE2&amp;ndash;EP receptor signaling represent promising preclinical targets for preventing placental dysfunctions in high-risk diabetic pregnancies.&lt;/span&gt;&lt;/li&gt;
	&lt;li&gt;&lt;span style="color:black"&gt;Regulatory Limitations:&amp;nbsp;Due to current knowledge gaps regarding exact quantitative CML thresholds for AhR activation at the human maternal-fetal interface and bidirectional PGE2 signaling kinetics, this AOP should currently be applied for qualitative read-across and screening-level hazard identification rather than deriving quantitative points of departure (PODs) for regulatory exposure limits.&lt;/span&gt;&lt;/li&gt;
&lt;/ol&gt;
</potential-applications>
    <aop-stressors>
      <aop-stressor stressor-id="3567f20c-d7cb-4772-8e3c-2b5cbd64d2ae">
        <evidence>Not Specified</evidence>
      </aop-stressor>
      <aop-stressor stressor-id="2b6845ea-b09b-4518-91d9-343753c6dc50">
        <evidence>Not Specified</evidence>
      </aop-stressor>
    </aop-stressors>
    <references>&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="color:#000000"&gt;&lt;span style="color:black"&gt;Bautista-Bautista G, Flores-Herrera H, et al.&amp;nbsp;Escherichia coli induced matrix metalloproteinase-9 activity and type IV collagen degradation is regulated by progesterone in human maternal decidua.&amp;nbsp;&lt;em&gt;BMC Pregnancy Childbirth&lt;/em&gt;. 2024;24(1):645.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="color:#000000"&gt;&lt;span style="color:black"&gt;Jia JP, Wu JH, Hu JR.&amp;nbsp;PGE2/EP4 signaling downregulates PPAR-gamma expression and impairs trophoblast differentiation in human placenta.&amp;nbsp;&lt;em&gt;Eur Rev Med Pharmacol Sci&lt;/em&gt;. 2022;26(3):771-778.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="color:#000000"&gt;&lt;span style="color:black"&gt;Jiang H, Meng H, Yang Y, et al.&amp;nbsp;Infection-related preterm birth and maternal vascular pathology.&amp;nbsp;&lt;em&gt;Front Cardiovasc Med&lt;/em&gt;. 2025;12:1567127.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="color:#000000"&gt;&lt;span style="color:black"&gt;Jiang Y, Zhu Y, Shi Y, et al.&amp;nbsp;Extracellular matrix stiffness regulates extravillous trophoblast invasion and migration.&amp;nbsp;&lt;em&gt;PLoS One&lt;/em&gt;. 2013;8(7):e69079.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="color:#000000"&gt;&lt;span style="color:black"&gt;Khankin EV, Royle C, Karumanchi SA.&amp;nbsp;Placental hypoxia and antiangiogenic factors in preeclampsia.&amp;nbsp;&lt;em&gt;Semin Thromb Hemost&lt;/em&gt;. 2010;36(3):309-320.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="color:#000000"&gt;&lt;span style="color:black"&gt;Kobara H, Miyamoto T, Shiozawa T, et al.&amp;nbsp;Peroxisome proliferator-activated receptor gamma (PPARgamma) regulates MMP-2 and MMP-9 expression in extravillous trophoblasts.&amp;nbsp;&lt;em&gt;Placenta&lt;/em&gt;. 2013;34(11):1036-1043.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="color:#000000"&gt;&lt;span style="color:black"&gt;Lee WJ, Liu SH, Sheu ML, et al.&amp;nbsp;Aryl hydrocarbon receptor deficiency attenuates oxidative stress-related mesangial cell activation and macrophage infiltration and extracellular matrix accumulation in diabetic nephropathy.&amp;nbsp;&lt;em&gt;Antioxid Redox Signal&lt;/em&gt;. 2016;24(4):217-231.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="color:#000000"&gt;&lt;span style="color:black"&gt;Li Y, Wang K, Zheng J, et al.&amp;nbsp;Altered COX-2/PGE2 signaling in human placenta and maternal vasculature during preeclampsia.&amp;nbsp;&lt;em&gt;Med Hypotheses&lt;/em&gt;. 2015;84(5):510-513.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="color:#000000"&gt;&lt;span style="color:black"&gt;Li Y, Zheng J, et al.&amp;nbsp;Roles of aryl hydrocarbon receptor in endothelial angiogenic responses.&amp;nbsp;&lt;em&gt;Biol Reprod&lt;/em&gt;. 2020;103(5):927-937.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="color:#000000"&gt;&lt;span style="color:black"&gt;Preeclampsia Organoid Study Group.&amp;nbsp;Constructing a preeclampsia organoid model to elucidate the mechanism of aspirin.&amp;nbsp;&lt;em&gt;Hypertension&lt;/em&gt;. 2025;82(4):800-803.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="color:#000000"&gt;&lt;span style="color:black"&gt;Rana S, Lemoine E, Granger JP, Karumanchi SA.&amp;nbsp;Preeclampsia: pathophysiology, challenges, and perspectives.&amp;nbsp;&lt;em&gt;Circ Res&lt;/em&gt;. 2019;124(7):1094-1112.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="color:#000000"&gt;&lt;span style="color:black"&gt;Roberts JM, Myatt L, et al.&amp;nbsp;Pathophysiology of preeclampsia: focus on endothelial dysfunction.&amp;nbsp;&lt;em&gt;Hypertension&lt;/em&gt;. 2021;77(5):1430-1441.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="color:#000000"&gt;&lt;span style="color:black"&gt;Smoking Mouse Model Study Group.&amp;nbsp;The role of the aryl hydrocarbon receptor in vascular factors related to preeclampsia in a smoking mouse model.&amp;nbsp;&lt;em&gt;Curr Issues Mol Biol&lt;/em&gt;. 2024;46(1):749-760.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="color:#000000"&gt;&lt;span style="color:black"&gt;Tossetta G, Giannubilo SR, et al.&amp;nbsp;Fibronectin and lumican expression in preeclamptic placentas and their role in trophoblast dysfunction.&amp;nbsp;&lt;em&gt;J Cell Physiol&lt;/em&gt;. 2019;234(5):6091-6098.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="color:#000000"&gt;&lt;span style="color:black"&gt;Vogel CF, Li W, Matsumura F, et al.&amp;nbsp;Dual path of cyclooxygenase-2 expression in TCDD-treated human monocytic cells.&amp;nbsp;&lt;em&gt;Am J Pathol&lt;/em&gt;. 2007;171(5):1538-1548.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="color:#000000"&gt;&lt;span style="color:black"&gt;Zhao YJ, Zhou C, Zheng J, et al.&amp;nbsp;Defective uterine spiral artery remodeling and placental insufficiency in preeclampsia.&amp;nbsp;&lt;em&gt;J Physiol&lt;/em&gt;. 2023;603(2):579-594.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="text-align:start"&gt;&lt;span style="font-size:medium"&gt;&lt;span style="color:#000000"&gt;&lt;span style="color:black"&gt;Zhou C, Zheng J, et al.&amp;nbsp;Vascular endothelial dysfunction and anti-angiogenic balance in preeclampsia.&amp;nbsp;&lt;em&gt;Hypertension&lt;/em&gt;. 2019;74(1):154-163.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
</references>
    <source>AOPWiki</source>
    <creation-timestamp>2026-11-16T21:18:26</creation-timestamp>
    <last-modification-timestamp>2026-11-17T19:51:51</last-modification-timestamp>
  </aop>
  <vendor-specific id="dcaa7743-a31c-4655-9ee2-eb0e66581c6e" name="AopWiki" version="2026-11-22 12:51:40 +0000">
    <biological-process-reference id="027addf6-122e-4553-8231-87946ff1d38b" aop-wiki-id="25996"/>
    <biological-process-reference id="ef32cf4d-166e-4cb1-aeb1-2568a0c476f7" aop-wiki-id="27348"/>
    <biological-process-reference id="2a9e9810-90f5-4a87-beee-31a21d9535dc" aop-wiki-id="5826"/>
    <biological-process-reference id="5a290a1e-c8f5-4939-9c70-924dda1ea517" aop-wiki-id="43729"/>
    <biological-process-reference id="0ca3ec48-d6fb-4d7e-8ef9-8ac3bb71af6e" aop-wiki-id="46924"/>
    <biological-process-reference id="f391422c-9e8d-417e-ae6e-348871e9938c" aop-wiki-id="12258"/>
    <biological-process-reference id="2dd85acd-9c86-4210-b0f9-7659276b58b9" aop-wiki-id="65547"/>
    <biological-action-reference id="858bfb7f-1f52-4390-9d28-4ea657198347" aop-wiki-id="1"/>
    <biological-action-reference id="daf07ded-b29b-4e00-9e44-8a8de58b3293" aop-wiki-id="2"/>
    <biological-action-reference id="40170979-dec4-42d2-93fa-9785e9edd1e8" aop-wiki-id="8"/>
    <biological-action-reference id="d174c842-9881-4c5e-a044-9c0b40492c6f" aop-wiki-id="4"/>
    <taxonomy-reference id="ab767424-1286-466f-a43f-6630467eccc5" aop-wiki-id="4962"/>
    <taxonomy-reference id="109ce903-310c-4030-80f5-fc444247f435" aop-wiki-id="609"/>
    <taxonomy-reference id="e3cbe271-c1f7-4f0b-acb4-bb8ff3c737de" aop-wiki-id="82885"/>
    <taxonomy-reference id="d460d086-b9b4-4c4c-8dbc-e3ffe6c8d44e" aop-wiki-id="4917"/>
    <taxonomy-reference id="f8570d25-a83d-45ec-9a91-ddc74459a135" aop-wiki-id="16309"/>
    <taxonomy-reference id="905fad6d-2c9c-42a0-b683-1537a9dd6fb7" aop-wiki-id="512"/>
    <taxonomy-reference id="5ca49bb1-3efc-4115-b334-82e2761a586f" aop-wiki-id="5028"/>
    <taxonomy-reference id="7f4f5ccb-4d94-4574-87e9-0dcfcfe92608" aop-wiki-id="596"/>
    <taxonomy-reference id="9df39eac-d707-4c00-b1ea-9a1505f20c77" aop-wiki-id="5303"/>
    <taxonomy-reference id="325e3fb3-0e5a-42ce-b834-ffaa584f3490" aop-wiki-id="610"/>
    <taxonomy-reference id="a2e1100f-2c73-42ee-9356-2381f3f9de0d" aop-wiki-id="624"/>
    <taxonomy-reference id="ba982cc1-0376-4470-bed3-29bba8aceec4" aop-wiki-id="31"/>
    <taxonomy-reference id="b667fbe7-4be4-45d5-a707-316c7aaea8bc" aop-wiki-id="68"/>
    <taxonomy-reference id="b8753f15-9ab7-4425-9f65-b67236d6993f" aop-wiki-id="459"/>
    <taxonomy-reference id="ca1e44ab-6ba7-4ca2-9dab-f769adf983d9" aop-wiki-id="11777"/>
    <taxonomy-reference id="44a12808-8bd9-48d3-9450-2b9e10e95068" aop-wiki-id="1"/>
    <taxonomy-reference id="cfd455a8-25ff-4287-9ff1-c9f6c99224c5" aop-wiki-id="653"/>
    <taxonomy-reference id="40a96606-3ba7-4743-a401-22460d1b3c4b" aop-wiki-id="5097"/>
    <taxonomy-reference id="0924b029-7b44-4e61-92f9-cdaba5fd44d5" aop-wiki-id="478"/>
    <taxonomy-reference id="42a83725-7234-4b5b-b126-4651c3467c4c" aop-wiki-id="720902"/>
    <taxonomy-reference id="f5c6c9e8-9327-462a-9035-4c7eb6f1eb01" aop-wiki-id="493"/>
    <taxonomy-reference id="6a5b376b-edcc-4703-a928-322458d212ae" aop-wiki-id="522"/>
    <taxonomy-reference id="3677faa1-063d-42d3-8e25-00291c6359cf" aop-wiki-id="720916"/>
    <taxonomy-reference id="3787a1aa-da69-47ff-926a-93ba5ba9626e" aop-wiki-id="720917"/>
    <chemical-reference id="7a4588c2-c96d-4be1-ad01-a95763a68f41" aop-wiki-id="1009025"/>
    <chemical-reference id="578a9f44-fc12-4d28-a645-dd99b7010bcd" aop-wiki-id="20137"/>
    <chemical-reference id="dddd3726-e7c5-4ada-8181-497246c8e98f" aop-wiki-id="20410"/>
    <chemical-reference id="c13b1899-9f0f-416c-88d3-a8f956877cc6" aop-wiki-id="20682"/>
    <chemical-reference id="bdc281b8-2e13-4291-841a-f14405aeba1e" aop-wiki-id="40969"/>
    <chemical-reference id="587a0fb8-5bff-401d-bcb1-af262d3fb787" aop-wiki-id="21480"/>
    <stressor-reference id="3567f20c-d7cb-4772-8e3c-2b5cbd64d2ae" aop-wiki-id="878"/>
    <stressor-reference id="2b6845ea-b09b-4518-91d9-343753c6dc50" aop-wiki-id="51"/>
    <stressor-reference id="0ca7fc0b-e48d-4025-be17-47dbff123078" aop-wiki-id="62"/>
    <stressor-reference id="c82a22dc-b1a0-40f1-871c-97e7c82aed60" aop-wiki-id="147"/>
    <stressor-reference id="fc8d1576-cdc5-44ac-8549-ba626ca01ec8" aop-wiki-id="148"/>
    <stressor-reference id="1f9d4df7-b11c-4106-af4e-ed65dd875310" aop-wiki-id="149"/>
    <stressor-reference id="06016acb-bf64-4755-ae45-0952f3499a41" aop-wiki-id="150"/>
    <stressor-reference id="0e1bc0e6-64ee-419e-8c36-061ceabc5ba0" aop-wiki-id="250"/>
    <stressor-reference id="99526a5f-9ee3-4f6c-8be2-bb2c9442440b" aop-wiki-id="249"/>
    <stressor-reference id="ff730375-7759-42a3-b14e-80f5c4250211" aop-wiki-id="284"/>
    <stressor-reference id="4079ce24-b951-4dae-8050-fef47d1f718a" aop-wiki-id="285"/>
    <biological-object-reference id="a695a3c6-32e7-48ff-aa26-69581260df08" aop-wiki-id="70472"/>
    <biological-object-reference id="ba198f4b-e042-407e-855c-f8842dbe1afd" aop-wiki-id="112477"/>
    <biological-object-reference id="ad466b20-827e-4c6c-9492-c1178dd8756f" aop-wiki-id="130760"/>
    <biological-object-reference id="c3dab278-d35a-43a5-a603-8db06423794a" aop-wiki-id="178180"/>
    <biological-object-reference id="5711cde6-e0e9-46b5-9762-6eec54ba7b96" aop-wiki-id="110557"/>
    <key-event-reference id="19a51ece-bc2e-4475-9636-2797e76dd4c4" aop-wiki-id="18"/>
    <key-event-reference id="677c3fa3-ea71-44fd-bd59-6740716305fb" aop-wiki-id="1893"/>
    <key-event-reference id="42b06a4d-5fe7-4f2b-8e56-047be78a1a2a" aop-wiki-id="1269"/>
    <key-event-reference id="79d28b81-b1b9-4c08-9beb-b50733211cdb" aop-wiki-id="948"/>
    <key-event-reference id="9c2a2b45-4f79-4a6e-b978-76aa8b123221" aop-wiki-id="317"/>
    <key-event-reference id="d75c9f09-3f16-4627-84f5-60ef45c1f533" aop-wiki-id="2103"/>
    <key-event-reference id="e648f918-6b20-4147-9b56-01a68955b349" aop-wiki-id="2466"/>
    <key-event-reference id="f47cf8c7-2e96-426f-8d68-5ccc30c16368" aop-wiki-id="233"/>
    <key-event-reference id="9fe06144-feee-45d3-95ba-e88bfd50610b" aop-wiki-id="1501"/>
    <key-event-reference id="16d77181-0da9-49c3-af36-4ff08e983c43" aop-wiki-id="2467"/>
    <key-event-reference id="542e80fe-a3ac-47ad-8f95-c441419980bf" aop-wiki-id="1892"/>
    <key-event-relationship-reference id="c2408ddd-80ae-4fcf-98e2-b9b2af63cb30" aop-wiki-id="3882"/>
    <key-event-relationship-reference id="a773ada8-f0ba-4ce6-adca-ff35a68684ea" aop-wiki-id="3876"/>
    <key-event-relationship-reference id="5c2e36e0-ebd1-43f9-8803-c00fcd3e3251" aop-wiki-id="1351"/>
    <key-event-relationship-reference id="6ecc4cdf-ae77-4d74-8fc5-82421b608a20" aop-wiki-id="3887"/>
    <key-event-relationship-reference id="d13b2d46-5240-41ea-9bd4-9a542cba8a07" aop-wiki-id="3877"/>
    <key-event-relationship-reference id="863e523f-7cba-4728-b9ab-3638ed4ee297" aop-wiki-id="3878"/>
    <key-event-relationship-reference id="5f566a42-e69a-4bba-b889-cd321435e40c" aop-wiki-id="3879"/>
    <key-event-relationship-reference id="35a215e1-fe63-42c3-9198-ff89a5dba322" aop-wiki-id="3885"/>
    <key-event-relationship-reference id="f9cd9abf-466b-4cb9-8465-e35ff6341fb9" aop-wiki-id="3886"/>
    <key-event-relationship-reference id="37579c2a-5f32-4b6a-afb9-5024ced61a47" aop-wiki-id="3888"/>
    <key-event-relationship-reference id="77bc8620-64a9-49e8-81a7-da371805038d" aop-wiki-id="3883"/>
    <key-event-relationship-reference id="3c6355c8-8c6f-4e8b-bd88-2c450a586e8b" aop-wiki-id="3881"/>
    <aop-reference id="eb852705-6668-4e0e-971e-ee891fb5c9be" aop-wiki-id="660"/>
  </vendor-specific>
</data>
